

DESCRIPTION

β -ALANINE DERIVATIVE AND A PROCESS
FOR THE PREPARATION THEREOF

5 TECHNICAL FIELD

The present invention relates to β -alanine derivative and a pharmaceutically acceptable salt thereof. More particularly, it relates to β -alanine derivative and a salt thereof which is glycoprotein IIb/IIIa antagonist, inhibitor of blood platelets aggregation and inhibitor of the binding of fibrinogen to blood platelets.

BACKGROUND ART

In European Patent Application No. 512,831 A1, there are disclosed fibrinogen receptor antagonists.

In European Patent Application No. 445,796 A2, there are disclosed inhibitor of blood platelets aggregation.

20 DISCLOSURE OF INVENTION

The present invention relates to β -alanine derivative and a salt thereof. More particularly, it relates to β -alanine derivative and a salt thereof which is glycoprotein IIb/IIIa antagonist and inhibitor of platelet aggregation, and useful as :

25 a drug for the prevention and/or the treatment of diseases caused by thrombus formation such as arterial thrombosis; arterial sclerosis; ischemic heart diseases [e.g. angina pectoris (e.g. stable angina pectoris, 30 unstable angina pectoris including imminent infarction, etc.), myocardial infarction (e.g. acute myocardial infarction, etc.), coronary thrombosis, etc.]; ischemic brain diseases [e.g. cerebral infarction (e.g. cerebral thrombosis (e.g. acute cerebral thrombosis, etc.), 35 cerebral embolism, etc.], transient cerebral ischemia

(e.g. transient ischemic attack, etc.), cerebrovascular spasm after cerebral hemorrhage (e.g. cerebrovascular spasm after subarachnoid hemorrhage, etc.), etc.]; pulmonary vascular diseases (e.g. pulmonary thrombosis, pulmonary embolism etc.); peripheral circulatory disorder [e.g. arteriosclerosis obliterans, thromboangiitis obliterans (i.e. B rger's disease), Raynaud's disease, complication of diabetes mellitus (e.g. diabetic angiopathy, diabetic neuropathy, etc.), phlebothrombosis (e.g. deep vein thrombosis, etc.), etc.] or the like;

a drug for the prevention and/or the treatment of restenosis and/or reocclusion such as restenosis and/or reocclusion after percutaneous transluminal coronary angioplasty (PTCA), restenosis and/or reocclusion after the administration of thrombolytic drug (e.g. tissue plasminogen activator (TPA), etc.) or the like;

a drug for the adjuvant therapy with thrombolytic drug (e.g. TPA, etc.) or anticoagulant (e.g. heparin, etc.);

a drug for the prevention and/or the treatment of the thrombus formation in case of vascular surgery, valve replacement, extracorporeal circulation [e.g. surgery (e.g. open heart surgery, pump-oxygenator, etc.) hemodialysis, etc.], transplantation, or the like;

a drug for the prevention and/or the treatment of disseminated intravascular coagulation (DIC), thrombotic thrombocytopenia, essential thrombocytosis, inflammation (e.g. nephritis, etc.), immune diseases, or the like;

a drug for inhibiting of metastasis; or the like.

The β -alanine derivative of the present invention is expected to be useful as an inhibitor of cell adhesion and so is expected to be useful as

a drug for the prevention and/or the treatment of disseminated intravascular coagulation (DIC), thrombotic

thrombocytopenia, essential thrombocytosis, inflammation (e.g. nephritis, etc.), immune diseases, or the like; a drug for inhibiting of metastasis; or the like.


Accordingly, one object of the present invention is to provide β -alanine derivative or a salt thereof which is useful as stated above.

Another object of the present invention is to provide processes for preparation of said β -alanine derivative or a salt thereof.

A further object of the present invention is to provide a pharmaceutical composition comprising, as an active ingredient, said β -alanine derivative or a salt thereof.

Still further object of this invention is to provide methods of using said β -alanine derivative or a salt thereof for the prevention and/or the treatment of aforesaid diseases in a human being or an animal.

The object β -alanine derivative of the present invention can be shown by the following formula (I) :



wherein R^1 is N-containing cycloalkyl which may have one or more suitable substituent(s),


R^2 is carboxy or protected carboxy,


A^1 is lower alkylene, lower alkanyl-ylidene or lower alkenylene, each of which may have one or more suitable substituent(s),

A^2 is lower alkylene,

A^3 is lower alkylene which may have one or more




suitable substituent(s),

 is a group of the formula:

(wherein  is N-containing heterocyclic group which may have one or more suitable substituent(s)),

X is O, S or NH,

Y is NH,


Z is  ,  or  ,

(wherein R³ is hydrogen or lower alkyl),
l, m and n are each the same or different an integer of 0 or 1,

or a pharmaceutically acceptable salt thereof.

The object compound (I) or a salt thereof can be prepared by the following processes.

Process 1




(II)

or its reactive derivative
at the carboxy group
or a salt thereof

(III)


or its reactive derivative
at the amino group
or a salt thereof



(Ia)

or a salt thereof

Process 2




(IV)

or its reactive derivative
at the carboxy group
or a salt thereof

(V)


or its reactive derivative
at the amino group
or a salt thereof



(Ib)

or a salt thereof

Process 3




(VI)

or its reactive derivative
at the amino group
or a salt thereof

(VII)


or its reactive derivative
at the carboxy group
or a salt thereof



(Ic)

or a salt thereof


Process 4



elimination reaction
of amino protective
group

(Id) /

or a salt thereof




(Ie)


or a salt thereof

Process 5

elimination reaction
of carboxy protective
group




(If)
or a salt thereof




(Ig)
or a salt thereof

Process 6

protecting reaction
of amino




(Ie)
or its reactive derivative
at the amino group
or a salt thereof



(Id)
or a salt thereof

Process 7


5



protecting reaction
of carboxy

(Ig)

or its reactive derivative
at the carboxy group
or a salt thereof




(If)

or a salt thereof

Process 8

25




elimination reaction
of amino protective
group

(Ih)

or a salt thereof


35



(Ii)

or a salt thereof


Process 9



acylation reaction
of amino

(Ii)

or its reactive derivative
at the amino group
or a salt thereof



(Ih)

or a salt thereof

wherein R^1 , R^2 , R^3 , A^1 , A^2 , A^3 , $\overset{\overset{N}{\curvearrowright}}{(\quad)}$, $-\overset{\overset{N}{\curvearrowright}}{(\quad)}$, X , Y , Z ,
 ℓ , m and n are each as defined above,

R^1_a is N-containing cycloalkyl having amino
protective group, which may have one or
more suitable substituent(s),

R^1_b is N-containing cycloalkyl which may
have one or more suitable substituent(s),


R^2_a is protected carboxy,

A^3_a is lower alkylene having protected amino, and

A_3 is lower alkylene having amino,
 A_3^C is acylamino.


The starting compound (IV) or a salt thereof is novel
 and can be prepared by the following schemes.

Process A




(II)

or its reactive derivative
 at the carboxy group
 or a salt thereof



(VIII)


or its reactive derivative
 at the amino group
 or a salt thereof



(IX)

or a salt thereof


Process B



(IX)

or a salt thereof

elimination reaction
 of carboxy protective
 group





(IV)


or a salt thereof

wherein R^1 , A^1 , A^2 , $-N\bigcirc-$, X , ℓ and n are each as defined above, and R^5 is protected carboxy.




The starting compound (V) or a salt thereof is novel and can be prepared by the following schemes.

Process C





Process D



wherein A⁴ is lower alkynylene,
 Three R⁶ are independently lower alkyl,
 R⁷ is lower alkyl,
 Two R⁸ are independently halogen,
5 Three R⁹ are independently lower alkyl, and
 R¹¹ is lower alkyl.

Among the starting compounds (II), (III), (IV), (V),
(VI), (VII), (VIII), and (IX), there are novel compounds.
10 They can be prepared from the known compounds in a
conventional manner in this field of the art or the
similar manners to those disclosed in Preparations and/or
Examples mentioned later in the present specification.

15 Suitable pharmaceutically acceptable salts of the
object compound (I) are conventional non-toxic salts and
include a metal salt such as an alkali metal salt [e.g.
sodium salt, potassium salt, etc.] and an alkaline earth
metal salt [e.g. calcium salt, magnesium salt, etc.] an
20 ammonium salt, an organic base salt [e.g. trimethylamine
salt, triethylamine salt, pyridine salt, picoline salt
dicyclohexylamine salt, N,N-dibenzylethylenediamine salt,
etc.], an organic acid addition salt [e.g. formate,
acetate, trifluoroacetate, maleate, tartrate,
25 methanesulfonate, benzenesulfonate, toluenesulfonate,
etc.], an inorganic acid addition salt [e.g.
hydrochloride, hydrobromide, hydroiodide, sulfate,
phosphate, etc.], a salt with an amino acid [e.g. arginine
salt, aspartic acid salt, glutamic acid salt, etc.] and
30 the like.

In the above and subsequent descriptions of this
specification, suitable examples of the various
definitions are explained in detail as follows :

The term "lower" is intended to mean 1 to 6 carbon atom(s), unless otherwise indicated.

The term "higher" is used to intend a group having 7 to 20 carbon atoms, unless otherwise provided.

5 The preferable number of the "one or more" in the term "one or more suitable substituent(s)" may be 1 to 4.

Suitable "lower alkyl" may be straight or branched ones such as methyl, ethyl, ~~isopropyl, propyl, butyl,~~ isobutyl, sec-butyl, t-butyl, pentyl, hexyl or the like.

10 Suitable "protected carboxy" may be a conventional protecting group such as an esterified carboxy group, or the like, and concrete examples of the ester moiety in said esterified carboxy group may be the ones such as
15 lower alkyl ester [e.g. methyl ester, ethyl ester, propyl ester, isopropyl ester, butyl ester, isobutyl ester, tert-butyl ester, pentyl ester, hexyl ester, 1-cyclopropylethyl ester, etc.] which may have suitable substituent(s), for example, lower alkanoyloxy(lower)alkyl ester [e.g. acetoxymethyl ester, propionyloxymethyl ester, butyryloxymethyl ester, valeryloxymethyl ester, pivaloyloxymethyl ester,
20 1-acetoxyethyl ester, 1-propionyloxyethyl ester, pivaloyloxyethyl ester, 2-propionyloxyethyl ester, hexanoyloxymethyl ester, etc.], lower-
25 alkanesulfonyl(lower)alkyl ester [e.g. 2-mesyloethyl ester, etc.] or mono(or di or tri)halo(lower)alkyl ester [e.g. 2-iodoethyl ester, 2,2,2-trichloroethyl ester, etc.];
higher alkyl ester [e.g. heptyl ester, octyl ester, 3,5-dimethyloctyl ester, 3,7-dimethyloctyl ester, nonyl
30 ester, decyl ester, undecyl ester, dodecyl ester, tridecyl ester, tetradecyl ester, pentadecyl ester, hexadecyl ester, heptadecyl ester, octadecyl ester, nonadecyl ester, adamantyl ester, etc.];
lower alkenyl ester [e.g. (C2-C6)alkenyl ester (e.g.
35 vinyl ester, allyl ester, etc.)];

lower alkynyl ester [e.g. (C2-C6)alkynyl ester (e.g. ethynyl ester, propynyl ester, etc.)];

ar(lower)alkyl ester which may have one or more suitable substituent(s) [e.g. phenyl(lower)alkyl ester which may have 1 to 4 lower alkoxy, halogen, nitro, hydroxy, lower alkyl, phenyl, or halo(lower)alkyl, (e.g. benzyl ester, 4-methoxybenzyl ester, 4-chlorobenzyl ester, 4-nitrobenzyl ester, phenethyl ester, trityl ester, benzhydryl ester, bis(methoxyphenyl)methyl ester, 3,4-dimethoxybenzyl ester, 4-hydroxy-3,5-di-tert-butylbenzyl ester, 4-trifluoromethylbenzyl ester, etc.)];

aryl ester which may have one or more suitable substituent(s) [e.g. phenyl ester which may have 1 to 4 lower alkyl, or halogen, (e.g. phenyl ester, 4-chlorophenyl ester, tolyl ester, 4-tert-butylphenyl ester, xylyl ester, mesityl ester, cumenyl ester, etc.)];

cycloalkyloxycarbonyloxy(lower)alkyl ester which may have lower alkyl (e.g., cyclopentyloxycarbonyloxymethyl ester, cyclohexyloxycarbonyloxymethyl ester, cycloheptyloxycarbonyloxymethyl ester, 1-methylcyclohexyloxycarbonyloxymethyl ester, 1-(or 2)-[cyclopentyloxycarbonyloxy]ethyl ester, 1-(or 2)-[cyclohexyloxycarbonyloxy]ethyl ester, 1-(or 2)-[cycloheptyloxycarbonyloxy]ethyl ester, etc.), etc.];

(5-(lower)alkyl-2-oxo-1,3-dioxol-4-yl)(lower)alkyl ester [e.g., (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl ester, (5-ethyl-2-oxo-1,3-dioxol-4-yl)methyl ester, (5-propyl-2-oxo-1,3-dioxol-4-yl)methyl ester, 1-(or 2)-(5-methyl-2-oxo-1,3-dioxol-4-yl)ethyl ester, 1-(or 2)-(5-ethyl-2-oxo-1,3-dioxol-4-yl)ethyl ester, 1-(or 2)-(5-propyl-2-oxo-1,3-dioxol-4-yl)ethyl ester, etc.]; or the like,

in which the preferred one may be lower alkyl ester, lower alkanoyloxy(lower)alkyl ester, ar(lower)alkyl ester which may have one or more suitable substituent(s), cycloalkyloxycarbonyloxy(lower)alkyl ester which may have

lower alkyl, higher alkyl ester, and [5-(lower)alkyl-2-oxo-1,3-dioxol-4-yl](lower)alkyl ester;

and the more preferred one may be methyl ester, ethyl ester, isobutyl ester, butyl ester, pentyl ester, hexyl ester, benzyl ester, 4-trifluoromethylbenzyl ester, 4-chlorobenzyl ester, adamantyl ester, (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl ester, (1-cyclohexyloxycarbonyloxy)ethyl ester and pivaloyloxymethyl ester.

Suitable "lower alkanyl-ylidene" may include straight or branched one such as methine, 1-ethanyl-2-ylidene, 1-propanyl-3-ylidene, 2-methyl-1-propanyl-3-ylidene, 7-pentanyl-5-ylidene, 1-hexanyl-6-ylidene and the like, in which the preferred one may be (C1-C4)alkanyl-ylidene; and the more preferred one may be methine.

Suitable "lower alkylene" may include straight or branched one such as methylene, ethylene, trimethylene, tetramethylene, pentamethylene, hexamethylene, methylmethylene, 1-ethylethylene, 2-ethylpropylene, and the like, in which the preferred one may be (C1-C4)alkylene; and the more preferred one may be methylene, ethylene and trimethylene.

Suitable "lower alkenylene" may include straight or branched one having 2 to 6 carbon atom(s) such as vinylene, propenylené, butenylené, 1 or 2 or 3-pentenylene, 1 or 2 or 3-hexenylené, methylvinylene, ethylvinylene, 1 or 2 or 3-methylpropenylené, 1 or 2 or 3-ethylpropenylené, 1 or 2 or 3 or 4-methyl-1 or 2-butenylene, or the like.

Suitable "amino protective group" may include acyl group as explained below, a conventional protecting group such as ar(lower)alkyl which may have 1 to 3 suitable substituent(s) (e.g. benzyl, phenethyl, 1-phenylethyl, benzhydryl, trityl, etc.), [5-(lower)alkyl-2-oxo-1,3-dioxol-4-yl](lower)alkyl [e.g. (5-methyl-2-oxo-

1,3-dioxol-4-yl)methyl, etc.] or the like; and the like.

Suitable "acyl group" and "acyl" may include aliphatic acyl, aromatic acyl, arylaliphatic acyl and heterocyclic-aliphatic acyl derived from carboxylic acid, carbonic acid, carbamic acid, sulfonic acid, and the like.

Suitable example of said "acyl group" may be illustrated as follows.

Aliphatic acyl such as lower or higher alkanoyl (e.g., formyl, acetyl, propanoyl, butanoyl, 2-methylpropanoyl, pentanoyl, 2,2-dimethylpropanoyl, hexanoyl, heptanoyl, octanoyl, nonanoyl, decanoyl, undecanoyl, dodecanoyl, tridecanoyl, tetradecanoyl, pentadecanoyl, hexadecanoyl, heptadecanoyl, octadecanoyl, nonadecanoyl, icosanoyl, etc.);

lower or higher alkoxycarbonyl (e.g., methoxycarbonyl, ethoxycarbonyl, t-butoxycarbonyl, t-pentyloxycarbonyl, heptyloxycarbonyl, etc.);

lower or higher alkylsulfonyl (e.g., methylsulfonyl, ethylsulfonyl, etc.);

lower or higher alkoxysulfonyl (e.g., methoxysulfonyl, ethoxysulfonyl, etc.); or the like;

Aromatic acyl such as

aroyl (e.g., benzoyl, toluoyl, naphthoyl, etc.);

ar(lower)alkanoyl [e.g., phenyl(C1-C6)alkanoyl (e.g., phenylacetyl, phenylpropanoyl, phenylbutanoyl, phenylisobutanoyl, phenylpentanoyl, phenylhexanoyl, etc.), naphthyl(C1-C6)alkanoyl (e.g., naphthylacetyl, naphthylpropanoyl, naphthylbutanoyl, etc.), etc.];

ar(lower)alkenoyl [e.g., phenyl(C3-C6)alkenoyl (e.g., phenylpropenoyl, phenylbutenoyl, phenylmethacryloyl, phenylpentenoyl, phenylhexenoyl, etc.), naphthyl(C3-C6)alkenoyl (e.g., naphthylpropenoyl, naphthylbutenoyl, etc.), etc.];

ar(lower)alkoxycarbonyl [e.g., phenyl(C1-C6)alkoxycarbonyl (e.g., benzyloxycarbonyl, etc.), etc.];

aryloxycarbonyl (e.g., phenoxycarbonyl,
naphthyloxycarbonyl, etc.);

aryloxy(lower)alkanoyl (e.g., phenoxyacetyl,
phenoxypropionyl, etc.);

5 arylcarbamoyl (e.g., phenylcarbamoyl, etc.);

arylthiocarbamoyl (e.g., phenylthiocarbamoyl, etc.);

arylglyoxyloyl (e.g., phenylglyoxyloyl,
naphthylglyoxyloyl, etc.);

10 arylsulfonyl which may have 1 to 4 lower alkyl (e.g.,
phenylsulfonyl, p-tolylsulfonyl, etc.); or the like;

Heterocyclic acyl such as

heterocycliccarbonyl;

15 heterocyclic(lower)alkanoyl (e.g., heterocyclicacetyl,
heterocyclicpropanoyl, heterocyclicbutanoyl,
heterocyclicpentanoyl, heterocyclichexanoyl, etc.);

heterocyclic(lower)alkenoyl (e.g., heterocyclicpropenoyl,
heterocyclicbutenoyl, heterocyclicpentenoyl,
heterocyclichexenoyl, etc.);

20 heterocyclicglyoxyloyl; or the like;

in which suitable "heterocyclic moiety" in the terms
"heterocycliccarbonyl", "heterocyclic(lower)alkyl",
"heterocyclic(lower)alkenoyl" and "heterocyclicglyoxyloyl"
as mentioned above means, in more detail, saturated or
25 unsaturated monocyclic or polycyclic heterocyclic group
containing at least one hetero-atom such as an oxygen,
sulfur, nitrogen atom and the like.

And, especially preferable heterocyclic group may be
heterocyclic group such as

30 unsaturated 3 to 8-membered (more preferably 5 or
6-membered) heteromonocyclic group containing 1 to 4
nitrogen atom(s), for example, pyrrolyl, pyrrolinyl,
imidazolyl, pyrazolyl, pyridyl, dihydropyridyl, pyrimidyl,
pyrazinyl, pyridazinyl, triazolyl (e.g., 4H-1,2,4-
35 triazolyl, 1H-1,2,3-triazolyl, 2H-1,2,3-triazolyl, etc.),
tetrazolyl (e.g., 1H-tetrazolyl, 2H-tetrazolyl, etc.),

etc.;

saturated 3 to 8-membered (more preferably 5 or 6-membered) heteromonocyclic group containing 1 to 4 nitrogen atom(s), for example, pyrrolidinyl, imidazolidinyl, piperidyl, piperazinyl, etc.;

unsaturated condensed heterocyclic group containing 1 to 4 nitrogen atom(s), for example, indolyl, isoindolyl, indolinyl, indolizinyl, benzimidazolyl, quinolyl, dihydroquinolyl, isoquinolyl, indazolyl, quinoxalinyl, dihydroquinoxalinyl, benzotriazolyl, etc.;

unsaturated 3 to 8-membered (more preferably 5 or 6-membered) heteromonocyclic group containing 1 to 2 oxygen atom(s) and 1 to 3 nitrogen atom(s), for example, oxazolyl, isoxazolyl, oxadiazolyl (e.g., 1,2,4-oxadiazolyl, 1,3,4-oxadiazolyl, 1,2,5-oxadiazolyl, etc.), etc.;

saturated 3 to 8-membered (more preferably 5 or 6-membered) heteromonocyclic group containing 1 to 2 oxygen atom(s) and 1 to 3 nitrogen atom(s), for example, morpholinyl, sydnonyl, etc.;

unsaturated condensed heterocyclic group containing 1 to 2 oxygen atom(s) and 1 to 3 nitrogen atom(s), for example, benzoxazolyl, benzoxadiazolyl, etc.;

unsaturated 3 to 8-membered (more preferably 5 or 6-membered) heteromonocyclic group containing 1 to 2 sulfur atom(s) and 1 to 3 nitrogen atom(s), for example, thiazolyl, isothiazolyl, thiadiazolyl (e.g., 1,2,3-thiadiazolyl, 1,2,4-thiadiazolyl, 1,3,4-thiadiazolyl, 1,2,5-thiadiazolyl, etc.), dihydrothiazinyl, etc.;

saturated 3 to 8-membered (more preferably 5 or 6-membered) heteromonocyclic group containing 1 to 2 sulfur atom(s) and 1 to 3 nitrogen atom(s), for example, thiazolidinyl, etc.;

unsaturated 3 to 8-membered (more preferably 5 or 6-membered) heteromonocyclic group containing 1 to 2 sulfur

atom(s), for example, thienyl, dihydrodithiinyl, dihydrodithionyl, etc.;

unsaturated condensed heterocyclic group containing 1 to 2 sulfur atom(s) and 1 to 3 nitrogen atom(s), for example, benzothiazolyl, benzothiadiazolyl, etc.;

unsaturated 3 to 8-membered (more preferably 5 or 6-membered) heteromonocyclic group containing an oxygen atom, for example, furyl, etc.;

unsaturated 3 to 8-membered (more preferably 5 or 6-membered) heteromonocyclic group containing an oxygen atom and 1 to 2 sulfur atom(s), for example, dihydrooxathiinyl, etc.;

unsaturated condensed heterocyclic group containing 1 to 2 sulfur atom(s), for example, benzothienyl, benzodithiinyl, etc.;

unsaturated condensed heterocyclic group containing an oxygen atom and 1 to 2 sulfur atom(s), for example, benzoxathiinyl, etc.; and the like.

The acyl moiety as mentioned above may have one to ten, same or different, suitable substituent(s) such as lower alkyl (e.g., methyl, ethyl, propyl, etc.); lower alkoxy (e.g., methoxy, ethoxy, propoxy, etc.); lower alkylthio (e.g., methylthio, ethylthio, etc.); lower alkylamino (e.g., methylamino, ethylamino, propylamino, etc.);

cyclo(lower)alkyl [e.g. cyclo(C3-C6)alkyl (e.g., cyclopentyl, cyclohexyl, etc.)];

cyclo(lower)alkenyl [e.g. cyclo(C3-C6)alkenyl (e.g., cyclohexenyl, cyclohexadienyl, etc.)];

halogen (e.g., fluorine, chlorine, bromine, iodine); amino; amino protective group as mentioned above; hydroxy; protected hydroxy as mentioned below; cyano; nitro; carboxy; protected carboxy as mentioned above; sulfo; sulfamoyl; imino; oxo;

amino(lower)alkyl (e.g., aminomethyl, aminoethyl, etc.);

carbamoyloxy; hydroxy(lower)alkyl (e.g., hydroxymethyl, 1 or 2-hydroxyethyl, 1 or 2 or 3-hydroxypropyl, etc.), or the like.

Suitable "protected hydroxy" may include acyl as mentioned above, phenyl(lower)alkyl which may have one or more suitable substituent(s) (e.g., benzyl, 4-methoxybenzyl, trityl, etc.), trisubstituted silyl [e.g., tri(lower)alkylsilyl (e.g., trimethylsilyl, t-butyldimethylsilyl, etc.), etc.], tetrahydropyranyl and the like.

The more preferred example of "amino protective group" may be lower alkoxycarbonyl or ar(lower)alkoxycarbonyl and the most preferred one may be t-butoxycarbonyl or benzyloxycarbonyl.

Suitable "lower alkylene" in the term "lower alkylene which may have one or more suitable substituent(s)" can be referred to the ones as exemplified above.

Suitable example of "suitable substituent(s)" in the term "lower alkylene which may have one or more suitable substituent(s)" may include lower alkyl (e.g., methyl, ethyl, propyl, isopropyl, butyl, isobutyl, t-butyl, pentyl, neopentyl, t-pentyl, hexyl, etc.);

lower alkoxy (e.g., methoxy, ethoxy, propoxy, isopropoxy, isobutoxy, t-butoxy, pentyloxy, neopentyloxy, t-pentyloxy, hexyloxy, etc.);

lower alkenyl [e.g. (C2-C6)alkenyl (e.g., vinyl, 1-propenyl, allyl, 1-methylallyl, 1 or 2 or 3-butenyl, 1 or 2 or 3 or 4-pentenyl, 1 or 2 or 3 or 4 or 5-hexenyl, etc.)];

lower alkynyl [e.g. (C2-C6)alkynyl (e.g., ethynyl, 1-propynyl, propargyl, 1-methylpropargyl, 1-ethylpropargyl, 1 or 2 or 3-butylnyl, 1 or 2 or 3 or 4-pentylnyl, 1 or 2 or 3 or 4 or 5 hexynyl, etc.)];

mono(or di or tri)halo(lower)alkyl (e.g., fluoromethyl, difluoromethyl, trifluoromethyl, chloromethyl,

dichloromethyl, trichloromethyl, bromomethyl,
dibromomethyl, tribromomethyl, 1 or
2-fluoroethyl, 1 or 2-bromoethyl, 1 or 2-chloroethyl,
1,1-difluoroethyl, 2,2-difluoroethyl, etc.);
5 halogen (e.g., chlorine, bromine, fluorine, iodine);
carboxy; protected carboxy as mentioned above; hydroxy;
protected hydroxy as mentioned above;
aryl (e.g., phenyl, naphthyl, etc.);
heterocyclic group as mentioned above [e.g. unsaturated
10 condensed heterocyclic group containing 1 to 4 nitrogen
atom(s) (e.g. indolyl, isoindolyl, indolynyl, indolizinyll,
benzimidazolyl, quinolyl, dihydroquinolyl, isoquinolyl,
indazolyl, quinoxalinyll, dihydroquinoxalinyll,
benzotriazolyl, etc.)];
5 ar(lower)alkyl such as phenyl(lower)alkyl (e.g., benzyl,
phenethyl, phenylpropyl, etc.);
ar(lower)alkyl having one or more suitable substituent(s)
such as ar(lower)alkyl having one or more (preferably 1 to
4) lower alkoxy, halogen, cyano, halo(lower)alkyl, lower
20 alkylene dioxy or the like;
carboxy(lower)alkyl; protected carboxy(lower)alkyl;
nitro; amino;
protected amino, i.e. amino protected by aforesaid "amino
protective group", preferably, acylamino, in which acyl
25 moiety can be aforementioned "acyl", such as aliphatic
acylamino such as lower or higher alkanoylamino (e.g.,
formylamino, acetylamino, propanoylamino, butanoylamino,
2-methylpropanoylamino, pentanoylamino, 2,2-
dimethylpropanoylamino, hexanoylamino, heptanoylamino,
30 octanoylamino, nonanoylamino, decanoylamino,
undecanoylamino, dodecanoylamino, tridecanoylamino,
tetradecanoylamino, pentadecanoylamino, hexadecanoylamino,
heptadecanoylamino, octadecanoylamino, nonadecanoylamino,
icosanoylamino, etc.), cyclo(lower)alkylcarbonylamino
35 [e.g. cyclo(C3-C6)alkylcarbonylamino (e.g.

cyclopropylcarbonylamino, cyclobutylcarbonylamino, cyclopentylcarbonylamino, cyclohexylcarbonylamino, etc.)], lower or higher alkoxy carbonylamino (e.g., methoxycarbonylamino, ethoxycarbonylamino, t-butoxycarbonylamino, pentyloxycarbonylamino, heptyloxycarbonylamino, etc.), lower alkoxy(lower)alkanoylamino (e.g. methoxyacetylamino, 2- or 3-methoxypropionylamino, ethoxyacetylamino, 2- or 3-ethoxypropionylamino, etc.), lower alkynylcarbonylamino [e.g. (C2-C6)alkynylcarbonylamino (e.g. propargylcarbonylamino, 1-methylpropargylcarbonylamino, 1- or 2- or 3-butynylcarbonylamino, etc.), lower or higher alkylsulfonylamino (e.g., methylsulfonylamino, ethylsulfonylamino, propylsulfonylamino, n-butylsulfonylamino, sec-butylsulfonylamino, t-butylsulfonylamino, n-pentylsulfonylamino, neo-pentylsulfonylamino, hexylsulfonylamino, etc.), lower or higher alkoxy sulfonylamino (e.g., methoxy-sulfonylamino, ethoxy sulfonylamino, etc.), aroylamino which may have one or more (preferably 1 to 3) suitable substituent(s) (e.g. benzoylamino, toluoylamino, naphthoylamino, 2- or 3- or 4-hydroxybenzoylamino, 2- or 3- or 4-methoxybenzoylamino, 2- or 3- or 4-chlorobenzoylamino, phenylbenzoylamino, etc.), ar(lower)alkanoylamino [e.g., phenyl(C1-C6)alkanoylamino (e.g., phenylacetylamino, phenylpropanoylamino, phenylbutanoylamino, phenylisobutanoylamino, phenylpentanoylamino, phenylhexanoylamino, etc.), naphthyl(lower)alkanoylamino (e.g., naphthylacetylamino, naphthylpropanoylamino, naphthylbutanoylamino, etc.), etc.], ar(lower)alkenoylamino [e.g., phenyl(C3-C6)alkenoylamino (e.g., phenylpropenoylamino, phenylbutenoylamino,

phenylmethacryloylamino, phenylpentenoylamino, phenylhexenoylamino, etc.), naphthyl(C3-C6)alkenoylamino (e.g., naphthylpropenoylamino, naphthylbutenoylamino, etc.), etc.],

5 ar(lower)alkoxycarbonylamino [e.g., phenyl(C1-C6)alkoxy-carbonylamino (e.g. benzyloxycarbonylamino, phenethyloxycarbonylamino, etc.), etc.],
aryloxycarbonylamino (e.g., phenoxycarbonylamino, naphthyloxycarbonylamino, etc.),
aryloxy(lower)alkanoylamino (e.g., phenoxyacetylamino, phenoxypropionylamino, etc.),
arylcarbamoylelamino (e.g., phenylcarbamoylelamino, etc.),
arylthiocarbamoylelamino (e.g., phenylthiocarbamoylelamino, etc.),
arylglyoxyloylamino (e.g., phenylglyoxyloylamino, naphthylglyoxyloylamino, etc.),
arylsulfonylamino (e.g. phenylsulfonylamino, p-tolylsulfonylamino, etc.), or the like;

20 di(lower)alkylamino (e.g., dimethylamino, diethylamino, diisopropylamino, ethylmethylamino, isopropylmethylamino, ethylmethylamino, ethylpropylamino, etc.);

hydroxy(lower)alkyl; protected hydroxy(lower)alkyl; acyl as mentioned above; cyano; mercapto; oxo;

25 lower alkylthio(lower)alkyl (e.g. methylthiomethyl, ethylthiomethyl, propylthiomethyl, isopropylthiomethyl, butylthiomethyl, methylthioethyl, ethylthioethyl, etc.);

arylthio(lower)alkyl (e.g. phenylthiomethyl, phenylthioethyl, etc.);

30 arylsulfonyl(lower)alkyl (e.g. phenylsulfonylmethyl, phenylsulfonylethyl, p-tolylsulfonylmethyl, p-tolylsulfonylethyl, etc.);

35 lower alkylsulfonyl(lower)alkyl (e.g. methylsulfonylmethyl, ethylsulfonylmethyl, propylsulfonylmethyl, etc.);

acylamino(lower)alkyl, in which acyl moiety can be
aforementioned "acyl" [e.g., arylsulfonylamino(lower)alkyl
(e.g., phenylsulfonylaminomethyl,
phenylsulfonylaminoethyl, p-tolylsulfonylaminomethyl,
p-tolylsulfonylethyl, etc.),

lower alkylsulfonylamino(lower)alkyl (e.g.,
methylsulfonylaminomethyl, ethylsulfonylaminomethyl,
propylsulfonylaminomethyl,
butylsulfonylaminomethyl, t-butylsulfonylaminomethyl,
pentylsulfonylaminoethyl, etc.), etc.];

lower alkylcarbonyl(lower)alkyl (e.g.
methylcarbonylmethyl, ethylcarbonylmethyl,
propylcarbonylmethyl, etc.);

aroyl(lower)alkyl (e.g. benzoylmethyl, naphthoylmethyl,
toluoylmethyl, anisoylmethyl, etc.);

heterocyclic(lower)alkyl such as (lower)alkyl having
heterocyclic group as exemplified above [e.g. (C1-C6)alkyl
having unsaturated condensed heterocyclic group containing
1 to 4 nitrogen atom(s) (e.g. indolylethyl,
isoindolylethyl, indolylnylmethyl, indolizinynelethyl,
benzimidazolylmethyl, quinolynelethyl,
dihydroquinolylmethyl, isoquinolylmethyl, indazolylmethyl,
quinoxalinynelethyl, dihydroquinoxalinynelethyl,
benzotriazolylmethyl, etc.)];

lower alkyl sulfamoyl(lower)alkyl (e.g.
methylsulfamoylmethyl, ethylsulfamoylmethyl,
n-propylsulfamoylmethyl, isopropylsulfamoylmethyl,
n-butylsulfamoylmethyl, t-butylsulfamoylmethyl,
methylsulfamoylethyl, etc.);

arylsulfamoyl(lower)alkyl (e.g. phenylsulfamoylmethyl,
tolylsulfamoylmethyl, phenylsulfamoylethyl,
naphthylsulfamoylmethyl, etc.);

lower alkylcarbamoyl(lower)alkyl (e.g.
methylcarbamoylmethyl, ethylcarbamoylmethyl,
n-propylcarbamoylmethyl, isopropylcarbamoylmethyl,

n-butylcarbamoylmethyl, t-butylcarbamoylmethyl,
methylcarbamoylethyl, etc.);

arylcarbamoyl(lower)alkyl (e.g. phenylcarbamoylmethyl,
tolylcarbamoylmethyl, phenylcarbamoylethyl,
naphthylcarbamoylmethyl, etc.);

ar(lower)alkylcarbamoyl which may have one or more
suitable substituent(s) [e.g. phenyl(C1-C6)alkylcarbamoyl
which may have 1 to 3 lower alkoxy (e.g. 2-
methoxyphenethylcarbamoyl, 3-methoxyphenethylcarbamoyl, 4-
methoxyphenethylcarbamoyl, etc.) and the like,

in which the more preferred one may be (C1-C6)alkyl; (C2-
C6)alkenyl; (C2-C6)alkynyl; phenyl; phenyl(C1-C6)alkyl;
phenyl(C1-C6)alkyl having 1 to 4 (C1-C6)alkoxy, halo(C1-
C6)alkyl or (C1-C6)alkylene dioxy; (C1-C6)alkyl having
unsaturated condensed heterocyclic group containing 1 to 4
nitrogen atom(s); cyano; amino; (C1-C6)alkanoylamino;
aroylamino which may have 1 to 3 hydroxy, (C1-C6)alkoxy,
halogen or phenyl; cyclo(C3-C6)alkylcarbonylamino; (C1-
C6)alkoxy(C1-C6)alkylcarbonylamino; (C2-
C6)alkynylcarbonylamino; (C1-C6)alkylsulfonylamino;
phenylsulfonylamino; phenyl(C1-C6)alkylcarbamoyl;

and the more preferred one may be methyl, ethyl, vinyl,
ethynyl, cyano, phenyl, phenethyl,
2-methoxyphenethyl, 3-methoxyphenethyl,
4-methoxyphenethyl, 3,4-dimethoxyphenethyl,
3-trifluoromethylphenethyl, 3,4-methylenedioxyphenethyl,
2-indolyethyl, 4-methoxyphenethylcarbamoyl,
phenylsulfonylamino, n-butylsulfonylaminomethyl,
benzoylamino, amino, acetylamino, p-hydroxybenzoylamino,
p-methoxybenzoylamino, p-chlorobenzoylamino,
n-butanoylamino, cyclopropylcarbonylamino,
3-methoxypropionylamino, biphenylcarbonylamino and
propargylcarbonylamino.

Suitable "N-containing heterocyclic group" may

include saturated or unsaturated monocyclic or polycyclic heterocyclic group containing at least nitrogen atom and which may also contain the other hetero-atom such as an oxygen, sulfur atom or the like.

5 And, especially preferable N-containing heterocyclic group may be heterocyclic group such as

10 unsaturated 3 to 8-membered (more preferably 5 or 6-membered) heteromonocyclic group containing 1 to 4 nitrogen atom(s), for example, pyrrolyl, pyrrolinyl, imidazolyl, pyrazolyl, pyridyl, dihydropyridyl, pyrimidyl, pyrazinyl, pyridazinyl, triazolyl (e.g., 4H-1,2,4-triazolyl, 1H-1,2,3-triazolyl, 2H-1,2,3-triazolyl, etc.), tetrazolyl (e.g., 1H-tetrazolyl, 2H-tetrazolyl, etc.), etc.;

15 saturated 3 to 8-membered (more preferably 5 or 6-membered) heteromonocyclic group containing 1 to 4 nitrogen atom(s), for example, pyrrolidinyl, imidazolidinyl, piperidyl, piperazinyl, etc.;

20 unsaturated condensed heterocyclic group containing 1 to 4 nitrogen atom(s), for example, indolyl, isoindolyl, indolinyl, indolizinyll, benzimidazolyl, quinolyl, tetrahydroquinolyl (e.g. 1,2,3,4-tetrahydroquinolyl, etc.), dihydroquinolyl, isoquinolyl, indazolyl, quinoxalinyl, dihydroquinoxalinyl, benzotriazolyl, etc.;

25 unsaturated 3 to 8-membered (more preferably 5 or 6-membered) heteromonocyclic group containing 1 to 2 oxygen atom(s) and 1 to 3 nitrogen atom(s), for example, oxazolyl, isoxazolyl, oxadiazolyl (e.g., 1,2,4-oxadiazolyl, 1,3,4-oxadiazolyl, 1,2,5-oxadiazolyl, etc.), etc.;

30 saturated 3 to 8-membered (more preferably 5 or 6-membered) heteromonocyclic group containing 1 to 2 oxygen atom(s) and 1 to 3 nitrogen atom(s), for example, morpholinyl, sydnonyl, etc.;

35 unsaturated condensed heterocyclic group containing 1

to 2 oxygen atom(s) and 1 to 3 nitrogen atom(s), for example, benzoxazolyl, benzoxadiazolyl, etc.;

unsaturated 3 to 8-membered (more preferably 5 or 6-membered) heteromonocyclic group containing 1 to 2 sulfur atom(s) and 1 to 3 nitrogen atom(s), for example, thiazolyl, isothiazolyl, thiadiazolyl (e.g., 1,2,3-thiadiazolyl, 1,2,4-thiadiazolyl, 1,3,4-thiadiazolyl, 1,2,5-thiadiazolyl, etc.), dihydrothiazinyl, etc.;

saturated 3 to 8-membered (more preferably 5 or 6-membered) heteromonocyclic group containing 1 to 2 sulfur atom(s) and 1 to 3 nitrogen atom(s), for example, thiomorpholinyl, thiazolidinyl, etc.;

unsaturated condensed heterocyclic group containing 1 to 2 sulfur atom(s) and 1 to 3 nitrogen atom(s), for example, benzothiazolyl, benzothiadiazolyl, etc. and the like,

in which the preferred one may be saturated 5 or 6-membered heteromonocyclic group containing 1 to 4 nitrogen atom(s), unsaturated condensed heterocyclic group containing 1 to 4 nitrogen atom(s), or saturated 5 or 6-membered heteromonocyclic group containing 1 to 2 oxygen atom(s) and 1 to 3 nitrogen atom(s);

and the more preferred one may be piperidyl, pyrrolidinyl, morpholinyl and 1,2,3,4-tetrahydroquinolyl.

Suitable "N-containing cyclo(lower)alkyl" in the term "N-containing cyclo(lower)alkyl which may have one or more suitable substituent(s)" may include 3 to 8-membered cycloalkyl containing 1 to 3 nitrogen atom(s), for example, azetidiny, pyrrolidinyl, piperidyl, piperazinyl, etc..

Suitable "suitable substituent(s)" in the term "N-containing cyclo(lower)alkyl which may have one or more suitable substituent(s)" may include oxo, amino protective group as mentioned above.


Suitable "suitable substituent(s)" in the term "lower alkylene, lower alkanyl-ylidene or lower alkenylene each of which may have one or more suitable substituent(s)" may include lower alkyl or oxo.

Suitable "suitable substituent(s)" in the term "N-containing heterocyclic group which may have one or more suitable substituent(s)" may include lower alkyl, phenyl, halogen or oxo.

Suitable "lower alkynylene" may include the ones having 2 to 6 carbon atoms such as ethynylene, 2-propynylene, 2- or 3-butynylene, 2- or 3- or 4-pentynylene or 2- or 3- or 4- or 5-hexynylene.

In the compound (I) as explained above, the preferred one is the following compound (I-A) :

Compound (I-A) :



wherein R^1 is 3 to 8 membered cycloalkyl containing 1 to 3 nitrogen atom(s) which may have one or more suitable substituent(s),


R^2 is carboxy or esterified carboxy,

A^1 is lower alkylene, lower alkanyl-ylidene or lower alkenylene, each of which may have one or more suitable substituent(s),

A^2 is lower alkylene,

A^3 is lower alkylene which may have one or more suitable substituent(s),


 is a group of the formula:



wherein is saturated 3 to 8 membered heteromonocyclic group containing 1 to 4 nitrogen atom(s) which may have one or more suitable substituent(s), unsaturated condensed heterocyclic group containing 1 to 4 nitrogen atom(s) which may have one or more suitable substituent(s) or saturated 3 to 8-membered heteromonocyclic group containing 1 to 2 oxygen atom(s) and 1 to 3 nitrogen atom(s) which may have one or more suitable substituent(s),

X is O, S, or NH,

Y is NH,



(wherein R^3 is hydrogen or lower alkyl),


ℓ is an integer of 0 or 1,

m is an integer of 0 or 1,

n is an integer of 0 or 1,

and the more preferred one is the aforementioned compound (I-A),

wherein R^1 is piperidyl which may have 1 or 2 oxo or [5-(lower)alkyl-2-oxo-1,3-dioxol-4-yl]-(lower)alkyl,



is piperidyl, morpholinyl,

tetrahydroquinolyl or pyrrolydinyll,

A^3 is lower alkylene which may have 1 to 3 suitable substituent(s) selected from the group consisting of (C1-C6)alkyl;, (C2-C6)alkenyl; (C2-C6)alkynyl; phenyl;

phenyl(C1-C6)alkyl; phenyl(C1-C6)alkyl
having 1 to 4 (C1-C6)alkoxy, halo(C1-
C6)alkyl or (C1-C6)alkylene dioxy; (C1-
C6)alkyl having unsaturated condensed
heterocyclic group containing 1 to 4
nitrogen atom(s); cyano; amino; (C1-
C6)alkanoylamino; aroylamino which may have
1 to 3 hydroxy, (C1-C6)alkoxy, halogen or
phenyl; cyclo(C3-C6)alkylcarbonylamino;
(C1-C6)alkoxy(C1-C6)alkylcarbonylamino;
(C2-C6)alkynylcarbonylamino; (C1-
C6)alkylsulfonylamino; phenylsulfonylamino;
and phenyl(C1-C6)alkylcarbonyl;

R^2 , R^3 , A^1 , A^2 , X, Y or Z are each as defined
above,


ℓ is an integer of 0,
 m is an integer of 0,
 n is an integer of 0,

and the much more preferred one is the aforementioned
compound (I-A),

wherein R^1 is piperidyl,

A^1 is lower alkylene or lower alkanyl-ylidene,

A^3 is lower alkylene which may have lower alkyl,
lower alkynyl or lower alkanoylamino,




R^2 , R^3 , A^2 , Y, ℓ , m and n are each as defined in
the more preferred one,

and the another much more preferred one is the
aforementioned compound (I-A),

wherein R^1 is piperidyl,

A^1 is lower alkylene or lower alkanyl-ylidene,


A³ is lower alkylene which may have lower alkyl, lower alkynyl or lower alkanoylamino,




R², R³, A², Y, ℓ, m and n are each as defined in the more preferred one.


In the compound (I) as explained above, another preferred one is the following compound (I-B) :


Compound (I-B) :



wherein R¹ is N-containing cycloalkyl which may have one or more suitable substituent(s),
 R² is carboxy or esterified carboxy,
 A¹ is lower alkylene, lower alkanyl-ylidene or lower alkenylene, each of which may have one or more suitable substituent(s),
 A² is lower alkylene,
 A³ is lower alkylene which may have one or more suitable substituent(s),


 is a group of the formula:



wherein  is N-containing heterocyclic group which may have one or more suitable substituent(s),

X is O,

Y is NH,

Z is $\begin{array}{c} \text{---}(\text{C}-\text{N})\text{---} \\ \parallel \quad | \\ \text{O} \quad \text{R}^3 \end{array}$, $\begin{array}{c} \text{---}(\text{N}-\text{C})\text{---} \\ | \quad \parallel \\ \text{R}^3 \text{O} \end{array}$ and $\begin{array}{c} \text{---}(\text{C})\text{---} \\ \parallel \\ \text{O} \end{array}$

(wherein R³ is hydrogen or lower alkyl),


l is an integer of 1,

m is an integer of 0 or 1,

n is an integer of 0 or 1,

and the more preferred one is the aforementioned compound (I-B),

wherein R¹ is piperidyl, piperazinyl or azetidiny, each of which may have 1 or 2 oxo or [5-(lower)alkyl-2-oxo-1,3-dioxol-4-yl]-(lower)alkyl,



is piperidyl, morpholinyl,

tetrahydroquinolyl or pyrrolydiny,

A³ is lower alkylene which may have 1 to 3 suitable substituent(s) selected from the group consisting of (C1-C6)alkyl; (C2-C6)alkenyl; (C2-C6)alkynyl; phenyl; phenyl(C1-C6)alkyl; phenyl(C1-C6)alkyl having 1 to 4 (C1-C6)alkoxy, halo(C1-C6)alkyl or (C1-C6)alkylene dioxy; (C1-C6)alkyl having unsaturated condensed heterocyclic group containing 1 to 4 nitrogen atom(s); cyano; amino; (C1-C6)alkanoylamino; aroylamino which may have 1 to 3 hydroxy, (C1-C6)alkoxy, halogen or phenyl; cyclo(C3-C6)alkanoylamino; (C1-

C6)alkoxy(C1-C6)alkylcarbonylamino; (C2-C6)alkynylcarbonylamino; (C1-C6)alkysulfonylamino; phenylsulfonylamino; and phenyl(C1-C6)alkylcarbonyl;

R^2 , R^3 , A^1 , A^2 , X , Y , Z or ℓ are each as defined above,

m is an integer of 0,


n is an integer of 0,

and the much more preferred one is the aforementioned compound (I-B),

wherein R^1 is piperidyl,

A^1 is lower alkylene,

A^3 is lower alkylene which may have lower alkyl, lower alkynyl or lower alkanoylamino,




R^2 , R^3 , A^2 , X , Y , ℓ , m and n are each as defined in the more preferred one.

and the much more preferred one is the aforementioned compound (I-B),

wherein R^1 is piperidyl,


A^1 is lower alkylene,

A^3 is lower alkylene which may have lower alkyl, lower alkynyl or lower alkanoylamino,



R^2 , R^3 , A^2 , X , Y , ℓ , m and n are each as defined in the more preferred one.

5



25




ℓ is 0,

n is an integer of 0 or 1,

35

wherein A³ is lower alkylene having lower alkynyl or lower alkanoylamino,



is piperidyl or morpholinyl,

R¹, R², R³, A¹, A², X, Y, Z, and ℓ are each as defined above.

m is an integer of 0,

n is an integer of 0.

The processes for preparing the object compound (I) of the present invention are explained in detail in the following.

Process 1

The object compound (Ia) or a salt thereof can be prepared by reacting a compound (II) or its reactive derivative at the carboxy group or a salt thereof with a compound (III) or its reactive derivative at the amino group or a salt thereof.

Suitable reactive derivative at the carboxy group of the compound (II) may include an acid halide, an acid anhydride, an activated amide, an activated ester, and the like. Suitable examples of the reactive derivatives may be an acid chloride; an acid azide; a mixed acid anhydride with an acid such as substituted phosphoric acid [e.g. dialkylphosphoric acid, phenylphosphoric acid, diphenylphosphoric acid, dibenzylphosphoric acid, halogenated phosphoric acid, etc.], dialkylphosphorous acid, sulfurous acid, thiosulfuric acid, sulfuric acid, sulfonic acid [e.g. methanesulfonic acid, etc.], aliphatic carboxylic acid [e.g. acetic acid, propionic acid, butyric acid, isobutyric acid, pivalic acid, pentanoic acid, isopentanoic acid, 2-ethylbutyric acid, trichloroacetic acid, etc.] or aromatic carboxylic acid [e.g. benzoic

acid, etc.]; a symmetrical acid anhydride; an activated amide with imidazole, 4-substituted imidazole, dimethylpyrazole, triazole, tetrazole or 1-hydroxy-1H-benzotriazole; or an activated ester [e.g. cyanomethyl ester, methoxymethyl ester, dimethyliminomethyl $[(CH_3)_2\overset{+}{N}=C-]$ ester, vinyl ester, propargyl ester, p-nitrophenyl ester, 2,4-dinitrophenyl ester, trichlorophenyl ester, pentachlorophenyl ester, mesylphenyl ester, phenylazophenyl ester, phenyl thioester, p-nitrophenyl thioester, p-cresyl thioester, carboxymethyl thioester, pyranyl ester, pyridyl ester, piperidyl ester, 8-quinolyl thioester, etc.], or an ester with a N-hydroxy compound [e.g. N,N-dimethylhydroxylamine, 1-hydroxy-2-(1H)-pyridone, N-hydroxysuccinimide, N-hydroxyphthalimide, 1-hydroxy-1H-benzotriazole, etc.], and the like. These reactive derivative can optionally be selected from them according to the kind of the compound (II) to be used.

Suitable salts of the compound (II) and its reactive derivative can be referred to the ones as exemplified for the compound (I).

Suitable reactive derivative at the amino group of the compound (III) may include Schiff's base type imino or its tautomeric enamine type isomer formed by the reaction of the compound (III) with a carbonyl compound such as aldehyde, ketone or the like; a silyl derivative formed by the reaction of the compound (III) with a silyl compound such as bis(trimethylsilyl)acetamide, mono(trimethylsilyl)acetamide, bis(trimethylsilyl)urea or the like; a derivative formed by reaction of the compound (III) with phosphorus trichloride or phosgene, and the like.

Suitable salts of the compound (III) and its reactive derivative can be referred to the ones as exemplified for the compound (I).

The reaction is usually carried out in a conventional solvent such as water, alcohol [e.g. methanol, ethanol, etc.], acetone, dioxane, acetonitrile, chloroform, methylene chloride, ethylene chloride, tetrahydrofuran, ethyl acetate, N,N-dimethylformamide, pyridine or any other organic solvent which does not adversely influence the reaction. These conventional solvent may also be used in a mixture with water.

In this reaction, when the compound (II) is used in a free acid form or its salt form, the reaction is preferable carried out in the presence of a conventional condensing agent such as N,N'-dicyclohexylcarbodiimide; N-cyclohexyl-N'-morpholinoethylcarbodiimide; N-cyclohexyl-N'-(4-diethylaminocyclohexyl)carbodiimide; N,N'-diethylcarbodiimide, N,N'-diisopropylcarbodiimide; N-ethyl-N'-(3-dimethylaminopropyl)carbodiimide; N,N'-carbonylbis-(2-methylimidazole); pentamethyleneketene-N-cyclohexylimine; diphenylketene-N-cyclohexylimine; ethoxyacetylene; 1-alkoxy-1-chloroethylene; trialkylphosphite; ethyl polyphosphate; isopropyl polyphosphate; phosphorous oxychloride (phosphoryl chloride); phosphorus trichloride; thionyl chloride; oxalyl chloride; lower alkyl haloformate [e.g. ethyl chloroformate, isopropyl chloroformate, etc.]; triphenylphosphine; 2-ethyl-7-hydroxybenzisoxazolium salt; 2-ethyl-5-(m-sulfophenyl)isoxazolium hydroxide intramolecular salt; 1-(p-chlorobenzenesulfonyloxy)-6-chloro-1H-benzotriazole; so-called Vilsmeier reagent prepared by the reaction of N,N-dimethylformamide with thionyl chloride, phosgene, trichloromethyl chloroformate, phosphorus oxychloride, methanesulfonyl chloride, etc.; or the like.

The reaction may also be carried out in the presence of an inorganic or organic base such as an alkali metal carbonate, alkali metal bicarbonate, tri(lower)alkylamine,

pyridine, N-(lower)alkylmorpholine,
N,N-di(lower)alkylbenzylamine, or the like.

The reaction temperature is not critical, and the
reaction is usually carried out under cooling to warming.

Process 2

The object compound (Ib) or a salt thereof can be
prepared by reacting a compound (IV) or its reactive
derivative at the carboxy group or a salt thereof with a
compound (V) or its reactive derivative at the amino group
or a salt thereof.

This reaction can be carried out in a similar manner
to that of Process 1 mentioned in the above, and therefore
the reaction mode and reaction conditions [e.g. reactive
derivative, solvent, reaction temperature, etc.] of this
reaction are to be referred to those as explained in
Process 1.

Process 3

The object compound (Ic) or a salt thereof can be
prepared by reacting a compound (VII) or its reactive
derivative at the carboxy group or a salt thereof with a
compound (VI) or its reactive derivative at the amino
group or a salt thereof.

This reaction can be carried out in a similar manner
to that of Process 1 mentioned in the above, and therefore
the reaction mode and reaction conditions [e.g. reactive
derivative, solvent, reaction temperature, etc.] of this
reaction are to be referred to those as explained in
Process 1.

Process 4

The object compound (Ie) or a salt thereof can be
prepared by subjecting a compound (Id) or a salt thereof
to elimination reaction of amino protective group.

This reaction is carried out in accordance with a conventional method such as hydrolysis, reduction or the like.

The hydrolysis is preferably carried out in the presence of a base or an acid including Lewis acid.

Suitable base may include an inorganic base and an organic base such as an alkali metal [e.g. sodium, potassium, etc.], an alkaline earth metal [e.g. magnesium, calcium, etc.], the hydroxide or carbonate or bicarbonate thereof, trialkylamine [e.g. trimethylamine, triethylamine, etc.], picoline, 1,5-diazabicyclo[4.3.0]non-5-ene, 1,4-diazabicyclo[2.2.2]octane, 1,8-diazabicyclo[5.4.0]undec-7-ene, or the like.

Suitable acid may include an organic acid [e.g. formic acid, acetic acid, propionic acid, trichloroacetic acid, trifluoroacetic acid, etc.] and an inorganic acid [e.g. hydrochloric acid, hydrobromic acid, sulfuric acid, hydrogen chloride, hydrogen bromide, etc.].

The elimination using Lewis acid such as trihaloacetic acid [e.g. trichloroacetic acid, trifluoroacetic acid, etc.] or the like is preferably carried out in the presence of cation trapping agents [e.g. anisole, phenol, etc.].

The reaction is usually carried out in a solvent such as water, an alcohol [e.g. methanol, ethanol, etc.], methylene chloride, tetrahydrofuran, a mixture thereof or any other solvent which does not adversely influence the reaction. A liquid base or acid can be also used as the solvent. The reaction temperature is not critical and the reaction is usually carried out under cooling to warming.

The reduction method applicable for the elimination reaction may include chemical reduction and catalytic reduction.

Suitable reducing agents to be used in chemical

reduction are a combination of metal [e.g. tin, zinc, iron, etc.] or metallic compound [e.g. chromium chloride, chromium acetate, etc.] and an organic or inorganic acid [e.g. formic acid, acetic acid, propionic acid, trifluoroacetic acid, p-toluenesulfonic acid, hydrochloric acid, hydrobromic acid, etc.].

Suitable catalysts to be used in catalytic reduction are conventional ones such as platinum catalysts [e.g. platinum plate, spongy platinum, platinum black, colloidal platinum, platinum oxide, platinum wire, etc.], palladium catalysts [e.g. spongy palladium, palladium black, palladium oxide, palladium on carbon, colloidal palladium, palladium on barium, sulfate, palladium on barium carbonate, etc.], nickel catalysts [e.g. reduced nickel, nickel oxide, Raney nickel, etc.], cobalt catalysts [e.g. reduced cobalt, Raney cobalt, etc.], iron catalysts [e.g. reduced iron, Raney iron, etc.], copper catalysts [e.g. reduced copper, Raney copper, Ullman copper, etc.] and the like.

The reduction is usually carried out in a conventional solvent which does not adversely influence the reaction such as water, methanol, ethanol, propanol, N,N-dimethylformamide, or a mixture thereof. Additionally, in case that the above-mentioned acids to be used in chemical reduction are in liquid, they can also be used as a solvent. Further, a suitable solvent to be used in catalytic reduction may be the above-mentioned solvent, and other conventional solvent such as diethyl ether, dioxane, tetrahydrofuran, etc., or a mixture thereof.

The reaction temperature of this reduction is not critical and the reaction is usually carried out under cooling to warming.

The present invention includes within the scope of the invention the case that protected carboxy in R^2 is transformed into carboxy.

Process 5

The object compound (Ig) or a salt thereof can be prepared by subjecting a compound (If) or a salt thereof to elimination reaction of the carboxy protective group.

This reaction can be carried out in a similar manner to that of Process 4 mentioned in the above, and therefore the reaction mode and reaction conditions [e.g. base, acid, catalyst, solvent, reaction temperature, etc.] of this reaction are to be referred to those as explained in Process 4.

Process 6

The object compound (Id) or a salt thereof can be prepared by reacting the compound (Ie) or a salt thereof to protecting reaction of amino.

This reaction can be carried out according to a conventional manner such as the one described in Examples or the similar manners thereto.

Process 7

The object compound (If) or a salt thereof can be prepared by subjecting the compound (Ig) or a salt thereof to protecting reaction of carboxy.

This reaction can be carried out according to a conventional manner such as the ones described in Examples or the similar manners thereto.

Process 8

The object compound (Ii) or a salt thereof can be prepared by subjecting a compound (Ih) or a salt thereof to elimination reaction of amino protective group.

This reaction can be carried out in a similar manner to that of Process 4 mentioned in the above, and therefore the reaction mode and reaction conditions [e.g. reactive derivative, solvent, reaction temperature, etc.] of this

reaction are to be referred to those as explained in Process 4.

Process 9

5 The object compound (Ih) or a salt thereof can be prepared by subjecting the compound (Ii) or its reactive derivative at the amino group, or a salt thereof to acylation reaction.

10 Suitable acylating agent to be used in the present acylation reaction may include the compound of the formula :



15 (wherein R^{10} is acyl as mentioned before) or its reactive derivative, or a salt thereof.

20 Suitable reactive derivative at the amino group of the compound (Ii) may include Schiff's base type imino or its tautomeric enamine type isomer formed by the reaction of the compound (Ii) with a carbonyl compound such as aldehyde, ketone or the like; a silyl derivative formed by the reaction of the compound (Ii) with a silyl compound such as N,O-bis(trimethylsilyl)acetamide, N-trimethylsilylacetamide or the like; a derivative formed by the reaction of the compound (Ii) with phosphorus trichloride or phosgene, and the like.

25 Suitable reactive derivative of the compound (X) may include an acid halide, an acid anhydride, an activated ester, and the like. The suitable example may be an acid chloride; acid azide; a mixed acid anhydride with an acid such as substituted phosphoric acid (e.g., dialkylphosphoric acid, phenylphosphoric acid, diphenylphosphoric acid, dibenzylphosphoric acid, halogenated phosphoric acid, etc.), dialkylphosphorous acid, sulfurous acid, thiosulfuric acid, alkanesulfonic acid (e.g., methanesulfonic acid, ethanesulfonic acid,

30

35

etc.), sulfuric acid, alkylcarbonic acid, aliphatic
carboxylic acid (e.g., pivalic acid, pentanoic acid,
isopentanoic acid, 2-ethylbutyric acid, trichloroacetic
acid, etc.); aromatic carboxylic acid (e.g., benzoic acid,
etc.); a symmetrical acid anhydride; an activated amide
with imidazole, 4-substituted imidazole, dimethylpyrazole,
triazole or tetrazole; an activated ester (e.g.,
cyanomethyl ester, methoxymethyl ester,
dimethyliminomethyl $[(CH_3)_2^+N=CH-]$ ester, vinyl ester,
propargyl ester, p-nitrophenyl ester, 2,4-dinitrophenyl
ester, trichlorophenyl ester, pentachlorophenyl ester,
mesylphenyl ester, phenylazophenyl ester, phenylthio
ester, p-nitrophenyl thioester, p-cresyl thioester,
carboxymethyl thioester, pyranlyl ester, pyridyl ester,
piperidyl ester, 8-quinolyl thioester, etc.); an ester
with a N-hydroxy compound (e.g.,
N,N-dimethylhydroxylamine, 1-hydroxy-2-(1H)-pyridone,
N-hydroxysuccinimide, N-hydroxybenzotriazole,
N-hydroxyphthalimide, 1-hydroxy-6-chloro-1H-benzotriazole,
etc.); and the like. These reactive derivatives can
optionally be selected from them accordingly to the kind
of the compound (Ii) to be used.

The reaction is usually carried out in a conventional
solvent such as water, acetone, dioxane, acetonitrile,
chloroform, methylene chloride, ethylene chloride,
tetrahydrofuran, ethyl acetate, N,N-dimethylformamide,
pyridine or any other organic solvents which do not
adversely affect the reaction, or the mixture thereof.

When the compound (Ii) is used in free acid form or
its salt form in the reaction, the reaction is preferably
carried out in the presence of a conventional condensing
agent such as N,N'-dicyclohexylcarbodiimide; N-cyclohexyl-
N'-morpholinoethylcarbodiimide; N-cyclohexyl-N'-(4-
diethylaminocyclohexyl)carbodiimide;
N,N'-diisopropylcarbodiimide; N-ethyl-N'-(3-

dimethylaminopropyl)carbodiimide; N,N-carbonyl-bis(2-methylimidazole); pentamethyleneketene-N-cyclohexylimine; diphenylketene-N-cyclohexylimine; ethoxyacetylene; 1-alkoxy-1-chloroethylene; trialkyl phosphite; isopropyl polyphosphate; phosphorous oxychloride (phosphoryl chloride); phosphorous trichloride; thionyl chloride; oxalyl chloride; triphenylphosphite; 2-ethyl-7-hydroxybenzisoxazolium salt; 2-ethyl-5-(m-sulfophenyl)isoxazolium hydroxide intra-molecular salt; 1-(p-chlorobenzenesulfonyloxy)-6-chloro-1H-benzotriazole; so-called Vilsmeier reagent prepared by the reaction of N,N-dimethylformamide with thionyl chloride, phosgene, phosphorous oxychloride, etc.; or the like.

The reaction may also be carried out in the presence of an organic or inorganic base such as an alkali metal bicarbonate, tri(lower)alkylamine, pyridine, N-(lower)alkylmorpholine, N,N-di(lower)alkylbenzylamine, or the like.

The reaction temperature is not critical, and the reaction is usually carried out under cooling to heating.

The processes for preparing the starting compounds (IV) and (V) are explained in detail in the following.

Process A

The object compound (IX) or a salt thereof can be prepared by reacting a compound (II) or its reactive derivative at the carboxy group or a salt thereof with a compound (VIII) or its reactive derivative at the amino group or a salt thereof.

This reaction can be carried out in a similar manner to that of Process 1 mentioned in the above, and therefore the reaction mode and reaction conditions [e.g. reactive derivative, solvent, reaction temperature, etc.] of this reaction are to be referred to those as explained in

Process 1.

Process B

5 The object compound (IV) or a salt thereof can be prepared by subjecting a compound (IX) or a salt thereof to elimination reaction of the carboxy protective group.

This reaction can be carried out in a similar manner to that of Process 4 mentioned in the above, and therefore the reaction mode and reaction conditions [e.g. base, acid, catalyst, solvent, reaction temperature, etc.] of this reaction are to be referred to those as explained in Process 4.

10 The present invention includes within the scope of the invention the case that amino protective group in R¹ is transformed into amino.

Process C

15 The object compound (Va) or a salt thereof can be prepared by reacting a compound (6) with acid.

Compound (6) can be prepared as follows.

20 Compound (2) can be prepared by reacting a compound (1) with formalin, and both compound (4) and compound (5) can be prepared by reacting a compound (2) with a compound (3) to Lipase-catalyzed reaction, and compound (6) can be prepared by reacting compound (5) with aqueous ammonia.

25 The reaction of each step can be carried out in a conventional manner such as the ones described in Preparations.

Process D

30 The object compound (Vb) or a salt thereof can be prepared by reacting a compound (11) with acid.

Compound (11) can be prepared as follows.

35 Compound (9) can be prepared by reacting a compound

(7) with a compound (8) (wittig reaction), and compound (11) can be prepared by reacting a compound (9) with a compound (10).

5 The reaction of each step can be carried out in a conventional manner such as the ones described in Preparations.

10 When the object compound (I) obtained by the above-mentioned processes is in a free form, it can be converted into a salt form in a conventional manner. On the other hand, when the object compound (I) thus obtained is in a salt form, it can be converted into a free form or another salt form also in a conventional manner.

15 The compounds obtained by the above Processes 1 to 9 and A to D can be isolated and purified by a conventional method such as pulverization, recrystallization, column-chromatography, reprecipitation of the like.

20 It is to be noted that each of the object compound (I) may include one or more stereoisomer such as optical isomer(s) and geometrical isomer(s) due to asymmetric carbon atom(s) and double bond(s) and all such isomers and mixture thereof are included within the scope of this invention.

25 Now in order to show the utility of the object compound (I), some pharmacological test data of the representative compound (I) of the present invention are shown in the following.

30 Test 1 : Effect on platelet aggregation induced by adenosine diphosphate (ADP)

Test Compound

35 (1) the compound of Example 21 (3)

Test Method

Platelet rich plasma (PRP) which contains 3×10^8 platelets/ml was prepared from human blood. To the 225 μ l of PRP, 25 μ l of drug solution* was added, and then stirred for 2 minutes at 37°C. To the solution 5 μ l of ADP (final 2.5 μ M) was added as an aggregation inducer. Aggregation was measured by using an aggregometer (NBS HEMA-TRACER 801). Activity of inhibitor (test compound) was expressed as IC₁₀₀ value i.e. dose required for complete inhibition of platelet aggregation.

Drug solution* --- Test compound was dissolved in water.

Test Result

Test Compound	IC ₁₀₀ (M)
(1)	1.0×10^{-6}

The pharmaceutical composition of the present invention can be used in the form of a pharmaceutical preparation, for example, in solid, semisolid or liquid form, which contains the object compound (I) or a pharmaceutically acceptable salt thereof, as an active ingredient in admixture with an organic or inorganic carrier or excipient suitable for rectal, pulmonary (nasal or buccal inhalation), nasal, ocular, external (topical), oral or parenteral (including subcutaneous, intravenous and intramuscular) administrations or insufflation.

The active ingredient may be compounded, for example, with the usual non-toxic, pharmaceutically acceptable carriers for tablets, pellets, troches, capsules, suppositories, creams, ointments, aerosols, powders for insufflation, solutions, emulsions, suspensions, and any other form suitable for use. And, if necessary, in

addition, auxiliary, stabilizing, thickening and coloring agents and perfumes may be used.

5 The object compound (I) or a pharmaceutically acceptable salt thereof is/are included in the pharmaceutical composition in an amount sufficient to produce the desired effect upon the process or condition of the diseases.

10 The pharmaceutical composition of the present invention can be manufactured by the conventional method in this field of the art. If necessary, the technique generally used in this field of the art for improving the bioavailability of a drug can be applied to the
15 pharmaceutical composition of the present invention.

20 For applying the composition to a human being or an animal, it is preferable to apply it by intravenous (including i.v. infusion), intramuscular, pulmonary, or oral administration, or insufflation including aerosols from metered dose inhalator, nebulizer or dry powder inhalator.

25 While the dosage of therapeutically effective amount of the object compound (I) varies from and also depends upon the age and condition of each individual patient to be treated, in the case of intravenous administration, a daily dose of 0.001-100 mg of the object compound (I) per
30 kg weight of a human being or an animal, in the case of intramuscular administration, a daily dose of 0.001-100 mg of the object compound (I) per kg weight of a human being or an animal, in case of oral administration, a daily dose of 0.001-200 mg of the object compound (I) per kg weight
35 of a human being or an animal in generally given for the prevention and/or the treatment of aforesaid diseases in a

human being or an animal.

5

10

15

20

25

The following Preparations and Examples are given for the purpose of illustrating the present invention in more detail.

Preparation 1

30

35

(1) To a mixture of (R)-ethyl nipecotate (1.86 g), 3-(1-tert-butoxycarbonyl-4-piperidyl)propionic acid (3.04 g) and 1-hydroxybenztriazole (1.60 g) in N,N-dimethylformamide (20 ml) was added 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (2.16 ml) under stirring at 0°C. After stirring at ambient temperature overnight, the mixture was poured into water and extracted with ethyl

acetate. The extract was washed with water, brine and dried over MgSO_4 , and evaporated in vacuo. The residue was purified by chromatography on silica gel eluting with $(\text{CHCl}_3:\text{MeOH}) = (100:1)$ to give (R)-ethyl 1-[3-(1-tert-butoxycarbonyl-4-piperidyl)propionyl]-3-piperidinecarboxylate as an oil (4.01 g).

IR (Film) : 2960, 2900, 2840, 1710, 1665, 1630 cm^{-1}

NMR (CDCl_3 , δ) : 1.00-1.20 (1H, m), 1.28 (3H, t, $J=7.1\text{Hz}$), 1.45 (9H, s), 1.48-1.88 (9H, m), 1.98-2.15 (1H, m), 2.31-2.51 (3H, m), 2.62-3.12 (4H, m), 3.35-3.47 (1/2H, m), 3.65-3.85 (1H, m), 4.00-4.22 (4H, m), 4.56-4.69 (1/2H, m)

Mass (m/z) : 397 (M^++1)

The following compounds were obtained according to a similar manner to that of Preparation 1 (1).

(2) Ethyl 1-[2-(1-benzyloxycarbonyl-4-piperidyloxy)acetyl]-3-piperidinecarboxylate

IR (Film) : 2930, 2860, 1720, 1690, 1640 cm^{-1}

NMR (CDCl_3 , δ) : 1.25 (3H, t, $J=7.1\text{Hz}$), 1.46-1.94 (7H, m), 2.00-2.16 (1H, m), 2.40-2.59 (1H, m), 2.85-3.40 (4H, m), 3.56-3.64 (1H, m), 3.73-3.98 (3H, m), 4.04-4.32 (2+1/2H, m), 4.15 (2H, q, $J=7.7\text{Hz}$), 4.49-4.60 (1/2H, m), 5.12 (2H, s), 7.30-7.37 (5H, m)

Mass (m/z) : 433 (M^++1)

(3) (R)-Ethyl 1-[3-(1-benzyloxycarbonyl-4-piperidyl)-propionyl]-3-piperidinecarboxylate

IR (Film) : 2980, 2920, 2840, 1715, 1690, 1630 cm^{-1}

NMR (CDCl_3 , δ) : 1.05-1.30 (5H, m), 1.40-1.88 (8H, m), 1.98-2.15 (1H, m), 2.30-2.50 (3H, m), 2.70-3.10 and 3.35-3.47 (total 4H, m), 3.67-3.83 (1H, m), 3.98-4.21 and 4.55-4.66 (total 5H, m), 5.12

(2H, s), 7.29-7.37 (5H, m)
Mass (m/z) : 431 ($M^+ + 1$)

(4) Methyl 1-[3-(1-tert-butoxycarbonyl-4-piperidyl)propionyl]-3-pyrrolidinecarboxylate

IR (Film) : 3450, 1730, 1680, 1630 cm^{-1}

NMR (CDCl_3 , δ) : 1.07-1.18 (2H, m), 1.453 (9H, s),
1.57-1.69 (3H, m), 1.63 (3H, s), 2.12-2.31 (3H, m),
2.61-2.73 (2H, m), 3.02-3.20 (1H, m), 3.45-3.75 (7H, m), 4.05-4.15 (2H, m)

Mass (m/z) : 369 ($M^+ + 1$)

(5) 3-[3-(1-tert-butoxycarbonyl-4-piperidyl)propionyl]aminopyridine

mp : 152-153°C

IR (Nujol) : 1680, 1600 cm^{-1}

NMR (CDCl_3 , δ) : 1.00-1.20 (2H, m), 1.45 (9H, s),
1.40-1.51 (1H, m), 1.61-1.75 (4H, m), 2.43 (2H, t, $J=7.6\text{Hz}$),
2.39-2.46 (2H, m), 4.03-4.14 (2H, m), 7.28 (1H, t, $J=7.0\text{Hz}$),
8.22 (1H, dd, $J=5.7$ and 2.3Hz), 8.32 (1H, dd, $J=4.7$ and 1.4Hz),
8.59 (1H, d, $J=2.4\text{Hz}$), 8.65 (1H, s)

Mass (m/z) : 334 ($M^+ + 1$)

(6) Ethyl (S)-1-[3-(1-tert-butoxycarbonyl-4-piperidyl)propionyl]-3-piperidinecarboxylate

IR (Film) : 2930, 2860, 1720, 1680, 1635 cm^{-1}

NMR (CDCl_3 , δ) : 1.03-1.23 (2H, m), 1.27 (3H, t, $J=7.1\text{Hz}$),
1.45 (9H, s), 1.53-1.74 (9H, m), 1.98-2.15 (1H, m),
2.32-2.51 (3H, m), 2.60-3.11 (4H, m), 3.68-3.86 (1H, m),
4.03-4.22 (4H, m)

Mass (m/z) : 397 ($M^+ + 1$)

(7) N-[(R)-(1-benzyloxycarbonyl)-3-piperidylcarbonyl]-2(S)-tert-butoxycarbonylamino- β -alanine ethyl ester

IR (Film) : 3320, 2975, 2930, 2860, 1700, 1680,
1660 cm^{-1}

NMR (CDCl_3 , δ) : 1.23-1.32 (1H, m), 1.28 (3H, t, $J=7.1\text{Hz}$), 1.43 (9H, s), 1.47-1.67 (4H, m), 1.72-2.03 (2H, m), 2.23-2.40 (1H, m), 3.45-3.90 (4H, m), 4.13-4.25 (3H, m), 4.31-4.42 (1H, m), 5.16 (2H, d, $J=6.7\text{Hz}$), 7.36-7.39 (5H, m)

Mass (m/z) : 478 (M^++1)

(8) N-(3-Pyridyl)-3(S)-(tert-butoxycarbonylamino)-succinamic acid methyl ester

IR (Film) : 2975, 1700, 1680, 1600 cm^{-1}

NMR (CDCl_3 , δ) : 1.49 (9H, s), 2.77 (1H, dd, $J=17.1$ and 6.2Hz), 3.05 (1H, dd, $J=17.1$ and 4.4Hz), 3.74 (3H, s), 4.63-4.72 (1H, m), 5.91-6.00 (1H, m), 7.23-7.30 (1H, m), 8.11 (1H, dq, $J=8.3$ and 1.0Hz), 8.36 (1H, dd, $J=4.8$ and 1.4Hz), 8.59 (1H, d, $J=2.4\text{Hz}$), 8.83-8.87 (1H, br)

Mass (m/z) : 324 (M^++1)

(9) N-[(3-Pyridyl)-2(S)-(tert-butoxycarbonylamino)]-succinamic acid ethyl ester

mp : 134-135°C

IR (Nujol) : 3300, 1720, 1680, 1665 cm^{-1}

NMR (CDCl_3 , δ) : 1.28 (3H, t, $J=7.1\text{Hz}$), 1.45 (9H, s), 2.96 (1H, dd, $J=16.1$ and 4.6Hz), 3.09 (1H, dd, $J=16.1$ and 5.2Hz), 4.24 (2H, q, $J=7.1\text{Hz}$), 4.58 (1H, dt, $J=8.3$ and 4.9Hz), 5.71-5.75 (1H, m), 7.24-7.30 (1H, m), 8.13-8.20 (1H, m), 8.32-8.37 (1H, m), 8.43-8.47 (1H, m), 8.57-8.61 (1H, m)

Mass (m/z) : 338 (M^++1)

(10) N-[(3-Pyridyl)-3(R)-(tert-butoxycarbonylamino)]-succinamic acid benzyl ester

IR (Film) : 2970, 1705, 1670 cm^{-1}

NMR (CDCl_3 , δ) : 1.47 (9H, s), 2.83 (1H, dd, $J=15.6$ and 6.3Hz), 3.07 (1H, dd, $J=17.1$ and 4.7Hz), 4.65-4.75 (1H, m), 5.15 (2H, s), 5.93 (1H, d, $J=8.4\text{Hz}$), 7.21-7.27 (1H, m), 7.33 (5H, s), 8.07 (1H, dq, $J=8.3$ and 1.0Hz), 8.35 (1H, dd, $J=4.7$ and 1.4Hz), 8.57 (1H, d, $J=2.4\text{Hz}$), 8.87 (1H, s)

Mass (m/z) : 4.00 (M^++1)

Preparation 2

(1) A solution of (R)-ethyl 1-[3-(1-tert-butoxycarbonyl-4-piperidyl)propionyl]-3-piperidinecarboxylate (3.99 g) in a mixture of methanol (10 ml), tetrahydrofuran (10 ml) and water (10 ml) was added lithium hydroxide (1.27 g) under stirring at 0°C . After stirring at ambient temperature for 1 hour, the mixture was acidified with 5% KHSO_4 aqueous solution and extracted with ethyl acetate. The extract was washed with water, brine and dried over MgSO_4 , and evaporated in vacuo to give (R)-1-[3-(1-tert-butoxycarbonyl-4-piperidyl)propionyl]-3-piperidinecarboxylic acid (3.34 g).

mp : $102-104^\circ\text{C}$

IR (Nujol) : 1720, 1680, 1630 cm^{-1}

NMR ($\text{DMSO}-d_6$, δ) : 0.84-1.10 (2H, m), 1.38-1.76 (8H, m), 1.38 (9H, s), 1.82-2.01 (1H, m), 2.20-2.45 (3H, m), 2.59-2.76 (2H, m), 2.89-3.09 (1H, m), 3.28-3.40 (1H, m), 3.69-3.98 and 4.31-4.44 (total 4H, m)

The following compounds were obtained according to a similar manner to that of Preparation 2 (1).

(2) (R)-1-[3-(1-Benzoyloxycarbonyl-4-piperidyl)propionyl]-3-piperidinecarboxylic acid

mp : $134-135^\circ\text{C}$

IR (Nujol) : 1715, 1680, 1600 cm^{-1}

NMR (DMSO-d_6 , δ) : 0.90-1.10 (2H, m), 1.30-1.73 (8H, m), 1.85-1.98 (1H, m), 2.20-2.49 (3H, m), 2.65-2.86 (2H, m), 2.94-3.06 (1H, m), 3.27-3.38 (1H, m), 3.69-3.84 and 4.34-4.42 (total 2H, m), 3.95-4.02 (2H, m), 5.06 (2H, s), 7.27-7.41 (5H, m), 12.38 (1H, s)

Mass (m/z) : 403 ($M^+ + 1$)

(3) (S)-1-[3-(1-tert-butoxycarbonyl-4-piperidyl)propionyl]-3-piperidinecarboxylic acid

mp : 111-112°C

IR (Nujol) : 3100, 1720, 1680, 1620, 1600 cm^{-1}

NMR (DMSO-d_6 , δ) : 0.88-1.09 (2H, m), 1.38 (9H, s), 1.28-1.74 (8H, m), 1.87-2.01 (1H, m), 2.15-2.79 (6H, m), 2.94-3.08 (1H, m), 3.70-3.94 (4H, m), 12.31-12.49 (1H, br)

Mass (m/z) : 269 ($M^+ + 1 - \text{Boc}$)

Preparation 3

(1) A mixture of ethyl 1-[2-(1-benzyloxycarbonyl-4-piperidyloxy)acetyl]-3-piperidinecarboxylate (2.06 g) and 1N NaOH aqueous solution (14.29 ml) in a solution of tetrahydrofuran (10 ml), ethanol (10 ml) and water (10 ml) was stirred for 1 hour at ambient temperature. The mixture was acidified with 10% aqueous solution of KHSO_4 and extracted with ethyl acetate. The extract was washed with water, brine and dried over MgSO_4 , and evaporated in vacuo. The residue was recrystallized from diethyl ether to give 1-[2-(1-benzyloxycarbonyl-4-piperidyloxy)acetyl]-3-piperidinecarboxylic acid (1.51 g).

mp : 102-104°C

IR (Nujol) : 1720, 1690, 1615, 1600 cm^{-1}

NMR (DMSO-d_6 , δ) : 1.34-2.00 (8H, m), 2.23-2.50 (1H, m), 2.73-3.86 (9H, m), 4.14-4.36 (2H, m), 5.07

(2H, s), 7.28-7.42 (5H, m), 12.34-12.55 (1H, br)
Mass (m/z) : 405 ($M^{+}+1$)

The following compound was obtained according to a
similar manner to that of Preparation 3 (1).

(2) 1-[3-(1-tert-butoxycarbonyl-4-piperidyl)propionyl]-3-pyrrolidinecarboxylic acid

mp : 102-103°C

IR (Nujol) : 1720, 1680, 1480 cm^{-1}

NMR (DMSO- d_6 , δ) : 0.92-0.98 (2H, m), 1.38 (9H, s),
1.60-1.66 (2H, m), 1.94-2.08 (2H, m), 2.11-2.23
(2H, m), 2.52-2.66 (2H, m), 2.96-3.14 (1H, m),
3.33-3.68 (7H, m), 3.88-3.94 (2H, m)

Preparation 4

(1) To a solution of N-tert-butoxycarbonyl-o-mesyl-(L)-serine ethyl ester (5 g) in N,N-dimethylformamide (50 ml) was added sodium azide (2.09 g) under stirring at ambient temperature. After stirring at 60°C for 3 hours, the mixture was poured into water and extracted with ethyl acetate. The extract was washed with water, brine and dried over MgSO_4 , and evaporated in vacuo. The residue was purified by column chromatography on silica gel eluting with (n-hexane:EtOAc = 7:1) to give ethyl 3-azidomethyl-2(S)-(tert-butoxycarbonyl)aminopropionate (1.5 g).

IR (Film) : 3450, 2960, 2090, 1700 cm^{-1}

NMR (CDCl_3 , δ) : 1.31 (3H, t, $J=7.1\text{Hz}$), 1.46 (9H, s), 3.73 (1H, d, $J=3.6\text{Hz}$), 4.26 (2H, q, $J=7.1\text{Hz}$), 4.41-4.51 (1H, m), 5.34-5.45 (1H, m)

Mass (m/z) : 159 ($M^{+}+1\text{-Boc}$)

The following compound was obtained according to a
similar manner to that of Preparation 4 (1).

(2) N-(Benzyloxycarbonyl)-3(S)-azidomethyl- β -alanine
tert-butyl ester

IR (Film) : 3300, 2100, 1720 cm^{-1}

NMR (CDCl_3 , δ) : 1.44 (9H, s), 2.51 (2H, d,
J=6.0Hz), 3.48-3.52 (2H, m), 4.08-4.18 (1H, m),
5.11 (2H, s), 5.40 (1H, br), 7.34-7.36 (5H, m)

Mass (m/z) : 333 (M^+-1)

Preparation 5

(1) A mixture of ethyl 3-azido-2(S)-(tert-butoxycarbonyl)aminopropionate (0.5 g) and 10% Pd-C (0.1 g, 50% wet) in ethanol (5 ml) was hydrogenated at atmospheric pressure for 1 hour. After the catalyst was removed by filtration, the filtrate was concentrated in vacuo to give 2(S)-(tert-butoxycarbonyl)amino- β -alanine ethyl ester (0.45 g).

IR (Film) : 3350, 2960, 1720, 1680, 1650 cm^{-1}

NMR (DMSO-d_6 , δ) : 1.17 (3H, t, J=7.4Hz), 1.39 (9H, s), 1.30-1.85 (3H, m), 2.75-2.78 (1H, m), 3.33-3.49 (1H, m), 4.07 (2H, q, J=7.1Hz), 6.80-6.89 and 7.11-7.23 (total 1H, m)

The following compound was obtained according to a similar manner to that of Preparation 5 (1).

(2) 2(S)-Acetylamino- β -alanine ethyl ester

$[\alpha]_D^{25} = -35.9^\circ$ (C=1.0, EtOH)

IR (Film) : 1740, 1630 cm^{-1}

NMR (DMSO-d_6 , δ) : 1.20 (3H, t, J=7.1Hz), 1.89 (3H, s), 2.99-3.23 (2H, m), 4.11 (2H, q, J=7.1Hz), 4.46-4.57 (1H, m), 8.30 (2H, br), 8.63 (1H, d, J=7.68Hz)

Mass (m/z) : 175 (M^++1)

Preparation 6

To a solution of N-tert-butoxycarbonyl-L-serine ethyl ester (8.20 g) in tetrahydrofuran (300 ml) was added triphenylphosphine (10.15 g, 38.7 m mol), diethyldiazocarbonate (6.09 ml, 38.7 m mol) and diphenylphosphonic acid (8.34 ml, 38.7 m mol) successively at -5°C. After stirring at room temperature for 3 hours, the mixture was poured into water and extracted with ethyl acetate. The extract was washed with water, saturated aqueous NaHCO₃ solution and brine, dried over MgSO₄ and evaporated in vacuo. The residue was purified by column chromatography on silica gel eluting with (EtOAc:n-hexane = 10:90) to give ethyl 3-azido-2(S)-(tert-butoxycarbonylamino)propionate (5.0 g).

IR (Film) : 3450, 2960, 2090, 1700 cm⁻¹

NMR (CDCl₃, δ) : 1.31 (3H, t, J=7.1Hz), 1.46 (9H, s), 3.73 (1H, d, J=3.6Hz), 4.26 (2H, q, J=7.1Hz), 4.41-4.51 (1H, m), 5.34-5.45 (1H, m)

Mass (m/z) : 159 (M⁺+1-Boc)

Preparation 7

To a solution of ethyl 3-azido-2(S)-(tert-butoxycarbonylamino)propionate (0.5 g) in ethyl acetate (5 ml) was added 4N HCl in ethyl acetate (5 ml) at 0°C. After stirring at room temperature for 2 hours, the mixture was evaporated in vacuo. The residue was recrystallized from diethyl ether to give ethyl 2(S)-amino-3-azidopropionate hydrochloride (0.3 g).

NMR (DMSO-d₆, δ) : 1.25 (3H, t, J=7.1Hz), 3.97 (2H, d, J=4.0Hz), 4.22 (2H, q, J=7.1Hz), 4.34 (1H, t, J=4.0Hz)

Mass (m/z) : 159 (M⁺+1) free of compound

Preparation 8

(1) To a solution of 3-aminopyridine (1 g) in dichloromethane (10 ml) was added triethylamine (1.63 ml)

and 3-methoxycarbonylpropionyl chloride (1.44 ml) under stirring at 0°C. After stirring at ambient temperature for 1 hour, the mixture was poured into water and extracted with dichloromethane. The extract was washed with water, saturated aqueous NaHCO₃ solution, water and brine, and dried over MgSO₄, and evaporated in vacuo. The residue was purified by column chromatography on silica gel eluting with (CHCl₃:MeOH = 100:1), and recrystallized from diethyl ether to give N-(3-pyridyl)succinamic acid methyl ester (0.73 g).

mp : 78-79°C

IR (Nujol) : 1730, 1685, 1610 cm⁻¹

NMR (CDCl₃, δ) : 2.66-2.81 (4H, m), 3.72 (3H, s), 7.22-7.29 (1H, m), 8.32 (1H, dd, J=8.3 and 1.2Hz), 8.58 (2H, d, J=8.6Hz)

Mass (m/z) : 209 (M⁺+1)

The following compound was obtained according to a similar manner to that of Preparation 8 (1).

(2) Ethyl 2(S)-acetylamino-3-azidopropionate

IR (Film) : 3300, 2100, 1720, 1650 cm⁻¹

NMR (CDCl₃, δ) : 1.32 (3H, t, J=7.1Hz), 2.07 (3H, s), 3.69-3.85 (2H, m), 4.27 (2H, q, J=7.1Hz), 4.70-4.77 (1H, m), 6.36 (1H, br)

Mass (m/z) : 201 (M⁺+1)

Preparation 9

A mixture of N-(3-pyridyl)-3(R)-(tert-butoxycarbonylamino)succinamic acid benzyl ester (4.28 g) and 10% Pd-C (0.86 g, 50% wet) in tetrahydrofuran (50 ml) was hydrogenated at atmospheric pressure for 2 hours. After the catalyst was removed by filtration, the filtrate was concentrated in vacuo. The residue was recrystallized from diethyl ether to give N-(3-pyridyl)-3(R)-(tert-

butoxycarbonylamino)succinamic acid (2.55 g).

mp : 98-100°C

IR (Nujol) : 3430, 1735, 1700, 1680 cm⁻¹

NMR (DMSO-d₆, δ) : 1.39 (9H, s), 2.57-2.77 (2H, m),
3.33-3.46 (1H, m), 4.39-4.50 (1H, m), 7.27-7.38
(2H, m), 8.03-8.07 (1H, m), 8.26-8.28 (1H, m),
8.76 (1H, s), 10.28 (1H, s)

Preparation 10

To a suspension of N-(3-pyridyl)-3(R)-(tert-butoxycarbonylamino)succinamic acid (1 g) and sodium hydrogen carbonate (0.54 g) in N,N-dimethylformamide (5 ml) was added to a solution of ethyl bromide (1.76 g) in N,N-dimethylformamide (5 ml). After stirring at room temperature for 4 days, the mixture was poured into water and extracted with ethyl acetate. The extract was washed with water and brine, and dried over MgSO₄, and evaporated in vacuo. The residue was purified by column chromatography on silica gel eluting with (CHCl₃:MeOH = 100:1) to give N-(3-pyridyl)-3(R)-(tert-butoxycarbonylamino)succinamic acid ethyl ester (0.63 g) as an oil.

IR (Film) : 2980, 2940, 1715, 1675 cm⁻¹

NMR (CDCl₃, δ) : 1.28 (3H, t, J=7.1Hz), 1.49 (9H, s), 2.76 (1H, dd, J=17.2 and 6.4Hz), 3.04 (1H, dd, J=17.2 and 4.3Hz), 4.19 (2H, q, J=7.1Hz), 4.60-4.72 (1H, m), 5.86-5.96 (1H, m), 7.23-7.30 (1H, m), 8.10 (1H, dq, J=8.3 and 1.1Hz), 8.36 (1H, dd, J=4.7 and 1.4Hz), 8.59 (1H, d, J=2.4Hz), 8.76-8.81 (1H, br)

Mass (m/z) : 338 (M⁺+1)

Preparation 11

(1) A mixture of N-(3-pyridyl)-3(S)-(tert-butoxycarbonylamino)succinamic acid methyl ester (3.91 g)

and 4N HCl in dioxane (3.36 ml) and PtO₂ (0.39 g) in methanol (40 ml) was hydrogenated at atmospheric pressure for 2 hours. After the catalyst was removed by filtration, the filtrate was concentrated in vacuo. The residue was recrystallized from diethyl ether to give N-(3-piperidyl)-3(S)-(tert-butoxycarbonylamino)succinamic acid methyl ester hydrochloride (3.67 g).

IR (Nujol) : 1740, 1680, 1640 cm⁻¹

NMR (DMSO-d₆, δ) : 1.38 (9H, s), 1.64-1.95 (4H, m), 2.48-2.92 (3H, m), 3.08-3.20 (2H, m), 3.60 (3H, d, J=5.1Hz), 3.83-4.04 (2H, m), 4.20-4.43 (1H, m), 7.06-7.20 (1H, m), 8.12-8.29 (1H, m)

Mass (m/z) : 330 (M⁺+1) free of compound

The following compounds were obtained according to a similar manner to that of Preparation 11 (1).

(2) N-(3-Piperidyl)succinamic acid methyl ester hydrochloride

mp : 87-89°C

IR (Nujol) : 3300, 2920, 1720, 1640 cm⁻¹

NMR (DMSO-d₆, δ) : 1.36-1.91 (5H, m), 2.34-2.40 (2H, m), 2.47-3.01 (3H, m), 3.04-3.20 (2H, m), 3.58 (3H, s), 3.84-4.02 (1H, m), 8.23 (1H, d, J=7.3Hz), 9.05-9.20 (1H, br), 9.28-9.40 (1H, br)

Mass (m/z) : 215 (M⁺+1) free of compound

(3) N-(3-Piperidyl)-2(S)-(tert-butoxycarbonylamino)-succinamic acid ethyl ester

IR (Film) : 3400, 1840, 1700, 1640 cm⁻¹

NMR (DMSO-d₆, δ) : 1.16 (3H, t, J=7.1Hz), 1.17-1.79 (6H, m), 1.37 (9H, s), 2.22-2.58 (2H, m), 2.71-2.93 (2H, m), 3.49-3.64 (1H, m), 4.06 (2H, q, J=7.1Hz), 4.29 (1H, q, J=7.4Hz), 7.04-7.10 (1H, m), 7.75 (1H, d, J=7.8Hz)

Mass (m/z) : 344 ($M^{+}+1$)

(4) 3-[[3-(1-tert-butoxycarbonyl-4-piperidyl)propionyl]-amino]piperidine

IR (Film) : 3400, 2930, 1635 cm^{-1}

NMR (DMSO- d_6 , δ) : 0.85-1.04 (2H, m), 1.27-1.49 (5H, m), 1.38 (9H, s), 1.55-1.77 (5H, m), 1.99-2.40 (2H, m), 2.60-2.91 (5H, m), 3.46-3.64 (2H, m), 3.86-3.96 (2H, m), 7.63-7.67 (1H, m)

Mass (m/z) : 340 ($M^{+}+1$)

Preparation 12

A mixture of N-(3-pyridyl)-3(R)-(tert-butoxycarbonylamino)succinamic acid ethyl ester (0.62 g) and PtO_2 (0.06 g) in acetic acid (12 ml) was hydrogenated at atmospheric pressure for 6 hours. After the catalyst was removed by filtration, the filtrate was concentrated in vacuo. The residue was dissolved in water. The solution was adjusted to pH 10 with saturated aqueous potassium carbonate solution, and extracted with ethyl acetate. The extract was washed with water and brine, and dried over MgSO_4 , and evaporated in vacuo to give N-(3-piperidyl)-3(R)-(tert-butoxycarbonylamino)succinamic acid ethyl ester (0.51 g) as an oil.

IR (Film) : 3500, 2980, 2940, 1710, 1660 cm^{-1}

NMR (DMSO- d_6 , δ) : 1.17 (3H, t, $J=7.1\text{Hz}$), 1.38 (9H, s), 1.32-1.70 (6H, m), 2.28-2.88 (4H, m), 3.50-3.64 (1H, br), 4.00 (2H, q, $J=7.1\text{Hz}$), 4.20-4.33 (1H, m), 7.04-7.11 (1H, m), 7.59-7.63 (1H, m)

Mass (m/z) : 344 ($M^{+}+1$)

Preparation 13

To a mixture of N-(benzyloxycarbonyl)-3(S)-hydroxymethyl- β -alanine tert-butyl ester (3.1 g) and triethylamine (1.35 ml) in dichloromethane (25 ml) was

added a solution of methanesulfonyl chloride (1.35 ml) in dichloromethane (5 ml), under ice cooling. After stirring at room temperature for 1 hour. The mixture was poured into water and extracted with dichloromethane. The extract was washed with water, brine and dried over MgSO_4 , and evaporated in vacuo. The residue was purified by column chromatography on silica gel eluting with CHCl_3 to give N-(benzyloxycarbonyl)-3(S)-methanesulfonyloxymethyl)- β -alanine tert-butyl ester (3.1 g) as an colorless oil.

IR (Film) : 3330, 1710 cm^{-1}

NMR (CDCl_3 , δ) : 1.44 (9H, s), 2.56-2.59 (2H, m), 2.74 (1H, br), 2.98 (3H, s), 4.25-4.34 (3H, m), 5.11 (2H, s), 5.44-5.48 (1H, m), 7.35-7.42 (5H, m)

Preparation 14

To a mixture of N-benzyloxycarbonyl(L)aspartic acid ω -tert-butyl ester (3.0 g) and triethylamine (1.55 ml) in tetrahydrofuran (30 ml) was added ethyl chlorocarbonate (1.06 ml) at -30°C under nitrogen atmosphere. After stirring for 1 hour, the precipitate was filtered off and the filtrate was added to a solution of NaBH_4 (1.05 g) in tetrahydrofuran (30 ml) - water (6 ml) at 0°C . After stirring for 30 minutes, the mixture was neutralized with 10% aqueous KHSO_4 solution and extract with ethyl acetate. The extract was washed with water, brine and dried over MgSO_4 , and evaporated in vacuo. The residue was purified by column chromatography on silica gel eluting with 2% ($\text{MeOH}/\text{CHCl}_3$) to give N-(benzyloxycarbonyl)-3(S)-hydroxymethyl- β -alanine tert-butyl ester (2.5 g) as an colorless oil.

IR (Film) : 3320, 1700 cm^{-1}

NMR (CDCl_3 , δ) : 1.43 (9H, s), 2.53-2.57 (3H, s), 3.68-3.73 (2H, m), 3.99-4.08 (1H, m), 5.10 (2H, m), 5.29-5.52 (1H, m), 7.35-7.37 (5H, m)

Mass (m/z) : 310 (M^++1)

Preparation 15

(1) A mixture of N-benzyloxycarbonyl-3(S)-hydroxymethyl- β -alanine tert-butyl ester (2.0 g), triphenylphosphine (1.87 g), imidazole (0.66 g) and I_2 (1.80 g) was stirred for 30 minutes at room temperature. The precipitate was filtered off and the filtrate was evaporated in vacuo. The residue was purified by column chromatography on silica gel eluting with 5% (EtOAc/n-hexane) to give N-benzyloxycarbonyl-3(S)-iodomethyl- β -alanine tert-butyl ester (1.8 g) as a white solid.

IR (Nujol) : 3350, 1700 cm^{-1}

NMR ($CDCl_3$, δ) : 1.44 (9H, s), 2.48-2.64 (2H, m), 3.41-3.43 (2H, m), 3.91-3.98 (1H, m), 5.11 (2H, s), 5.30-5.35 (1H, m), 7.35-7.37 (5H, m)

The following compound was obtained according to a similar manner to that of Preparation 15 (1).

(2) N-(Benzyloxycarbonyl)-3(S)-(n-butanesulfonyl)-aminomethyl)- β -alanine tert-butyl ester

IR ($CHCl_3$) : 1710 cm^{-1}

NMR ($CDCl_3$, δ) : 0.93 (3H, t, $J=7.2Hz$), 1.43 (9H, s), 1.66-1.83 (4H, m), 2.54 (2H, d, $J=6.0Hz$), 2.95-3.03 (2H, m), 3.26-3.32 (2H, m), 4.00-4.10 (1H, m), 4.84-4.92 (1H, m), 5.10 (2H, s), 5.60-5.61 (1H, m), 7.35-7.37 (5H, m)

Mass (m/z) : 429 (M^++1)

Preparation 16

To a solution of thiophenol (0.15 ml) in N,N-dimethylformamide (6 ml) was added NaH (58 mg) under ice cooling. After stirring at room temperature for 30 minutes, N-(benzyloxycarbonyl)-3(S)-iodomethyl- β -alanine tert-butyl ester (0.6 g) was added and stirred for additional 1 hour. The mixture was poured into water and

extracted with ethyl acetate. The extract was washed with water, brine and dried over MgSO_4 , and evaporated in vacuo. The residue was purified by column chromatography on silica gel eluting with 5% (EtOAc/n-hexane) to give N-(benzyloxycarbonyl)-3(S)-phenylthiomethyl- β -alanine tert-butyl ester (0.64 g) as a pale yellow oil.

IR (Film) : 3320, 1720 cm^{-1}

NMR (CDCl_3 , δ) : 1.41 (9H, s), 2.50-2.66 (2H, m), 3.02-3.25 (2H, m), 4.10-4.38 (1H, m), 5.08 (2H, s), 5.45-5.50 (1H, m), 7.18-7.38 (10H, m)

Mass (m/z) : 402 ($\text{M}^+ + 1$)

Preparation 17

To a solution of N-(benzyloxycarbonyl)-3(S)-phenylthiomethyl- β -alanine tert-butyl ester (0.60 g) in chloroform (10 ml) was added m-chloroperbenzoic acid (0.64 g) at 0°C. After stirring at room temperature for 2 hours, the mixture was poured into saturated aqueous NaHCO_3 solution and extracted with chloroform. The extract was washed with aqueous NaHSO_3 solution, water, brine and dried over MgSO_4 , and evaporated in vacuo to give N-(benzyloxycarbonyl)-3(S)-phenylsulfonylmethyl- β -alanine tert-butyl ester (0.4 g) as a colorless oil.

IR (Film) : 3350, 1720, 1520 cm^{-1}

NMR (CDCl_3 , δ) : 1.42 (9H, s), 2.64-2.79 (2H, m), 3.36-3.46 (1H, m), 3.58-4.61 (1H, m), 4.33-4.37 (1H, m), 5.02 (2H, s), 5.37-5.65 (1H, m), 7.33-7.36 (5H, m), 7.49-7.64 (3H, m), 7.88-7.92 (2H, m)

Mass (m/z) : 434 ($\text{M}^+ + 1$)

Preparation 18

(1) A mixture of N-(benzyloxycarbonyl)-3(S)-phenylsulfonylmethyl- β -alanine tert-butyl ester (0.44 g) and 10% Pd-C (0.1 g, 50% wet) in acetic acid (5 ml) was

hydrogenated at 1 atmospheric pressure of hydrogen for 1 hour. The catalyst was filtered off and the filtrate was evaporated in vacuo. The residue was dissolved in ethyl acetate and washed with saturated aqueous NaHCO_3 solution. The organic layer was dried over MgSO_4 and evaporated in vacuo to give 3(S)-phenylsulfonylmethyl- β -alanine tert-butyl ester (0.3 g) as a colorless oil.

IR (Film) : 3570, 3370, 1710 cm^{-1}

NMR (CDCl_3 , δ) : 1.42 (9H, s), 2.31-2.52 (2H, m), 3.21-3.30 (2H, m), 3.68-3.78 (1H, m), 7.54-7.72 (3H, m), 7.91-7.96 (2H, m)

Mass (m/z) : 300 ($\text{M}^+ + 1$)

The following compound was obtained according to a similar manner to that of Preparation 18 (1).

(2) 3(S)-(n-butanesulfonylamino)methyl- β -alanine tert-butyl ester

NMR ($\text{DMSO}-d_6$, δ) : 0.89 (3H, t, $J=7.2\text{Hz}$), 1.40 (9H, s), 1.54-2.13 (4H, m), 2.31-2.41 (1H, m), 2.81-2.87 (2H, m), 2.94-3.02 (4H, m)

Mass (m/z) : 295 ($\text{M}^+ + 1$)

Preparation 19

To a solution of N-[(R)-(1-benzyloxycarbonyl-3-piperidyl)carbonyl]-2(S)-(tert-butoxycarbonylamino)- β -alanine ethyl ester (0.4 g) in ethyl acetate (4 ml) was added 4N HCl in ethyl acetate (2.1 ml) under stirring at 0°C . After stirring at ambient temperature for 2 hours, the resulting precipitates were collected by filtration to give N-[(R)-1-benzyloxycarbonyl-3-piperidyl)carbonyl]-2(S)-amino- β -alanine ethyl ester hydrochloride (0.31 g).

IR (Nujol) : 3300, 1735, 1680, 1640 cm^{-1}

NMR ($\text{DMSO}-d_6$, δ) : 1.02-1.91 (7H, m), 2.21-2.35 (1H, m), 2.80-2.89 (2H, m), 3.42-3.67 (2H, m), 3.90-

4.15 (5H, m), 5.07 (2H, d, $J=2.7\text{Hz}$), 7.28-7.42
(5H, m), 8.43-8.49 (1H, m), 8.64-8.73 (2H, br)
Mass (m/z) : 378 (M^++1) free of compound

5 Preparation 20

10 A solution of N-[(R)-(1-benzyloxycarbonyl-3-
piperidyl)carbonyl]-2(S)-amino- β -alanine ethyl ester
hydrochloride (300 mg) in dichloromethane (3 ml) was added
triethylamine (222 μl) and benzoyl chloride (93 μl) under
15 stirring at 0°C . After stirring at ambient temperature
for 1 hour, the mixture was poured into water and
extracted with dichloromethane. The extract was washed
with water, saturated aqueous NaHCO_3 solution, water and
brine, and dried over MgSO_4 , and evaporated in vacuo. The
residue was recrystallized from diethyl ether to give N-
[(R)-(1-benzyloxycarbonyl-3-piperidyl)carbonyl]-2(S)-
benzoylamino- β -alanine ethyl ester (349 mg).

mp : 135°C

IR (Nujol) : 3290, 1730, 1685, 1655, 1640 cm^{-1}

20 NMR (CDCl_3 , δ) : 1.30 (3H, t, $J=7.1\text{Hz}$), 1.33-2.10
(6H, m), 2.26-2.43 (1H, m), 3.26-4.03 (5H, m),
4.14-4.30 (2H, m), 4.78-4.89 (1H, m), 5.10 (2H,
d, $J=3.9\text{Hz}$), 7.24-7.55 (10H, m), 7.85-7.95 (1H, m)

25 Mass (m/z) : 482 (M^++1)

Preparation 21

30 (1) A solution of N-[(1R)-(1-benzyloxycarbonyl-3-
piperidyl)carbonyl]-2(S)-amino- β -alanine hydrochloride in
water was made basic with aqueous K_2CO_3 solution, and
extracted with ethyl acetate. The extract was dried over
 MgSO_4 , and evaporated in vacuo. The residue (198 mg) was
dissolved in ethyl acetate (5 ml), and added NaHCO_3 (269
mg) and benzenesulfonyl chloride (136 μl). The mixture
was refluxed for 4 hours. After the insoluble material
35 was removed by filtration, the filtrate was concentrated

in vacuo. The residue was purified by column chromatography on silica gel eluting with (CHCl₃:MeOH = 100:1) to give N-[(R)-1-benzyloxycarbonyl-3-piperidyl)carbonyl]-2(S)-phenylsulfonylamino-β-alanine ethyl ester as an oil (255 mg).

IR (Film) : 1720, 1640 cm⁻¹

NMR (CDCl₃, δ) : 1.12 (3H, t, J=7.1Hz), 1.40-2.11 (7H, m), 2.23-2.50 (1H, m), 3.33-3.83 (3H, m), 3.98 (2H, q, J=7.1Hz), 3.93-4.19 (1H, m), 5.16 (2H, q, J=10.0Hz), 7.31-7.40 (10H, m), 7.81-7.86 (2H, m)

Mass (m/z) : 518 (M⁺+1)

The following compound was obtained according to a similar manner to that of Preparation 21 (1).

(2) N-[(R)-(1-benzyloxycarbonyl-3-piperidyl)carbonyl]-2(S)-(n-butanesulfonylamino)-β-alanine ethyl ester

IR (Film) : 2940, 2860, 1730, 1665 cm⁻¹

NMR (CDCl₃, δ) : 0.93 (3H, t, J=7.3Hz), 1.31 (3H, t, J=7.2Hz), 1.37-1.48 (4H, m), 1.56-1.84 (7H, m), 1.91-2.43 (1H, m), 2.97-3.05 (2H, m), 3.35-3.87 (4H, m), 4.15-4.31 (3H, m), 5.10-5.25 (2H, m), 5.82-6.01 (1/2H, m), 6.63-6.83 (1/2H, m), 7.33-7.37 (5H, m)

Mass (m/z) : 498 (M⁺+1)

Preparation 22

To a solution of trimethylsilylacetylene (1715 ml) in tetrahydrofuran (18.0 l) was added ethyl magnesium chloride (2.0M solution in tetrahydrofuran; 6.19 l) was added dropwise below -30°C under nitrogen atmosphere. The reaction mixture was allowed to 0°C and stirred for 1 hour. After cooling to -30°C, 4-acetoxy-2-azetidinone (320 g) was added and warmed to room temperature, and

stirred for 2 hours. After cooling to -20°C , saturated ammonium chloride (4.0 l) was added. Ethyl acetate (20 l) was added and washed with water (10 l x 2) and brine. The organic layer was dried over magnesium sulfate, filtered off and evaporated in vacuo to give 4-(2-trimethylsilylethynyl)-2-azetidinone (425 g), which was essentially pure, so it was used to the next step without further purification.

IR (Nujol) : 3150, 2130, 1740, 1330, 1240, 1090,
1060, 950, 840, 750, 740 cm^{-1}

NMR (CDCl_3 , δ) : 0.16 (9H, s), 3.02 (1H, ddd, $J=14.7$ and 2.7 and 1.6Hz), 3.30 (1H, ddd, $J=14.7$ and 5.3 and 1.8Hz), 4.24 (1H, dd, $J=5.3$ and 2.7Hz), 6.41 (1H, br)

Preparation 23

4-(2-Trimethylsilylethynyl)-2-azetidinone (485 g) and paraformaldehyde (261 g) was heated at 135°C for 45 minutes. The resulting mixture was cooled to room temperature and purified with column chromatography on silica gel ($\text{CH}_2\text{Cl}_2:\text{EtOAc} = 8:2$) to give N-hydroxymethyl-4-(2-trimethylsilylethynyl)-2-azetidinone (429 g).

IR (Nujol) : 3300, 1710, 1280, 1230, 1020, 820 cm^{-1}

NMR (CDCl_3 , δ) : 0.18 (9H, s), 3.02 (1H, dd, $J=14.8$ and 2.7Hz), 3.26 (1H, dd, $J=14.8$ and 5.4Hz), 3.69 (1H, dd, $J=9.4$ and 5.3Hz), 4.41 (2H, m), 5.01 (1H, dd, $J=11.8$ and 5.2Hz)

FAB-Mass : 197 (M^++1)

Preparation 24

To a solution of N-hydroxymethyl-4-(2-trimethylsilylethynyl)-2-azetidinone (250 g) in dichloromethane (6.5 l) was added vinyl acetate (350 ml) and Lipase PS (trademark; Amano Pharmaceutical Co., Ltd.) (190 g). The mixture was warmed to 37°C and stirred for

32 hours. Catalyst was filtered off and washed with dichloromethane. Solvent was evaporated in vacuo. The residue was subjected to silica gel column chromatography eluting with (n-hexane:EtOAc = 8:2 to 0:1) to give (R)-N-hydroxymethyl-4-(2-trimethylsilylethynyl)-2-azetidinone (192 g).

$[\alpha]_D^{20} = -133.9^\circ$ (C=1.12, CHCl₃)

IR (Nujol) : 3300, 1710, 1280, 1230, 1020, 820 cm⁻¹

NMR (CDCl₃, δ) : 0.18 (9H, s), 3.02 (1H, dd, J=14.8 and 2.7Hz), 3.26 (1H, dd, J=14.8 and 5.4Hz), 3.69 (1H, dd, J=9.4 and 5.3Hz), 4.41 (2H, m), 5.01 (1H, dd, J=11.8 and 5.2Hz)

FAB-Mass : 197.8 (M⁺)

Preparation 25

To aqueous ammonia (300 ml) and methanol (1000 ml) was added (S)-N-hydroxymethyl-4-(2-trimethylsilylethynyl)-2-azetidinone (101 g). The resulting mixture was stirred at room temperature for overnight. Solvent was evaporated in vacuo and the residue was added ethyl acetate (1.5 l) and washed with water (100 ml x 3) and brine. The organic layer was dried over MgSO₄, filtered off and evaporated in vacuo. The residue was purified by column chromatography on silica gel eluting with (CH₂Cl₂:EtOAc = 9:1) to (S)-4-ethynyl-2-azetidinone (29.8 g).

$[\alpha]_D^{20} = -63.3^\circ$ (C=1.09, CHCl₃)

IR (Nujol) : 3200, 2080, 1400, 1320, 1160 cm⁻¹

NMR (CDCl₃, δ) : 2.46 (1H, d, J=2.0Hz), 3.11 (1H, ddd, J=14.8 and 2.5 and 1.6Hz), 3.35 (1H, ddd, J=14.8 and 5.3 and 1.8Hz), 4.27 (1H, m), 6.46 (1H, br)

Preparation 26

To a solution of (S)-4-ethynyl-2-azetidinone (28.5 g) in ethanol (140 ml) was added a solution of HCl in ethanol

(5.86N) below 10°C, and stirred for 1 hour at room temperature. The mixture was evaporated in vacuo. The residue was washed with diethyl ether and collected by filtration to give ethyl (S)-3-amino-4-pentynoate hydrochloride (50.3 g) as white crystal. The ratio of enantiomers was determined to be 98.5:1.5 by chiral HPLC using CROWNPAK CR(+) (trademark; DAICEL CHEMICAL INDUSTRIES, LTD.).

$[\alpha]_D^{20} = -6.27^\circ$ (C=1.11, MeOH)

IR (Nujol) : 3210, 2190, 1710, 1560 cm^{-1}

NMR (DMSO- d_6 , δ) : 1.21 (3H, t, J=7.1Hz), 2.84 (1H, dd, J=16.1 and 9.1Hz), 3.07 (1H, dd, J=16.1 and 5.0Hz), 4.13 (2H, q, J=7.1Hz), 4.29 (1H, m), 8.94 (3H, br)

Mass (m/z) : 142 ($M^+ + 1$)

Preparation 27

To a solution of CBr_4 (3.11 g) in dichloromethane (15 ml) was added dropwise a solution of triphenylphosphine (4.92 g) in dichloromethane (15 ml) at 0°C. After stirring for 10 minutes a solution of (S)-N-tert-butyldimethylsilyl-4-formyl-2-azetidinone (1.0 g) in dichloromethane (10 ml) was added dropwise at 0°C and stirred for 20 minutes. The mixture was poured into saturated aqueous NaHCO_3 solution and extracted with dichloromethane. The extract was washed with water, dried over MgSO_4 and evaporated in vacuo. The residue was purified by chromatography on silica gel eluting with (diethyl ether:n-hexane = 1:5) to give (S)-N-tert-butyldimethylsilyl-4-(2,2-dibromoethenyl)-2-azetidinone (0.83 g) as a pale yellow oil.

IR (Film) : 3450, 3300, 1740, 1600 cm^{-1}

NMR (CDCl_3 , δ) : 0.12 (3H, s), 0.16 (3H, s), 0.85 (9H, s), 2.75 (1H, dd, J=2.8 and 15.6Hz), 3.30 (1H, dd, J=5.6 and 15.6Hz), 4.13-4.22 (1H, m),

6.38 (1H, d, J=8.8Hz)
Mass (m/z) : 370 (M⁺+1)

Preparation 28

5 To a solution of (S)-N-tert-butyldimethylsilyl-4-(2,2-dibromoethenyl)-2-azetidinone (0.63 g) was added lithium bis(trimethylsilyl)amide (3.75 ml, 1 mol solution in n-hexane) at -75°C. After stirring at -75°C for 1 hour, a saturated aqueous NH₄Cl solution was added and extracted with ethyl acetate. The extract was washed with water and brine, dried over MgSO₄, and evaporated in vacuo. The residue was purified by chromatography on silica gel eluting with (diethyl ether:n-hexane = 1:5) to give (S)-N-tert-butyldimethylsilyl-4-ethynyl-2-azetidinone (0.20 g) as an colorless oil.

10
15 $[\alpha]_D^{20} = -61.5^\circ$ (C=1.0, MeOH)

IR (Film) : 3420, 3250, 2100, 1720 cm⁻¹

NMR (CDCl₃, δ) : 0.19 (6H, s), 0.88 (9H, s), 2.35 (1H, d, J=2.2Hz), 3.02 (1H, dd, J=3.0 and 15.1Hz), 3.28 (1H, dd, J=5.6 and 15.1Hz), 4.00-4.05 (1H, m)

20
25 Mass (m/z) : 210 (M⁺+1)

Preparation 29

25 To a solution of (S)-N-tert-butyldimethylsilyl-4-ethynyl-2-azetidinone (120 mg) was added 4N HCl in ethanol (2 ml) at room temperature. After stirring for 1 hour, the mixture was evaporated in vacuo. The residue was recrystallized from diethyl ether to give ethyl (S)-3-amino-4-pentynoate hydrochloride (50 ml) as a white solid. The ratio of enantiomers was determined to be 99.5:0.5 by chiral HPLC using CROWNPAK CR(+).

30
35 $[\alpha]_D^{20} = -7.1^\circ$ (C=1.0, MeOH)

IR (Nujol) : 3210, 2190, 1710, 1560 cm⁻¹

NMR (DMSO-d₆, δ) : 1.21 (3H, t, J=7.1Hz), 2.84 (1H,

dd, J=16.1 and 9.1Hz), 3.07 (1H, dd, J=16.1 and 5.0Hz), 4.13 (2H, q, J=7.1Hz), 4.29 (1H, m), 8.94 (3H, br)

Mass (m/z) : 142 (M⁺+1)

Preparation 30

To a mixture of zinc (11.9 g) in tetrahydrofuran (215 ml) was added titanium (IV) isopropoxide (6.0 ml) at ambient temperature and the resultant mixture was stirred for 1 hour. A solution of methyleneiodide (8.1 ml) was then added to the mixture was stirred for 30 minutes. To the resultant mixture was added dropwise a solution of (S)-N-tert-butyldimethylsilyl-4-formyl-2-azetidinone (4.3 g) in tetrahydrofuran (130 ml) and stirred for 2 hours. The mixture was poured into a mixture of diethyl ether (500 ml) and 1N HCl (300 ml). The organic layer was washed with water, saturated aqueous NaHCO₃ solution and brine, dried over MgSO₄, and evaporated in vacuo. The residue was purified by chromatograph on silica gel eluting with (EtOAc:n-hexane = 1:10) to give (S)-N-tert-butyldimethylsilyl-4-vinyl-2-azetidinone (2.13 g) as a colorless oil.

$[\alpha]_D^{20} = -15.6^\circ$ (C=1.0, MeOH)

IR (Film) : 2940, 2860, 1730 cm⁻¹

NMR (CDCl₃, δ) : 0.17 (3H, s), 0.19 (3H, s), 0.96 (9H, s), 2.77 (1H, dd, J=2.8 and 14.7Hz), 3.30 (1H, dd, J=5.6 and 14.7Hz), 3.97-4.06 (1H, m), 5.15-5.13 (2H, m), 5.58-5.76 (1H, m)

Mass (m/z) : 212 (M⁺+1)

Preparation 31

To a solution of (S)-N-tert-butyldimethylsilyl-4-vinyl-2-azetidinone (1.0 g) in ethanol (5 ml) was added 6N HCl in ethanol (5 ml) at 0°C. After stirring for 1 hour, the mixture was evaporated in vacuo and the resultant

solid was washed with diethyl ether to give ethyl (S)-3-amino-4-pentenoate hydrochloride (0.67 g) as a white solid.

$[\alpha]_D^{20} = -8.9^\circ$ (C=1.0, MeOH)

IR (Nujol) : 3420, 2100, 1720, 1600 cm^{-1}

NMR (DMSO- d_6 , δ) : 1.19 (3H, t, $J=7.1\text{Hz}$), 2.70 (1H, dd, $J=8.4$ and 16.0Hz), 2.91 (1H, dd, $J=5.7$ and 16.0Hz), 3.93-4.00 (1H, m), 4.05 (2H, q, $J=7.1\text{Hz}$), 5.31 (1H, d, $J=8.0\text{Hz}$), 5.38 (1H, d, $J=15.0\text{Hz}$), 5.80-5.97 (1H, m), 8.54 (3H, br)

Elemental Analysis $\text{C}_7\text{H}_{13}\text{NO}_2 \cdot \text{HCl} \cdot 0.2\text{C}_2\text{H}_5\text{OH}$

Calcd. : C 47.11, H 8.01, N 7.42

Found : C 47.26, H 8.37, N 7.79

Example 1

(1) To a mixture of ethyl 3-amino-2-ethynylpropionate hydrochloride (0.5 g), (R)-1-[3-(1-tert-butoxycarbonyl-4-piperidyl)propionyl]-3-piperidinecarboxylic acid (1.04 g) and 1-hydroxybenztriazole (0.38 g) in N,N-dimethylformamide (5 ml) was added 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (0.51 ml) under stirring at 0°C . After stirring at ambient temperature overnight, the mixture was poured into water and extracted with ethyl acetate. The extract was washed with water, brine and dried over MgSO_4 , and evaporated in vacuo. The residue was purified by chromatography on silica gel eluting with $\text{CHCl}_3:\text{MeOH} = (100:1)$ to give N-[(R)-1-[3-(1-tert-butoxycarbonyl-4-piperidyl)propionyl]-3-piperidylcarbonyl]-3-ethynyl- β -alanine ethyl ester as an oil (1.38 g).

IR (Film) : 3440, 3270, 2960, 2920, 2850, 1720, 1710, 1640 cm^{-1}

NMR (CDCl_3 , δ) : 0.98-1.20 (1H, m), 1.28 (3H, t, $J=7.1\text{Hz}$), 1.45 (9H, s), 1.45-1.78 (8H, m), 1.89-2.07 (2H, m), 2.26-2.39 (4H, m), 2.61-2.74 (4H,

m), 3.20-3.34 (2H, m), 3.53-3.69 and 3.82-3.97
(total 1H, m), 4.02-4.50 (5H, m), 5.03-5.18 (1H,
m), 6.80-6.90 and 7.06-7.16 (total 1H, m)
Mass (m/z) : 492 ($M^+ + 1$)

5

The following compounds were obtained according to a
similar manner to that of Example 1 (1).

(2) (3R)-N-[(R)-1-{3-(1-tert-butoxycarbonyl-4-
piperidyl)propionyl}-3-piperidylcarbonyl]-3-methyl- β -
alanine methyl ester

10

IR (Film) : 3350, 2980, 2930, 2860, 1710, 1620 cm^{-1}

NMR (CDCl_3 , δ) : 1.02-1.15 (2H, m), 1.22 (3H, d,
J=6.8Hz), 1.45 (9H, s), 1.34-1.79 (9H, m), 1.99-
2.16 (1H, m), 2.05-2.73 (7H, m), 3.18-3.58 (2H,
m), 3.67-3.70 (3H, m), 3.85-4.14 (3H, m), 4.29-
4.49 (1H, m), 6.32-6.43 and 6.69-6.79 (total 1H,
m)

15

Mass (m/z) : 468 ($M^+ + 1$)

20

(3) N-[(R)-1-{3-(1-tert-butoxycarbonyl-4-piperidyl)-
propionyl}-3-piperidylcarbonyl]- β -alanine ethyl ester

IR (Film) : 3420, 3300, 2920, 2850, 1725, 1665,
1630 cm^{-1}

25

NMR (CDCl_3 , δ) : 1.00-1.21 (2H, m), 1.27 (3H, t,
J=7.1Hz), 1.45 (9H, s), 1.52-1.77 (7H, m), 1.83-
2.09 (2H, m), 2.17-2.39 (3H, m), 2.48-2.73 (4H,
m), 3.16-3.68 and 3.83-3.96 (total 5H, m), 4.02-
4.25 and 4.36-4.99 (total 3H, m), 4.16 (2H, q,
J=7.2Hz), 6.23-6.26 and 6.55-6.66 (total 1H, m)

30

Mass (m/z) : 468 ($M^+ + 1$)

(4) N-[1-{2-(1-benzyloxycarbonyl-4-piperidyloxy)acetyl}-
3-piperidylcarbonyl]- β -alanine methyl ester

35

IR (Film) : 3320, 3000, 2940, 2860, 1730, 1640 cm^{-1}

NMR (CDCl₃, δ) : 1.40-2.01 (9H, m), 2.21-2.36 (1H, m), 2.53 (2H, t, J=5.9Hz), 3.13-3.34 (3H, m), 3.48-3.61 (3H, m), 3.70 (3H, s), 3.97-4.00 (3H, m), 4.11-4.41 (3H, m), 5.12 (2H, s), 6.20-6.30 and 6.42-6.51 (total 1H, m), 7.30-7.37 (5H, m)

Mass (m/z) : 490 (M⁺+1)

(5) N-[(R)-1-{3-(1-tert-butoxycarbonyl-4-piperidyl)-propionyl}-3-piperidylcarbonyl]-3(S)-(4-methoxyphenethyl)aminocarbonyl-β-alanine benzyl ester
mp : 143°C

IR (Nujol) : 3280, 1735, 1680, 1635 cm⁻¹

NMR (CDCl₃, δ) : 0.98-1.26 (3H, m), 1.34-1.84 (9H, m), 1.45 (9H, s), 2.19-2.36 (3H, m), 2.52-2.82 (6H, m), 3.01-3.28 (1H, m), 3.39-3.64 (3H, m), 3.78 (3H, s), 4.01-4.44 (3H, m), 4.76-4.86 (1H, m), 5.17 (2H, s), 5.64-5.72 (1/3H, m), 6.00-6.07 (2/3H, m), 6.83 (2H, d, J=8.6Hz), 6.86-7.20 (3H, m), 7.34 (5H, s)

Mass (m/z) : 607 (M⁺+1-Boc)

(6) N-[(R)-1-{3-(1-tert-butoxycarbonyl-4-piperidyl)-propionyl}-3-piperidylcarbonyl]-3(R)-phenethyl-β-alanine ethyl ester

IR (Film) : 3450, 3310, 2980, 2930, 2860, 1720, 1640 cm⁻¹

NMR (CDCl₃, δ) : 1.01-1.20 (2H, m), 1.22-1.30 (3H, m), 1.45 (9H, s), 1.45-2.05 (13H, m), 2.28-2.72 (8H, m), 3.16-3.59 (2H, m), 3.91-4.48 (4H, m), 4.11 (2H, q, J=7.1Hz), 6.40 (1/3H, d, J=9.0Hz), 6.76 (2/3H, d, J=8.8Hz), 7.16-7.31 (5H, m)

Mass (m/z) : 572 (M⁺+1)

(7) N-[(R)-1-{3-(1-tert-butoxycarbonyl-4-piperidyl)propionyl}-3-piperidylcarbonyl]-β-alanine

benzyl ester

IR (Film) : 2910, 2840, 1720, 1630 cm^{-1}

NMR (CDCl_3 , δ) : 1.01-1.22 (3H, m), 1.45 (9H, s),
1.33-2.00 (6H, m), 2.18-2.35 (3H, m), 2.54-2.73
(5H, m), 3.15-3.32 (2H, m), 3.45-3.65 (3H, m),
3.81-3.95 (1/2H, m), 4.02-4.19 (3H, m), 4.35-
4.49 (1/2H, m), 5.14 (2H, s), 6.12-6.25 (1/3H,
m), 6.54-6.63 (2/3H, m), 7.36 (5H, s)

Mass (m/z) : 530 ($\text{M}^+ + 1$)

(8) N-[(R)-1-{3-(1-tert-butoxycarbonyl-4-
piperidyl)propionyl}-3-piperidylcarbonyl]- β -alanine
1-cyclohexyloxycarbonyloxy)ethyl ester

IR (Film) : 2920, 2850, 1740, 1630 cm^{-1}

NMR (DMSO-d_6 , δ) : 1.00-1.83 (13H, m), 1.45 (9H, s),
1.53 (3H, d, $J=5.5\text{Hz}$), 1.89-2.08 (5H, m), 2.02-
2.44 (4H, m), 2.52-2.73 (5H, m), 3.11-3.29 (2H,
m), 3.39-3.72 (3H, m), 3.88-4.31 (4H, m), 3.87-
4.48 (1H, m), 6.30-6.40 (1/3H, m), 6.60-6.69
(2/3H, m), 6.72-6.77 (1H, m)

Mass (m/z) : 610 ($\text{M}^+ + 1$)

(9) N-[(R)-1-{3-(1-tert-butoxycarbonyl-4-
piperidyl)propionyl}-3-piperidylcarbonyl]-3(S)-
phenylsulfonylmethyl- β -alanine tert-butyl ester

IR (Film) : 3300, 1720, 1660, 1620 cm^{-1}

NMR (CDCl_3 , δ) : 1.08-1.14 (2H, m), 1.42 (9H, s),
1.45 (9H, s), 1.52-1.87 (8H, m), 2.20-2.36 (3H,
m), 2.67-2.72 (4H, m), 3.27-3.38 (3H, m), 3.60-
3.70 (2H, m), 3.86-4.15 (3H, m), 4.48-4.60 (2H,
m), 7.58-7.62 (3H, m), 7.90-7.94 (2H, m)

Mass (m/z) : 650 ($\text{M}^+ + 1$)

(10) N-[(R)-1-{3-(1-tert-butoxycarbonyl-4-
piperidyl)propionyl}-3-piperidylcarbonyl]-3(S)-(n-

butanesulfonylaminomethyl)- β -alanine tert-butyl ester

IR (Film) : 3280, 1720, 1650, 1620 cm^{-1}

NMR (CDCl_3 , δ) : 0.95 (3H, t, $J=7.2\text{Hz}$), 1.18-1.20
(2H, m), 1.45 (18H, s), 1.50-2.10 (15H, m),
2.36-2.40 (3H, m), 2.48-2.72 (4H, m), 2.89-3.05
(3H, m), 3.28-3.35 (2H, m), 3.42-3.55 (1H, m),
3.98-4.24 (3H, m), 4.90-5.10 (1H, m)

Mass (m/z) : 645 (M^+1)

(11) N-(R)-1-{3-(1-tert-butoxycarbonyl-4-piperidyl)-
propionyl}-3-piperidylcarbonyl]-3(R)-(4-
methoxyphenethyl)- β -alanine methyl ester

IR (Film) : 2930, 2860, 1730, 1630 cm^{-1}

NMR (CDCl_3 , δ) : 1.02-1.21 (2H, m), 1.45 (9H, s),
1.53-1.89 (10H, m), 2.00-2.23 (1H, m), 2.29-2.73
(9H, m), 3.16-3.59 (3H, m), 3.66 (3H, s), 3.78
(3H, s), 3.91 (1H, dd, $J=13.8$ and 3.6Hz), 4.08
(2H, d, $J=12.7\text{Hz}$), 4.23-4.37 (1H, m), 6.72-6.80
(1H, m), 6.82 (2H, d, $J=8.6\text{Hz}$), 7.09 (2H, d,
 $J=8.6\text{Hz}$)

Mass (m/z) : 588 (M^++1)

(12) Ethyl [N-[(R)-1-{3-(1-tert-butoxycarbonyl-4-
piperidyl)propionyl}-3-piperidylcarbonyl]-2-
piperidyl]acetate

IR (Film) : 2980, 2930, 2860, 1720, 1675, 1625 cm^{-1}

NMR (CDCl_3 , δ) : 1.00-1.30 (4H, m), 1.45 (9H, s),
1.53-1.87 (14H, m), 2.31-3.28 (11H, m),
3.61-3.89 (2H, m), 4.03-4.16 (4H, m), 4.50-4.69
(2H, m), 4.69-4.75 (1/3H, m), 5.13-5.28 (2/3H,
m)

Mass (m/z) : 522 (M^++1)

(13) N-[4-{3-(1-tert-butoxycarbonyl-4-piperidyl)-
propionyl}-2-morpholinylcarbonyl]- β -alanine ethyl

ester

IR (Film) : 2910, 2850, 1720, 1600 cm^{-1}

NMR (CDCl_3 , δ) : 1.01-1.21 (1H, m), 1.28 (3H, t, $J=7.1\text{Hz}$), 1.45 (9H, m), 1.45-1.73 (6H, m), 2.30-2.47 (2H, m), 2.52-2.93 (5H, m), 3.04-3.16 (1H, m), 3.49-3.62 (3H, m), 3.86-4.38 (6H, m), 4.18 (2H, q, $J=7.2\text{Hz}$), 7.09-7.19 (1H, m)

Mass (m/z) : 470 (M^++1)

14) N-[(R)-1-{3-(1-tert-butoxycarbonyl-4-piperidyl)propionyl}-3-piperidylcarbonyl]-3-phenyl- β -alanine methyl ester

IR (Film) : 2940, 2860, 1735, 1630 cm^{-1}

NMR (CDCl_3 , δ) : 0.99-1.24 (2H, m), 1.45 (9H, s), 1.45-1.89 (9H, m), 2.00-2.16 (1H, m), 2.25-2.44 (3H, m), 2.61-2.96 (4H, m), 3.19-3.55 (2H, m), 3.55 (3H, s), 3.62-4.48 (4H, m), 5.37-5.47 (1H, m), 7.28-7.35 (5H, m)

Mass (m/z) : 530 (M^++1)

(15) N-[(R)-1-{3-(1-tert-butoxycarbonyl-4-piperidyl)propionyl}-3-piperidylcarbonyl]-3(R)-(3,4-dimethoxyphenethyl)- β -alanine methyl ester

IR (Film) : 3290, 2980, 2925, 2850, 1720, 1650, 1620 cm^{-1}

NMR (CDCl_3 , δ) : 1.02-1.23 (3H, m), 1.45 (9H, s), 1.45-1.94 (9H, m), 2.03-2.73 (11H, m), 3.18-3.67 (3H, m), 3.66 (3H, s), 3.85 (3H, s), 3.88 (3H, s), 3.92-4.11 (2H, m), 4.23-4.47 (1H, m), 6.69-6.81 (4H, m)

Mass (m/z) : 618 (M^++1)

(16) N-[(R)-1-{3-(1-tert-butoxycarbonyl-4-piperidyl)propionyl}-3-piperidylcarbonyl]-3(S)-hydroxymethyl- β -alanine tert-butyl ester

NMR (CDCl₃, δ) : 1.08-1.18 (3H, m), 1.45 (18H, s),
1.56-1.99 (8H, m), 2.32-2.36 (3H, m), 2.50-2.73
(4H, m), 3.00-3.33 (2H, m), 3.52-3.62 (1H, m),
3.69 (3H, t, J=5.2Hz), 4.04-4.20 (4H, m), 6.92
and 7.27 (total 1H, br)

(17) N-[(R)-1-{3-(1-tert-butoxycarbonyl-4-
piperidyl)propionyl}-3-piperidylcarbonyl]-3(R)-(3-
methoxyphenethyl)-β-alanine methyl ester

IR (Film) : 3280, 1640, 1420, 1240, 1150, 860, 740,
680 cm⁻¹

NMR (DMSO-d₆, δ) : 0.80-1.15 (6H, m), 1.38 (9H, s),
1.50-1.96 (6H, m), 2.02-3.10 (16H, m), 3.55 (3H,
s), 3.72 (3H, s), 3.95 (2H, m), 4.08-4.22 (1H,
m), 6.73 (3H, m), 7.17 (1H, m), 7.84 (1H, m),
8.31 (1H, s)

Mass (m/z) : 588 (M⁺+1)

(18) N-[(R)-1-{3-(1-tert-butoxycarbonyl-4-
piperidyl)propionyl}-3-piperidylcarbonyl]-3(R)-[2-(3-
indolyl)ethyl]-β-alanine methyl ester

IR (Film) : 3450, 1710, 1660, 1610 cm⁻¹

NMR (CDCl₃, δ) : 1.08-1.14 (1H, m), 1.42 (9H, s),
1.45-2.24 (18H, m), 2.34-2.79 (7H, m), 3.35-3.50
(1H, m), 3.64 and 3.68 (total 1H, s), 3.91-4.11
(2H, m), 4.37 (1H, br), 6.67-6.71 (1H, m), 7.01
(1H, s), 7.04-7.26 (2H, m), 7.32-7.37 (1H, m),
7.56-7.60 (1H, m), 8.14-8.20 (1H, m)

Mass (m/z) : 597 (M⁺+1)

(19) N-[(R)-1-{3-(1-tert-butoxycarbonyl-4-
piperidyl)propionyl}-3-piperidylcarbonyl]-3(R)-(3-
trifluoromethylphenethyl)-β-alanine methyl ester

IR (Film) : 2980, 2925, 2860, 1720, 1645 cm⁻¹

NMR (CDCl₃, δ) : 1.00-1.21 (2H, m), 1.45 (9H, s),

1.45-1.72 (9H, m), 1.84-2.20 (3H, m), 2.34-2.77
(9H, m), 3.39-3.50 (1H, m), 3.63-3.69 (4H, m),
3.80-3.81 (1H, m), 4.02-4.17 (2H, m), 4.25-4.39
(1H, m), 6.45-6.53 (1/3H, m), 6.89-6.93 (2/3H,
m), 7.35-7.43 (4H, m)

Mass (m/z) : 626 ($M^+ + 1$)

(20) N-[(R)-1-{3-(1-tert-butoxycarbonyl-4-

piperidyl)propionyl}-3-piperidylcarbonyl]-3(R)-(2-
methoxyphenethyl)- β -alanine methyl ester

IR (Film) : 2990, 2930, 2860, 1725, 1660, 1620 cm^{-1}

NMR (CDCl_3 , δ) : 1.00-1.21 (2H, m), 1.45 (9H, s),
1.53-2.15 (11H, m), 2.21-2.38 (3H, m), 2.48-2.66
(6H, m), 3.15-3.60 (2H, m), 3.65 (3H, s), 3.81
(3H, s), 3.86-4.50 (4H, m), 6.23-6.35 (1H, m),
6.64 (1H, d, $J=8.6\text{Hz}$), 6.81-6.91 (2H, m), 7.09-
7.19 (2H, m)

Mass (m/z) : 588 ($M^+ + 1$)

(21) N-[(R)-1-{3-(1-tert-butoxycarbonyl-4-

piperidyl)propionyl}-3-piperidylcarbonyl]-3(R)-(3,4-
methylenedioxyphenethyl)- β -alanine methyl ester

IR (Film) : 2980, 2925, 2860, 1725, 1630 cm^{-1}

NMR (CDCl_3 , δ) : 1.00-1.21 (2H, m), 1.45 (9H, s),
1.56 (2H, d, $J=7.4\text{Hz}$), 1.45-2.11 (8H, m), 2.34-
2.73 (10H, m), 3.16-3.60 (3H, m), 3.66 (3H, s),
3.91 (1H, dd, $J=13.7$ and 3.5Hz), 4.02-4.15 (2H,
m), 4.20-4.34 (1H, m), 5.91 (2H, s), 6.59-6.74
(3H, m), 6.79 (1H, d, $J=8.7\text{Hz}$)

Mass (m/z) : 602 ($M^+ + 1$)

(22) N-[(R)-1-{3-(1-tert-butoxycarbonyl-4-

piperidyl)propionyl}-3-piperidylcarbonyl]-3(S)-vinyl-
 β -alanine ethyl ester

IR (Film) : 3300, 1720, 1680, 1630, 1530 cm^{-1}

NMR (CDCl₃, δ) : 1.03-1.21 (2H, m), 1.26 (3H, t, J=7.2Hz), 1.45 (9H, s), 1.52-2.05 (10H, m), 2.33-2.41 (3H, m), 2.55-2.73 (4H, m), 3.27-3.54 (2H, m), 4.07-4.18 (5H, m), 4.62-4.90 (1H, m), 5.12-5.24 (2H, m), 5.76-5.92 (1H, m), 6.64-6.68, 6.88-6.92 (total 1H, m)

Mass (m/z) : 494 (M⁺+1)

(23) N-[(R)-1-{3-(1-tert-butoxycarbonyl-4-piperidyl)propionyl}-3-piperidylcarbonyl]-3(S)-ethynyl-β-alanine ethyl ester

IR (Film) : 3250, 1730, 1670, 1630, 1610 cm⁻¹

NMR (CDCl₃, δ) : 1.00-1.21 (2H, m), 1.28 (3H, t, J=7.2Hz), 1.50 (9H, s), 1.52-2.03 (9H, m), 1.98 (1H, s), 2.28-2.40 (4H, m), 2.62-2.73 (4H, m), 3.21-3.62 (2H, m), 4.07-4.23 (5H, m), 5.08-5.12 (1H, m), 7.06 and 7.28 (total 1H, br)

(24) N-[(R)-1-{3-(1-tert-butoxycarbonyl-4-piperidyl)propionyl}-3-piperidylcarbonyl]-3(S)-propargylaminocarbonyl-β-alanine benzyl ester

IR (Film) : 3020, 2910, 2840, 1720, 1640, 1620 cm⁻¹

NMR (CDCl₃, δ) : 0.98-1.19 (2H, m), 1.45 (9H, s), 1.51-1.71 (7H, m), 1.84-2.04 (2H, m), 2.20-2.40 (4H, m), 2.60-3.10 (5H, m), 3.16-3.36 (2H, m), 3.54-3.91 (1H, m), 3.97-4.44 (5H, m), 4.79 (1H, q, J=6.4Hz), 5.14 (2H, s), 6.81-6.89 (1H, m), 7.35 (5H, s)

Mass (m/z) : 611 (M⁺+1)

(25) N-[1-{3-(1-tert-butoxycarbonyl-4-piperidyl)propionyl}-3-pyrrolidinylcarbonyl]-3(S)-ethynyl-β-alanine ethyl ester

IR (Film) : 3280, 1730, 1670, 1630, 1530 cm⁻¹

NMR (CDCl₃, δ) : 1.8-1.18 (2H, m), 1.26-1.33 (3H, t,

J=7.4Hz), 1.45 (9H, s), 1.59-1.69 (2H, m), 1.64 (3H, s), 2.09-2.31 (5H, m), 2.61-2.96 (5H, m), 3.44-3.76 (4H, m), 4.15-4.19 (2H, m), 4.22 (2H, q, J=7.4Hz), 5.05-5.12 (1H, m), 6.50-6.70 (1H, m)

(26) N-[(R)-1-{3-(1-tert-butoxycarbonyl-4-piperidyl)propionyl}-3-piperidylcarbonyl]-2-methyl- β -alanine methyl ester

IR (Film) : 3260, 1720 cm^{-1}

NMR (CDCl_3 , δ) : 1.08-1.45 (4H, m), 1.52 (9H, s), 1.60-1.63 (7H, m), 1.92-1.97 (2H, m), 2.25-2.39 (3H, m), 2.62-2.73 (3H, m), 3.24-3.56 (5H, m), 3.71 (3H, s), 3.56-3.70 (1H, m), 4.05-4.11 (3H, m), 6.42-6.58 (1H, m)

Mass (m/z) : 468 (M^++1)

(27) N-[(S)-1-{3-(1-tert-butoxycarbonyl-4-piperidyl)propionyl}-3-piperidylcarbonyl]-3-ethynyl- β -alanine ethyl ester

IR (Film) : 2980, 2930, 2860, 1730, 1640 cm^{-1}

NMR (CDCl_3 , δ) : 1.01-1.21 (2H, m), 1.28 (3H, t, J=7.1Hz), 1.45 (9H, s), 1.40-1.80 (7H, m), 1.88-2.00 (2H, m), 2.28 (1H, d, J=2.4Hz), 2.32-2.46 (3H, m), 2.61-2.74 (6H, m), 3.33 (1H, dd, J=13.6 and 9.2Hz), 4.02-4.14 (3H, m), 4.19 (2H, q, J=7.1Hz), 5.03-5.14 (1H, m), 6.68-7.02 (1H, m)

Mass (m/z) : 492 (M^++1)

(28) 4-[3-{3-(1-tert-butoxycarbonyl-4-piperidyl)propionyl-amino}-1-piperidyl]-4-oxo-butyric acid methyl ester

IR (Film) : 2970, 2920, 2850, 1725, 1650, 1630 cm^{-1}

NMR (CDCl_3 , δ) : 0.98-1.21 (2H, m), 1.45 (9H, s), 1.53-1.92 (9H, m), 2.23 (2H, q, J=7.0Hz), 2.36-2.99 (6H, m), 3.15-3.59 (3H, m), 3.69 (3H, s),

3.74-3.92 (1H, m), 4.00-4.13 (3H, m), 6.09 and
6.24 (total 1H, d, J=6.5 and 7.6Hz)

Mass (m/z) : 354 ($M^+ + 1$ -Boc)

5 (29) 4-[3-{3-(1-tert-butoxycarbonyl-4-
piperidyl)propionylamino}piperidyl]-4-oxo-2(S)-
benzyloxycarbonylamino butyric acid tert-butyl ester
IR (Film) : 2950, 2900, 2850, 1700, 1640 cm^{-1}

10 NMR (CDCl_3 , δ) : 0.97-1.19 (2H, m), 1.43 (9H, s),
1.44 (9H, s), 1.52-2.05 (9H, m), 2.14-2.33 (2H,
m), 2.45-2.74 (4H, m), 2.88-3.58 (3H, m), 3.73-
4.48 (5H, m), 4.81-5.19 (3H, m), 6.75-6.79 and
6.76-6.82 (total 1H, m), 7.34 (5H, s)

15 Mass (m/z) : 645 ($M^+ + 1$)

15 (30) N-[(R)-1-{3-(1-tert-butoxycarbonyl-4-
piperidyl)propionyl}-3-piperidylcarbonyl]-2(S)-
acetyl amino- β -alanine ethyl ester

20 IR (Film) : 3300, 1730, 1660 cm^{-1}

20 NMR (CDCl_3 , δ) : 1.08-1.13 (2H, m), 1.28 (3H, t,
J=7.1Hz), 1.45 (9H, s), 1.54-1.74 (10H, m), 2.06
(3H, s), 2.25-2.47 (4H, m), 2.62-2.74 (2H, m),
3.25-3.38 (2H, m), 3.82-3.90 (1H, m), 4.03-4.26
(6H, m), 4.72-4.76 (1H, m), 7.19-7.26 (1H, m)

25 Mass (m/z) : 525 ($M^+ + 1$)

30 (31) Ethyl N-[(R)-1-{3-(1-tert-butoxycarbonyl-4-
piperidyl)propionyl}-3-piperidylcarbonyl]-2-piperidyl
carboxylate

30 NMR ($\text{DMSO}-d_6$, δ) : 0.82-1.09 (2H, m), 1.17 (3H, t,
J=7.1Hz), 1.38 (9H, s), 1.31-1.99 (11H, m),
2.25-2.39 (2H, m), 2.53-3.14 (8H, m), 3.32-4.08
(6H, m), 4.03 (2H, q, J=7.1Hz), 4.16-4.37 (2H,
m)

35 Mass (m/z) : 508 ($M^+ + 1$)

(32) N-[(R)-1-{3-(1-tert-butoxycarbonyl-4-piperidyl)propionyl}-3-piperidylcarbonyl]-2-benzyl-β-alanine ethyl ester

NMR (DMSO-d₆, δ) : 0.84-1.21 (5H, m), 1.38 (9H, s), 1.38-1.89 (11H, m), 2.26-2.37 (2H, m), 2.52-3.29 (9H, m), 3.68-4.08 (4H, m), 4.13-4.41 (1H, m), 7.14-7.31 (5H, m), 7.95-8.12 (1H, m)

Mass (m/z) : 558 (M⁺+1)

(33) N-[(R)-1-{3-(1-tert-butoxycarbonyl-4-piperidyl)propionyl}-3-piperidylcarbonyl]-2-phenyl-β-alanine ethyl ester

NMR (DMSO-d₆, δ) : 0.85-1.07 (2H, m), 1.14 (3H, t, J=7.1Hz), 1.38 (9H, s), 1.38-1.86 (9H, m), 1.99-2.43 (3H, m), 2.51-3.08 (4H, m), 3.33-4.34 (9H, m), 7.28-7.38 (5H, m), 7.96-8.12 (1H, m)

Mass (m/z) : 544 (M⁺+1)

Example 2

(1) To a mixture of 2(S)-(tert-butoxycarbonyl)amino-β-alanine ethyl ester (2.89 g), (R)-1-[3-(1-benzyloxy-carbonyl-4-piperidyl)propionyl]-3-piperidinecarboxylic acid (5.02 g) and 1-hydroxybenztriazole (1.69 g) in N,N-dimethylformamide (2.27 ml) under stirring at 0°C. After stirring at ambient temperature for overnight, the mixture was poured into water and extracted with ethyl acetate. The extract was washed with water, brine and dried over MgSO₄, and evaporated in vacuo. The residue was purified by chromatography on silica gel eluting with (CHCl₃:MeOH = 100:1) to give N-[(R)-1-{3-(1-benzyloxycarbonyl-4-piperidyl)propionyl}-3-piperidylcarbonyl]-2(S)-(tert-butoxycarbonyl)amino-β-alanine ethyl ester (6.0 g).

IR (Film) : 2970, 2930, 2850, 1720, 1680 cm⁻¹

NMR (CDCl₃, δ) : 1.04-1.34 (6H, m), 1.47 (9H, s), 1.47-1.81 (9H, m), 2.18-2.49 (3H, m), 2.70-2.82

(2H, m), 3.18-3.40 (2H, m), 3.46-3.60 (2H, m),
3.91-4.25 (6H, m), 4.33-4.45 (1H, m), 5.12 (2H,
s), 5.86-5.96 and 7.09-7.17 (total 1H, m), 7.32-
7.36 (5H, m)

Mass (m/z) : 617 ($M^+ + 1$)

The following compounds were obtained according to a
similar manner to that of Example 2 (1).

(2) N-[1-{3-(1-benzyloxycarbonyl-4-piperidyl)propionyl}-
3-piperidylcarbonyl]-3-methyl- β -alanine methyl ester
IR (Film) : 3050, 2930, 2850, 1730, 1680, 1635 cm^{-1}
NMR (CDCl_3 , δ) : 1.02-1.30 (5H, m), 1.40-2.69 (14H,
m), 2.76 (2H, t, $J=12.9\text{Hz}$), 3.19-3.68 (5+1/2H,
m), 3.83-4.01 (1/2H, m), 4.10-4.50 (4h, m), 5.12
(2h, s), 6.30-6.39 (1/3H, m), 6.50-6.54 (1/3H,
m), 6.68-6.72 (1/3H, m), 7.30-7.37 (5H, m)
Mass (m/z) : 502 ($M^+ + 1$)

(3) N-[(R)-1-{2-(1-benzyloxycarbonyl-4-piperidyloxy)-
acetyl}-3-piperidylcarbonyl]- β -alanine ethyl ester
IR (Film) : 3300, 2940, 2870, 1720, 1680, 1640 cm^{-1}
NMR (CDCl_3 , δ) : 1.27 (3H, t, $J=7.1\text{Hz}$), 1.43-1.96
(8H, m), 2.19-2.34 (1H, m), 2.51 (2H, t,
 $J=6.0\text{Hz}$), 3.05-3.31 (4H, m), 3.47-3.63 (3H, m),
3.69-3.96 (3H, m), 4.15 (2H, q, $J=7.1\text{Hz}$), 4.17-
4.37 (3H, m), 5.12 (2H, s), 6.30-6.38 (1/3H, m),
6.51-6.59 (2/3H, m), 7.30-7.37 (5H, m)
Mass (m/z) : 504 ($M^+ + 1$)

(4) N-[(R)-1-{2-(1-benzyloxycarbonyl-4-piperidyloxy)-
acetyl}-3-piperidylcarbonyl]-3-ethynyl- β -alanine
ethyl ester
IR (Film) : 2930, 2860, 1720, 1640 cm^{-1}
NMR (CDCl_3 , δ) : 1.28 (3H, t, $J=7.1\text{Hz}$), 1.45-1.97

(8H, m), 2.23-2.38 (1H, m), 2.27 (1H, d, J=1.5Hz), 2.70 (2H, t, J=5.7Hz), 3.13-3.29 (4H, m), 3.54-3.64 (1H, m), 3.75-4.04 (3H, m), 4.07-4.37 (5H, m), 5.03-5.12 (1H, m), 5.12 (2H, s), 6.66-6.97 (1H, m), 7.30-7.36 (5H, m)
Mass (m/z) : 528 (M⁺+1)

(5) N-[(S)-1-{2-(1-benzyloxycarbonyl-4-piperidyloxy)-acetyl}-3-piperidylcarbonyl]-β-alanine ethyl ester
IR (Film) : 3305, 2940, 2860, 1720, 1680, 1640 cm⁻¹
NMR (CDCl₃, δ) : 1.27 (3H, t, J=7.1Hz), 1.41-1.68 (4H, m), 1.76-1.97 (4H, m), 2.19-2.34 (1H, m), 2.51 (2H, t, J=5.9Hz), 3.06-3.31 (4H, m), 3.47-3.61 (3H, m), 3.70-4.00 (3H, m), 4.15 (2H, q, J=7.1Hz), 4.14-4.37 (3H, m), 5.12 (2H, s), 6.23-6.34 (1/3H, m), 6.44-6.53 (2/3H, m), 7.32-7.37 (5H, m)
Mass (m/z) : 504 (M⁺+1)

(6) N-[(R)-1-{3-(1-benzyloxycarbonyl-4-piperidyl)propionyl}-3-piperidylcarbonyl]-2(R)-tert-butoxycarbonylamino-β-alanine methyl ester
IR (Film) : 3000, 2970, 2930, 2850, 1740, 1680, 1650, 1630 cm⁻¹
NMR (CDCl₃, δ) : 1.03-1.24 (2H, m), 1.44 (9H, s), 1.53-2.05 (9H, m), 2.20-2.44 (3H, m), 2.60-2.84 (2H, m), 3.19-3.61 (4H, m), 3.75 (3H, s), 3.85-4.47 (5H, m), 5.12 (2H, s), 5.51-5.67 (1H, m), 6.44-6.51 and 6.74-6.81 (total 1H, m), 7.30-7.37 (5H, m)
Mass (m/z) : 603 (M⁺+1)

Example 3

(1) To a mixture of N-[(3-piperidyl)carbonyl]-β-alanine methyl ester hydrochloride (1.57 g), 3-(1-tert-

butoxycarbonyl-4-piperidyl)propionic acid (1.61 g) and 1-hydroxybenztriazole (0.96 g) in N,N-dimethylformamide (16 ml) was added 1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide (1.14 ml) under stirring at 0°C. After stirring at ambient temperature for 1 hour, the mixture was poured into water and extracted with ethyl acetate. The extract was washed with water, brine and dried over MgSO₄, and evaporated in vacuo. The residue was purified by chromatography on silica gel eluting with (CHCl₃:MeOH = 100:1) to give N-[1-{3-(1-tert-butoxycarbonyl-4-piperidyl)propionyl}-3-piperidylcarbonyl]-β-alanine methyl ester as an oil (2.19 g).

IR (Film) : 3410, 3280, 3070, 2910, 2850, 1725, 1680, 1630 cm⁻¹

NMR (CDCl₃, δ) : 1.03-1.21 (2H, m), 1.45 (9H, s), 1.45-2.05 (10H, m), 2.23-2.39 (3H, m), 2.49-2.73 (4H, m), 3.18-3.64 (4H, m), 3.32 (3H, s), 3.81-4.23 and 4.36-4.49 (total 3H, m), 6.23-6.35 and 6.52-6.62 (total 1H, m)

Mass (m/z) : 454 (M⁺+1)

The following compounds were obtained according to a similar manner to that of Example 3 (1).

(2) N-[1-{3-(1-tert-butoxycarbonyl-4-piperidyl)-propionyl}-4-piperidylcarbonyl]-β-alanine methyl ester

mp : 79°C

IR (Nujol) : 3290, 3100, 1740, 1690, 1640, 1615 cm⁻¹

NMR (CDCl₃, δ) : 1.00-1.20 (2H, m), 1.45 (9H, s), 1.52-1.77 (7H, m), 1.77-1.92 (2H, m), 2.23-2.38 (3H, m), 2.54 (2H, t, J=5.8Hz), 2.62-2.73 (3H, m), 2.99-3.10 (1H, m), 3.52 (2H, q, J=5.8Hz), 3.71 (3H, s), 3.82-3.95 (1H, m), 4.02-4.15 (2H, m), 4.53-4.67 (1H, m), 6.20-6.29 (1H, m)

Mass (m/z) : 454 ($M^+ + 1$)

(3) N-[2-[1-{3-(1-tert-butoxycarbonyl-4-piperidyl)-
propionyl}-4-piperidyl]acetyl]- β -alanine methyl ester

IR (Film) : 3300, 1730, 1660 cm^{-1}

NMR (CDCl_3 , δ) : 1.08-1.14 (4H, m), 1.45 (9H, s),
1.52-1.76 (9H, m), 2.05-2.07 (2H, m), 2.29-2.37
(2H, m), 2.52-2.73 (4H, m), 2.96-3.01 (1H, m),
3.48-3.57 (2H, m), 3.71 (3H, s), 3.78-3.82 (1H,
m), 4.04-4.08 (2H, m), 4.58-4.64 (1H, m), 6.04-
6.08 (1H, m)

Mass (m/z) : 468 ($M^+ + 1$)

(4) N-[1-{3-(1-tert-butoxycarbonyl-4-piperidyl)-
propionyl}-3-piperidylcarbonyl]-N-methyl- β -alanine
methyl ester

IR (Film) : 3450, 2900, 1720, 1670, 1650, 1620 cm^{-1}

NMR (CDCl_3 , δ) : 1.08-1.36 (2H, m), 1.45 (9H, s),
1.50-1.87 (10H, m), 2.36-2.45 (2H, m), 2.53-2.72
(6H, m), 2.91, 3.11 (total 3H, s), 3.60-3.70
(3H, m), 3.80-3.88 (1H, m), 4.05-4.60 (2H, m),
4.60-4.66 (1H, m)

Mass (m/z) : 468 (M^+)

(5) N-[2-[1-{2-(1-tert-butoxycarbonyl-4-piperidyl)-
acetyl}-3-piperidyl]acetyl]- β -alanine methyl ester

IR (Film) : 3300, 2920, 2850, 1730, 1630 cm^{-1}

NMR (CDCl_3 , δ) : 1.03-1.30 (3H, m), 1.30-2.11 (12H,
m), 1.45 (9H, s), 2.13-2.19 (1/2H, m), 2.25 (2H,
d, $J=6.5\text{Hz}$), 2.52-2.60 (2H, m), 2.64-2.81
(2+1/2H, m), 3.05-3.15 (1/2H, m), 3.23-3.36
(1/2H, m), 3.48-3.57 (2+1/2H, m), 3.70 (3H, d,
 $J=1.5\text{Hz}$), 4.31-4.44 (1/2H, m), 6.07-6.17 (1/2H,
m), 6.59-6.69 (1/2H, m)

Mass (m/z) : 454 ($M^+ + 1$)

- (6) N-[1-{4-(1-tert-butoxycarbonyl-4-piperidyl)butyryl}-3-piperidylcarbonyl]glycine methyl ester

IR (Film) : 3280, 2910, 2650, 1740 cm^{-1}

NMR (CDCl_3 , δ) : 0.99-1.36 (4H, m), 1.45 (9H, s), 1.53-2.30 (9H, m), 2.31-2.54 (3H, m), 2.61-2.75 (2H, m), 3.44-3.55 (1H, m), 3.73 (3H, s), 3.78-4.20 and 4.37-4.52 (total 7H, m), 6.25-6.35 and 6.96-7.04 (total 1H, m)

Mass (m/z) : 454 ($\text{M}^+ + 1$)

- (7) N-[2-[1-{2-(1-tert-butoxycarbonyl-4-piperidylidene)-acetyl}-3-piperidyl]acetyl]- β -alanine methyl ester

IR (Nujol) : 3320, 1735, 1680, 1630 cm^{-1}

NMR (CDCl_3 , δ) : 1.15-1.80 (3H, m), 1.47 (9H, s), 1.80-2.11 (4H, m), 2.25 (2H, t, $J=5.0\text{Hz}$), 2.46 (2H, t, $J=5.7\text{Hz}$), 2.56 (2H, q, $J=6.3\text{Hz}$), 2.74-2.87 (1H, m), 3.10-3.40 (1H, m), 3.43-3.55 (6+1/2H, m), 3.70 (3H, s), 3.82-3.96 (1H, m), 4.29-4.42 (1/2H, m), 5.86 (1H, s), 6.10-6.23 and 6.65-6.80 (total 1H, m)

Mass (m/z) : 452 ($\text{M}^+ + 1$)

- (8) N-[1-{3-(1-tert-butoxycarbonyl-4-piperidyl)-propionyl}-3-piperidyl]succinamic acid methyl ester

IR (Film) : 2960, 2920, 2850, 1725, 1650, 1620 cm^{-1}

NMR (CDCl_3 , δ) : 1.00-1.21 (2H, m), 1.45 (9H, s), 1.53-1.99 (9H, m), 2.31-2.48 (4H, m), 2.60-2.76 (4H, m), 3.04-3.44 (2H, m), 3.60-3.95 (3H, m), 3.69 (3H, s), 4.03-4.11 (2H, m), 5.70-5.93 (1H, m)

Mass (m/z) : 454 ($\text{M}^+ + 1$)

- (9) N-[2-[1-{3-(1-benzyloxycarbonyl-4-piperidyl)-propionyl}-3-piperidyl]acetyl]glycine methyl ester

IR (Film) : 2920, 2850, 1740, 1675, 1615 cm^{-1}

NMR (CDCl_3 , δ) : 1.01-1.80 (10H, m), 1.80-2.43 (6H, m), 2.63-2.88 (3H, m), 3.37-3.69 (2H, m), 3.75 (3H, s), 3.82-3.95 (1/2H, m), 4.01-4.29 (4H, m), 4.29-4.42 (1/2H, m), 5.12 (2H, s), 6.01-6.10 (1/2H, m), 6.99-7.08 (1/2H, m), 7.30-7.37 (5H, m)

Mass (m/z) : 488 (M^++1)

(10) N-[1-{3-(1-benzyloxycarbonyl-4-piperidyl)propionyl}-3-piperidyl]-2(S)-(tert-butoxycarbonylamino)-succinamic acid ethyl ester

IR (Film) : 3300, 2930, 2860, 1735, 1680, 1635 cm^{-1}

NMR (CDCl_3 , δ) : 1.01-1.27 (2H, m), 1.27 (3H, t, $J=7.1\text{Hz}$), 1.45 (9H, s), 1.49-1.98 (9H, m), 2.30-2.40 (2H, m), 2.68-2.84 (4H, m), 2.96-3.17 (1H, m), 3.35-3.53 (1H, m), 3.62-4.23 (5H, m), 4.21 (2H, q, $J=7.1\text{Hz}$), 4.43-4.54 (1H, m), 5.12 (2H, s), 5.58-5.74 (1H, m), 5.83-5.96 (1H, m), 7.35-7.37 (5H, m)

Mass (m/z) : 617 (M^++1)

(11) N-[1-{3-(1-benzyloxycarbonyl-4-piperidyl)propionyl}-3-piperidyl]-3(S)-(tert-butoxycarbonylamino)-succinamic acid methyl ester

IR (Film) : 3000, 2940, 2860, 1720, 1680, 1640 cm^{-1}

NMR (CDCl_3 , δ) : 1.03-1.24 (2H, m), 1.46 (9H, s), 1.52-1.78 (11H, m), 2.30-2.40 (2H, m), 2.60-3.39 (6H, m), 3.70 (3H, d, $J=2.6\text{Hz}$), 3.64-3.95 (2H, m), 4.11-4.23 (2H, m), 4.38-4.49 (1H, m), 5.12 (2H, s), 5.62-5.75 and 6.55-6.69 (total 1H, m), 7.35-7.37 (5H, m)

Mass (m/z) : 603 (M^++1)

(12) N-[1-{3-(1-benzyloxycarbonyl-4-piperidyl)propionyl}-3-

piperidyl]-3(R)-(tert-butoxycarbonylamino)succinamic
acid ethyl ester

IR (Film) : 2960, 2910, 2840, 1710, 1680, 1660,
1640 cm^{-1}

NMR (CDCl_3 , δ) : 1.03-1.26 (3H, t, $J=7.1\text{Hz}$), 1.46
(9H, s), 1.46-1.98 (9H, m), 2.35 (2H, t,
 $J=7.9\text{Hz}$), 2.59-3.52 (6H, m), 3.65-3.98 (3H, m),
4.14 (2H, q, $J=7.1\text{Hz}$), 4.09-4.20 (2H, m), 4.39-
4.49 (1H, m), 5.12 (2H, s), 5.62-5.76 (1H, m),
6.59-6.61 (1H, m), 7.29-7.37 (5H, m)

Mass (m/z) : 617 (M^++1)

Example 4

(1) A mixture of N-[(R)-3-(1-benzyloxycarbonyl)-
piperidylcarbonyl]-2(S)-benzoylamino- β -alanine ethyl ester
(230 mg) and 10% Pd-C (50 mg, 50% wet) in ethanol (5 ml)
and tetrahydrofuran (3 ml) was hydrogenated at atmospheric
pressure for 1 hour. After the catalyst was removed by
filtration, the filtrate was concentrated in vacuo. The
residue, 3-(1-tert-butoxycarbonyl-4-piperidyl)propionic
acid (123 mg) and 1-hydroxybenzotriazole (65 mg) was
dissolved in N,N-dimethylformamide (5 ml), and 1-ethyl-3-
(3-dimethylaminopropyl)carbodiimide (87 μl) was added
under stirring at 0°C . After stirring at ambient
temperature for overnight, the mixture was poured into
water and extracted with ethyl acetate. The extract was
washed with water, brine and dried over MgSO_4 , and
evaporated in vacuo. The residue was purified by
chromatography on silica gel eluting with ($\text{CHCl}_3:\text{MeOH} =$
100 : 1) to give N-[(R)-1-{3-(1-tert-butoxycarbonyl-4-
piperidyl)propionyl}-3-piperidylcarbonyl]-2(S)-
benzoylamino- β -alanine ethyl ester as an oil (213 mg).

IR (Film) : 2960, 2920, 2850, 1730, 1650 cm^{-1}

NMR (CDCl_3 , δ) : 0.85-1.33 (2H, m), 1.29 (3H, t,
 $J=7.1\text{Hz}$), 1.45 (9H, s), 1.45-2.12 (9H, m), 2.20-

2.70 (7H, m), 3.14-3.79 (4H, m), 3.97-4.30 (5H, m), 4.80-4.96 (1H, m), 7.39-7.48 (3H, m), 7.51-7.60 (2/3H, m), 7.8-7.84 (1/3H, m), 7.96-8.04 (2H, m)

Mass (m/z) : 587 ($M^+ + 1$).

The following compounds were obtained according to a similar manner to that of Example 4 (1).

(2) N-[(R)-1-{3-(1-tert-butoxycarbonyl-4-piperidyl)propionyl}-3-piperidylcarbonyl]-2(S)-(n-butanesulfonylamino)- β -alanine ethyl ester
IR (Film) : 2910, 2850, 1720, 1630 cm^{-1}
NMR (CDCl_3 , δ) : 0.94 (3H, t, $J=7.3\text{Hz}$), 1.02-1.38 (2H, m), 1.30 (3H, t, $J=7.1\text{Hz}$), 1.45 (9H, s), 1.45-1.89 (13H, m), 1.27-2.51 (4H, m), 2.61-2.73 (2H, m), 2.97-3.05 (2H, m), 3.25-3.40 (2H, m), 3.60-3.75 (1H, m), 4.01-4.30 (7H, m), 6.18 (1H, d, $J=8.9\text{Hz}$), 7.35-7.42 (1H, m)
Mass (m/z) : 603 ($M^+ + 1$)

(3) N-[(R)-1-{3-(1-tert-butoxycarbonyl-4-piperidyl)propionyl}-3-piperidylcarbonyl]-2(S)-phenylsulfonylamino- β -alanine ethyl ester
IR (Film) : 3400, 1720, 1645, 1620 cm^{-1}
NMR (CDCl_3 , δ) : 1.14 (2H, t, $J=7.1\text{Hz}$), 1.08-1.17 (3H, m), 1.46 (9H, s), 1.46-1.77 (9H, m), 2.24-2.50 (4H, m), 2.56-2.78 (2H, m), 3.17-3.34 (2H, m), 3.58-3.73 (1H, m), 3.87-4.23 (7H, m), 6.48 (1H, d, $J=9.3\text{Hz}$), 7.19-7.27 (1H, m), 7.45-7.56 (3H, m), 7.81-7.88 (2H, m)
Mass (m/z) : 623 ($M^+ + 1$)

Example 5

To a solution of 3-(1-benzyloxycarbonyl-4-

piperidyl)propionic acid (0.18 g) in N,N-dimethylformamide (3 ml) was added N-methylmorpholine (0.09 ml) and isobutylchloroformate (0.1 ml) under stirring at -15°C. After stirring at -15°C for 2 hours, N-[(1,2,3,4-tetrahydro-3-quinolyl)carbonyl]- β -alanine ethyl ester (0.22 g) and N-methylmorpholine (0.12 ml) in tetrahydrofuran (2 ml) was added. After stirring at 0°C for 2 hours and ambient temperature for overnight, the mixture was poured into water, and extracted with ethyl acetate. The extract was washed with 5% KHSO₄ aqueous solution saturated NaHCO₃ aqueous solution and brine, and dried over MgSO₄, and evaporated in vacuo. The residue was purified by chromatography on silica gel eluting with (CHCl₃:MeOH = 100:1) to give N-[1-{3-(1-benzyloxycarbonyl-4-piperidyl)propionyl}-1,2,3,4-tetrahydro-3-quinolylcarbonyl]- β -alanine ethyl ester as an oil (0.18 g).

NMR (CDCl₃, δ) : 1.01-1.14 (2H, m), 1.27 (3H, t, J=7.1Hz), 1.54-1.65 (4H, m), 2.48-2.56 (4H, m), 2.65-2.83 (3H, m), 2.95-3.07 (2H, m), 3.53 (2H, q, J=6.0Hz), 3.72-3.87 (1H, m), 4.05-4.21 (4H, m), 4.16 (2H, q, J=7.2Hz), 5.10 (2H, s), 6.60-6.67 (1H, m), 7.00-7.36 (9H, m)

Mass (m/z) : 550 (M⁺+1)

Example 6

A solution of N-fluorenylmethoxycarbonyl-3-amino-3(S)-cyanopropionic acid tert-butyl ester (0.3 g) in diethylamine (6 ml) was stirred for 1 hour, and concentrated in vacuo. The residue was purified by column chromatography on silica gel eluting with (CHCl₃:MeOH = 100:3) to give an oil. To a mixture of 212 mg of this oil, (R)-1-[3-(tert-butoxycarbonyl)-4-piperidyl)propionyl]-3-piperidine]carboxylic acid (571 mg) 1-hydroxybenztriazole (209 mg) in N,N-dimethylformamide (4

ml) and 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (283
μl) were added under stirring at 0°C. After stirring at
ambient temperature for overnight, the mixture was poured
into water and extracted with ethyl acetate. The extract
was washed with water, brine and dried over MgSO₄, and
evaporated in vacuo. The residue was purified by
chromatography on silica gel eluting with (CHCl₃:MeOH =
100:1) to give N-[(R)-1-{3-(1-tert-butoxycarbonyl-4-
piperidyl)propionyl}-3-piperidylcarbonyl]-3(S)-cyano-β-
alanine tert-butyl ester (0.4 g).

IR (Film) : 2980, 2930, 2860, 2250, 1720, 1640 cm⁻¹

NMR (CDCl₃, δ) : 1.05-1.25 (2H, m), 1.45 (9H, s),
1.49 (9H, s), 1.54-2.09 (10H, m), 2.32-2.39 (3H,
m), 2.61-2.79 (2H, m), 2.74 (2H, d, J=5.6Hz),
3.23-3.62 (3H, m), 4.00-4.14 (2H, m), 5.12-5.22
(1H, m), 7.51 (1h, d, J=8.4Hz)

Mass (m/z) : 521 (M⁺+1)

Example 7

(1) To a solution of N-[(R)-1-{3-(1-benzyloxycarbonyl-4-
piperidyl)propionyl}-3-piperidylcarbonyl]-2(S)-(tert-
butoxycarbonyl)amino-β-alanine ethyl ester (5.98 g) in
ethyl acetate (60 ml) was added a solution of 4N HCl in
ethyl acetate (24.2 ml) under stirring at 0°C. After
stirring at ambient temperature for 2 hours, the resulting
precipitates were collected by filtration to give N-[(R)-
1-{3-(1-benzyloxycarbonyl-4-piperidyl)propionyl}-3-
piperidylcarbonyl]-2(S)-amino-β-alanine ethyl ester
hydrochloride (3.41 g).

IR (Nujol) : 1745, 1695, 1650 cm⁻¹

NMR (DMSO-d₆, δ) : 0.89-1.10 (2H, m), 1.19-1.91
(13H, m), 2.11-2.43 (3H, m), 2.57-3.17 (4H, m),
3.46-4.38 (4H, m), 5.06 (7H, s), 7.28-7.42 (5H,
m)

Mass (m/z) : 517 (M⁺+1) free of compound

The following compounds were obtained according to a similar manner to that of Example 7 (1).

- 5 (2) N-[1-{3-(1-benzyloxycarbonyl-4-piperidyl)propionyl-3-piperidyl]-2(S)-aminosuccinamic acid ethyl ester hydrochloride

IR (Nujol) : 1730, 1640 cm^{-1}

NMR (DMSO- d_6 , δ) : 1.17 (3H, t, $J=7.1\text{Hz}$), 1.33-1.51 (6H, m), 1.60-1.84 (5H, m), 2.22-2.37 (2H, m), 2.69-3.06 (7H, m), 3.51-3.87 (2H, m), 3.94-4.05 (1H, m), 4.12-4.29 (4H, m), 5.06 (2H, s), 7.30-7.42 (5H, m), 8.27-8.43 (1H, m)

Mass (m/z) : 517 (M^++1) free of compound

- 15 (3) N-[(R)-1-{3-(1-benzyloxycarbonyl-4-piperidyl)propionyl}-3-piperidylcarbonyl]-2(R)-amino- β -alanine methyl ester hydrochloride

IR (Nujol) : 1740, 1640 cm^{-1}

20 NMR (DMSO- d_6 , δ) : 0.90-1.09 (2H, m), 1.21-1.91 (13H, m), 2.11-2.43 (4H, m), 2.61-3.17 (6H, m), 3.45-4.46 (5H, m), 5.06 (2H, s), 7.30-7.42 (5H, m), 8.38-8.59 (1H, m)

Mass (m/z) : 503 (M^++1) free of compound

- 25 (4) N-[1-{3-(1-benzyloxycarbonyl-4-piperidyl)-propionyl}-3-piperidyl]-3(S)-aminosuccinamic acid methyl ester hydrochloride

mp : 75°C

IR (Nujol) : 1725, 1670, 1640, 1600 cm^{-1}

30 NMR (DMSO- d_6 , δ) : 0.90-1.09 (2H, m), 1.31-1.88 (11H, m), 2.20-2.38 (2H, m), 2.60-3.25 (7H, m), 3.49-3.74 (2H, m), 3.91-4.09 (4H, m), 5.06 (2H, s), 7.35 (5H, s), 8.66-8.84 (1H, m)

35 Mass (m/z) : 503 (M^++1) free of compound

(5) N-[1-{3-(1-benzyloxycarbonyl-4-piperidyl)propionyl}-3-piperidyl]-3(R)-aminosuccinamic acid ethyl ester hydrochloride

IR (KBr, pellet) : 2939, 2864, 1732, 1684, 1616 cm^{-1}

NMR (DMSO-d_6 , δ) : 0.90-1.09 (2H, m), 1.20 (3H, t, $J=7.0\text{Hz}$), 1.37-1.53 (6H, m), 1.60-1.86 (4H, m), 2.20-2.39 (2H, m), 2.60-3.26 (6H, m), 3.51-3.73 (2H, m), 3.88-4.28 (3H, m), 4.09 (2H, q, $J=7.0\text{Hz}$), 5.06 (2H, s), 7.30-7.42 (5H, m), 8.64-8.75 (1H, m)

Mass (m/z) : 517 (M^++1) free of compound

Example 8

(1) To a solution of N-[(R)-1-{3-(1-benzyloxycarbonyl-4-piperidyl)propionyl}-3-piperidylcarbonyl]-2(S)-amino- β -alanine ethyl ester hydrochloride (270 mg) in dichloromethane (4 ml) was added triethylamine (150 μl) and acetyl chloride (38 μl) under stirring at 0°C . After stirring at ambient temperature for 2 hours, the mixture was poured into water and extracted with dichloromethane. The extract was washed with water, saturated NaHCO_3 aqueous solution, water and brine, and dried over MgSO_4 , and evaporated in vacuo. The residue was purified by column chromatography on silica gel eluting with ($\text{CHCl}_3:\text{MeOH} = 100:1$) to give N-[(R)-1-{3-(1-benzyloxy-carbonyl-4-piperidyl)propionyl}-3-piperidylcarbonyl]-2(S)-acetyl-amino- β -alanine ethyl ester as an oil (130 mg).

IR (Film) : 3290, 3060, 3000, 2930, 2850, 1725, 1675, 1640 cm^{-1}

NMR (CDCl_3 , δ) : 1.06-1.34 (2H, m), 1.27 (3H, t, $J=7.1\text{Hz}$), 1.41-1.76 (10H, m), 2.09 (3H, s), 2.31-2.50 (3H, m), 2.70-2.83 (2H, m), 3.16-3.31 (3H, m), 3.64-3.74 (1H, m), 4.05-4.34 (6H, m), 4.70-4.80 (1H, m), 5.12 (2H, m), 7.05-7.22 (1H, m), 7.26-7.37 (5H, m)

Mass (m/z) : 559 (M^{++1})

The following compounds were obtained according to a similar manner to that of Example 8 (1).

(2) N-[(R)-1-{3-(1-benzyloxycarbonyl-4-piperidyl)-propionyl}-3-piperidylcarbonyl]-2(S)-n-hexanoylamino- β -alanine ethyl ester

IR (Film) : 3000, 2940, 2870, 1735, 1655, 1640 cm^{-1}

NMR (CDCl_3 , δ) : 0.89 (3H, t, $J=7.1\text{Hz}$), 1.12-1.38 (12H, m), 1.51-1.75 (7H, m), 2.24-2.51 (5H, m), 2.70-2.84 (2H, m), 3.25-3.70 (7H, m), 4.05-4.25 (5H, m), 4.69-4.80 (1H, m), 5.12 (2H, s), 7.03-7.15 (1H, m), 7.30-7.38 (5H, m)

Mass (m/z) : 615 (M^{++1})

(3) N-[(R)-1-{3-(1-benzyloxycarbonyl-4-piperidyl)propionyl}-3-piperidylcarbonyl]-2(S)-(4-chlorobenzoylamino)- β -alanine ethyl ester

IR (Film) : 3000, 2930, 2860, 1740, 1680, 1650, 1600 cm^{-1}

NMR (CDCl_3 , δ) : 0.89-1.13 (2H, m), 1.29 (3H, t, $J=7.1\text{Hz}$), 1.29-1.80 (11H, m), 2.20-2.55 (3H, m), 2.65-2.80 (2H, m), 3.12-3.28 (2H, m), 3.32-3.42 (1H, m), 3.61-3.79 (1H, m), 4.07-4.42 (5H, m), 4.90-4.98 (1H, m), 5.12 (2H, s), 7.35-7.43 (6H, m), 7.41 (2H, d, $J=8.6\text{Hz}$), 8.00 (2H, d, $J=8.6\text{Hz}$)

Mass (m/z) : 655 (M^{++1})

(4) N-[(R)-1-{3-(1-benzyloxycarbonyl-4-piperidyl)propionyl}-3-piperidylcarbonyl]-2(S)-4-methoxybenzoylamino- β -alanine ethyl ester

IR (Film) : 2920, 1730, 1685, 1630, 1600 cm^{-1}

NMR (CDCl_3 , δ) : 0.84-1.80 (13H, m), 1.29 (3H, t, $J=7.1\text{Hz}$), 2.26-2.56 (3H, m), 2.64-2.80 (2H, m),

3.15-3.86 (3H, m), 3.83 (3H, s), 4.05-4.38 and
5.87-5.97 (total 6H, m), 5.11 (2H, s), 5.92 (2H,
d, J=8.8Hz), 7.33-7.45 (6H, m), 7.75-7.81 (1H,
m), 8.00 (2H, d, J=8.8Hz)

Mass (m/z) : 651 (M^+ +1)

- (5) N-[1-{3-(1-benzyloxycarbonyl-4-piperidyl)propionyl}-
3-piperidyl]-2(S)-benzoylamino succinamic acid ethyl
ester

IR (Film) : 2920, 1730, 1680, 1640 cm^{-1}

NMR (CDCl_3 , δ) : 1.03-1.33 (3H, m), 1.29 (3H, t,
J=7.1Hz), 1.38-1.97 (8H, m), 2.22-2.40 (2H, m),
2.64-3.13 (5H, m), 3.34-4.00 (4H, m), 4.08-4.28
(2H, m), 4.26 (2H, q, J=7.1Hz), 4.91-5.01 (1H,
m), 5.12 (2H, s), 5.86-6.00 (1H, m), 7.28-7.36
(5H, m), 7.41-7.56 (4H, m), 7.78-7.87 (2H, m)

Mass (m/z) : 621 (M^+ +1)

- (6) N-[(R)-1-{3-(1-benzyloxycarbonyl-4-
piperidyl)propionyl}-3-piperidylcarbonyl]-2(S)-
cyclopropylcarbonylamino- β -alanine ethyl ester

IR (Film) : 3000, 2930, 2860, 1730, 1650 cm^{-1}

NMR (CDCl_3 , δ) : 0.73-1.37 (6H, m), 1.27 (3H, t,
J=7.1Hz), 1.40-1.80 (11H, m), 2.31-2.54 (3H, m),
2.68-2.88 (2H, m), 3.20-3.40 (2H, m), 3.62-3.75
(1H, m), 4.08-4.32 (6H, m), 4.72-4.81 (1H, m),
5.12 (2H, s), 6.70-6.80 and 7.08-7.15 (total 1H,
m), 7.21-7.48 (6H, m)

Mass (m/z) : 585 (M^+ +1)

- (7) N-[(R)-1-{3-(1-benzyloxycarbonyl-4-piperidyl)-
propionyl}-3-piperidylcarbonyl]-2(R)-benzoylamino- β -
alanine methyl ester

IR (Film) : 3060, 3010, 2960, 2860, 1740, 1690,
1640, 1610 cm^{-1}

NMR (CDCl₃, δ) : 0.99-1.21 (2H, m), 1.32-1.87 (8H, m), 2.03-2.48 (2H, m), 2.33 (2H, t, J=7.7Hz), 2.62-2.83 (2H, m), 3.36-3.45 (2H, m), 3.62-3.80 and 4.33-4.44 (total 4H, m), 3.77 (3H, s), 4.10-4.22 (2H, m), 4.70-4.86 (1H, m), 5.11 (2H, s), 7.29-7.59 (9H, m), 7.81-7.89 (2H, m), 8.04-8.09 (1H, m)

Mass (m/z) : 607 (M⁺+1)

(8) N-[1-{3-(1-benzyloxycarbonyl-4-piperidyl)propionyl}-3-piperidyl]-3(S)-benzoylamino succinamic acid methyl ester

IR (Film) : 3000, 2940, 2860, 1735, 1680, 1640 cm⁻¹

NMR (CDCl₃, δ) : 0.98-1.24 (2H, m), 1.34-1.95 (9H, m), 2.16-2.40 (2H, m), 2.66-2.83 (3H, m), 3.01-4.00 (6H, m), 4.15 (3H, s), 4.07-4.23 (2H, m), 4.89-5.00 (1H, m), 5.12 (2H, s), 6.88-7.20 (1H, m), 7.31-7.37 (5H, m), 7.43-7.56 (3H, m), 7.78-7.89 (3H, m)

Mass (m/z) : 607 (M⁺+1)

(9) N-[1-{3-(1-benzyloxycarbonyl-4-piperidyl)propionyl}-3-piperidyl]-2(S)-acetylaminosuccinamic acid ethyl ester

IR (Film) : 3050, 2990, 2920, 2850, 1725, 1650, 1620 cm⁻¹

NMR (CDCl₃, δ) : 1.04-1.24 (2H, m), 1.27-1.28 (total 3H, t, J=7.1Hz), 1.41-1.99 (9H, m), 2.03 (3H, s), 2.31-2.41 (2H, m), 2.69-3.16 (5H, m), 3.34-4.05 (4H, m), 4.11-4.24 (2H, m), 4.22 (2H, q, J=7.1Hz), 4.71-4.82 (1H, m), 5.12 (2H, s), 6.02 and 6.09 (total 1H, d, J=7.1Hz), 6.71-6.88 (1H, m), 7.30-7.37 (5H, m)

Mass (m/z) : 559 (M⁺+1)

- (10) N-[(R)-1-{3-(1-benzyloxycarbonyl-4-piperidyl)propionyl}-3-piperidylcarbonyl]-2(R)-acetylamino- β -alanine methyl ester

IR (Film) : 2940, 2850, 1740, 1650 cm^{-1}

NMR (CDCl_3 , δ) : 1.03-1.28 (2H, m), 1.40-1.79 (9H, m), 2.03 (3H, s), 2.20-2.40 (3H, m), 2.64-2.84 (2H, m), 3.20-3.69 (5H, m), 3.75 (3H, s), 3.82-3.89 (1H, m), 4.11-4.23 (2H, m), 4.55-4.68 (1H, m), 5.12 (2H, s), 7.00-7.09 (2H, m), 7.27-7.37 (5H, m)

Mass (m/z) : 545 ($\text{M}^+ + 1$)

- (11) N-[1-{3-(1-benzyloxycarbonyl-4-piperidyl)propionyl}-3-piperidyl]-3(R)-benzoylamino succinamic acid ethyl ester

IR (Film) : 2990, 2920, 2850, 1720, 1660, 1635 cm^{-1}

NMR (CDCl_3 , δ) : 0.96-1.16 (2H, m), 1.30 (3H, t, $J=7.2\text{Hz}$), 1.40-1.95 (9H, m), 2.10-2.40 (2H, m), 2.63-2.84 (3H, m), 2.99-3.15 (2H, m), 5.22-3.41 (1H, m), 3.54-4.00 (3H, m), 4.09-4.27 (4H, m), 4.86-5.00 (1H, m), 5.13 (2H, s), 6.89-7.20 (1H, m), 7.30-7.37 (5H, m), 7.41-7.55 (3H, m), 7.65-7.84 (3H, m)

Mass (m/z) : 621 ($\text{M}^+ + 1$)

- (12) 4-[3-{3-(1-tert-butoxycarbonyl-4-piperidyl)propionylamino}-1-piperidyl]-4-oxo-2(S)-benzoylamino butyric acid tert-butyl ester

IR (Film) : 3050, 2970, 2930, 2850, 1750, 1640 cm^{-1}

NMR (CDCl_3 , δ) : 0.94-1.20 (2H, m), 1.45-1.79 (10H, m), 1.45 (9H, s), 1.46 (9H, s), 2.12-2.39 (7H, m), 2.52-2.80 (3H, m), 3.87-4.36 (4H, m), 7.31-7.58 (4H, m), 7.75-7.85 (2H, m)

Mass (m/z) : 615 ($\text{M}^+ + 1$)

Example 9

(1) To a mixture of N-[(R)-1-{3-(1-benzyloxycarbonyl-4-piperidyl)propionyl}-3-piperidylcarbonyl]-2(S)-amino-β-alanine ethyl ester hydrochloride (1 g), 3-methoxypropionic acid (0.17 ml) and 1-hydroxybenztriazole (0.24 g) in N,N-dimethylformamide (10 ml) was added 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (0.33 ml) under stirring at 0°C. After stirring at ambient temperature for overnight, the mixture was poured into water and extracted with ethyl acetate. The extract washed with water, brine and dried over MgSO₄, and evaporated in vacuo. The residue was purified by column chromatography on silica gel eluting with (CHCl₃:MeOH = 100:1) to give N-[(R)-1-{3-(1-benzyloxycarbonyl-4-piperidyl)propionyl}-3-piperidylcarbonyl]-2(S)-(3-methoxypropionyl)amino-β-alanine ethyl ester (0.59 g) as an oil.

IR (Film) : 3050, 2980, 2860, 1730, 1660, 1640, 1620 cm⁻¹

NMR (CDCl₃, δ) : 1.05-1.33 (2H, m), 1.28 (3H, t, J=7.2Hz), 1.42-1.82 (14H, m), 2.11-2.61 (4H, m), 2.67-2.84 (2H, m), 3.37 (3H, s), 3.40-3.57 (2H, m), 3.61-3.76 (2H, m), 3.85-4.03 (1H, m), 4.12-4.26 (4H, m), 4.67-4.76 and 6.93-7.06 (total 1H, m), 5.12 (2H, s), 7.32-7.39 (6H, m)

Mass (m/z) : 603 (M⁺+1)

The following compounds were obtained according to a similar manner to that of Example 9 (1).

(2) N-[(R)-1-{3-(1-benzyloxycarbonyl-4-piperidyl)propionyl}-3-piperidylcarbonyl]-2(S)-(4-hydroxybenzoylamino)-β-alanine ethyl ester

IR (Film) : 2930, 1735, 1650, 1630 cm⁻¹

NMR (CDCl₃, δ) : 0.89-1.15 (2H, m), 1.28 (3H, t,

J=7.2Hz), 1.30-1.82 (9H, m), 2.18-2.51 (4H, m), 2.60-2.79 (2H, m), 3.11-3.86 (4H, m), 4.01-4.30 (6H, m), 4.76-4.93 (1H, m), 5.12 (2H, s), 6.79-6.87 (2H, m), 7.29-7.36 (5H, m), 7.50-7.58 and 7.65-7.72 (total 2H, m), 7.83 (1H, d, J=8.6Hz), 8.25-8.30 and 8.60-8.70 (total 1H, br)

Mass (m/z) : 637 (M⁺+1)

(3) N-[(R)-1-{3-(1-benzyloxycarbonyl-4-piperidyl)propionyl}-3-piperidylcarbonyl]-2(S)-4-biphenylcarbonylamino-β-alanine ethyl ester

IR (Film) : 2930, 2850, 1735, 1660, 1640 cm⁻¹

NMR (CDCl₃, δ) : 0.90-1.15 (2H, m), 1.30 (3H, t, J=7.1Hz), 1.34-1.80 (10H, m), 2.29-2.77 (5H, m), 3.13-3.71 (4H, m), 4.02-4.40 (5H, m), 4.93-5.03 (1H, m), 5.09 (2H, s), 7.34 (5H, s), 7.36-7.51 (4H, m), 7.59-7.69 (4H, m), 7.80-7.99 (1H, m), 8.11 (2H, d, J=8.4Hz)

Mass (m/z) : 697 (M⁺+1)

Example 10

(1) A solution of N-[(R)-1-{3-(1-tert-butoxycarbonyl-4-piperidyl)propionyl}-3-piperidylcarbonyl]-3-ethynyl-β-alanine ethyl ester (1.38 g) in tetrahydrofuran (5 ml), ethanol (5 ml) and water (5 ml) was added lithium hydroxide (0.35 g) under stirring at 0°C. After stirring at ambient temperature for 1 hour, the mixture was acidified with 5% KHSO₄ aqueous solution and extracted with ethyl acetate. The extract was washed with water, brine and dried over MgSO₄, and evaporated in vacuo to give N-[(R)-1-{3-(1-tert-butoxycarbonyl-4-piperidyl)propionyl}-3-piperidylcarbonyl]-3-ethynyl-β-alanine (1.12 g).

IR (Nujol) : 3200, 1720, 1630 cm⁻¹

NMR (DMSO-d₆, δ) : 0.68-1.16 (4H, m), 1.21 (9H, s),
1.44-2.29 (9H, m), 2.40-2.60 (5H, m), 2.70-3.08
(2H, m), 3.52-4.28 (5H, m), 4.58-4.75 (1H, m),
8.22-8.29 (1H, m), 12.17-12.31 (1H, br)
Mass (m/z) : 464 (M⁺+1)

The following compounds were obtained according to a
similar manner to that of Example 10 (1).

(2) (3R)-N-[(R)-1-{3-(1-tert-butoxycarbonyl-4-piperidyl)-
propionyl}-3-piperidylcarbonyl]-3-methyl-β-alanine
IR (Film) : 3410, 2970, 2930, 2880, 1710, 1630 cm⁻¹
NMR (DMSO-d₆, δ) : 0.83-1.90 (5H, m), 1.38 (9H, s),
1.40-1.84 (9H, m), 2.03-2.42 (5H, m), 2.55-2.74
(3H, m), 2.87-3.11 (1H, m), 3.69-4.37 (5H, m),
7.83 (1H, d, J=8.0Hz)
Mass (m/z) : 452 (M⁺+1)

(3) N-[(R)-1-{3-(1-tert-butoxycarbonyl-4-
piperidyl)propionyl}-3-piperidylcarbonyl]-β-alanine
IR (Film) : 3400, 2910, 1700, 1630 cm⁻¹
NMR (DMSO-d₆, δ) : 0.84-1.09 (2H, m), 1.38 (9H, s),
1.32-1.83 (9H, m), 2.26-2.40 (5H, m), 2.55-2.75
(3H, m), 2.84-3.27 (3H, m), 3.71-3.98 (3H, m),
4.11-4.38 (1H, m), 7.90-8.02 (1H, m)
Mass (m/z) : 440 (M⁺+1)

Example 11

(1) To a solution of N-[(R)-1-{3-(1-benzyloxycarbonyl-4-
piperidyl)propionyl}-3-piperidylcarbonyl]-2(S)-
acetyl-amino-β-alanine ethyl ester (130 mg) in a mixture of
ethanol (1.5 ml) and tetrahydrofuran (1.5 ml) was added a
solution of lithium hydroxide (11 mg) in water (1.5 ml)
under stirring at 0°C. After stirring at ambient
temperature for 1 hour, the mixture was acidified with 10%

KHSO₄ aqueous solution and extracted with ethyl acetate. The extract was washed with water, brine and dried over MgSO₄ and evaporated in vacuo to give N-[(R)-1-{3-(1-benzyloxycarbonyl-4-piperidyl)propionyl}-3-piperidyl-carbonyl]-2(S)-acetylamino-β-alanine as an oil (67 mg).

IR (Film) : 3810, 3000, 2950, 2880, 1730, 1655 cm⁻¹

NMR (DMSO-d₆, δ) : 0.80-1.09 (2H, m), 1.24-1.80 (10H, m), 1.99 (3H, s), 2.05-2.36 (3H, m), 2.56-3.51 (6H, m), 3.74-3.83 (1H, m), 3.94-4.04 (2H, m), 4.16-4.40 (2H, m), 5.06 (2H, s), 7.30-7.37 (5H, m), 7.95-8.09 (2H, m)

Mass (m/z) : 531 (M⁺+1)

The following compounds were obtained according to a similar manner to that of Example 11 (1).

(2) N-[(R)-1-{3-(1-tert-butoxycarbonyl-4-piperidyl)propionyl}-3-piperidylcarbonyl]-3(R)-phenethyl-β-alanine

IR (Film) : 3400, 2920, 2850, 1700, 1640 cm⁻¹

NMR (DMSO-d₆, δ) : 0.63-0.86 (2H, m), 1.17 (9H, s), 1.17-1.29 (8H, m), 1.26-1.66 (5H, m), 2.04-2.18 (4H, m), 2.30-2.54 (5H, m), 3.49-3.90 (4H, m), 3.95-4.23 (1H, m), 6.94-7.09 (5H, m), 7.65 (1H, d, J=8Hz)/

Mass (m/z) : 544 (M⁺+1)

(3) N-[(R)-1-{2-(4-piperidyloxy)acetyl}-3-piperidylcarbonyl]-3(S)-ethynyl-β-alanine trifluoroacetate

[α]_D²⁰ = -19.11° (C=1.0, MeOH)

IR (Film) : 3360, 2940, 1760, 1710, 1625 cm⁻¹

NMR (DMSO-d₆, δ) : 1.22-2.36 (8H, m), 2.59 (1H, d, J=6.6Hz), 2.49-2.74 (1H, m), 2.84-3.21 (6H, m), 3.57-3.70 (2H, m), 4.03-4.26 (3H, m), 4.77-4.88

(4H, m), 8.31-8.43 (2H, m)

Mass (m/z) : 366 (M^+ +1) free of compound
and

N-[(R)-1-{2-(4-piperidyloxy)acetyl}-3-
piperidylcarbonyl]-3(R)-ethynyl- β -alanine
trifluoroacetate

IR (Film) : 3250, 2920, 1710, 1625 cm^{-1}

NMR (DMSO- d_6 , δ) : 1.20-2.00 (6H, m), 2.11-2.76 (3H,
m), 2.58 (1H, d, $J=7.4\text{Hz}$), 2.86-3.23 (6H, m),
3.95-4.32 (8H, m), 4.75-4.89 (1H, m), 8.42 (2H,
t, $J=8.6\text{Hz}$)

Mass (m/z) : 366 (M^+ +1) free of compound

(4) N-[(R)-1-{3-(1-tert-butoxycarbonyl-4-
piperidyl)propionyl}-3-piperidylcarbonyl]-2-
piperidylacetic acid

IR (Film) : 3410, 2930, 2850, 1710, 1680, 1610 cm^{-1}

NMR (DMSO- d_6 , δ) : 0.83-1.07 (3H, m), 1.34-1.71
(11H, m), 1.38 (9H, s), 2.25-2.40 (3H, m), 2.55-
3.14 (9H, m), 3.68-3.97 (4H, m), 4.27-4.39 (2H,
m), 4.45-4.58 (1/3H, m), 4.88-5.03 (2/3H, m)

Mass (m/z) : 494 (M^+ +1)

(5) N-[(R)-1-{3-(1-tert-butoxycarbonyl-4-
piperidyl)propionyl}-3-piperidylcarbonyl]-2(S)-
benzoylamino- β -alanine

IR (Film) : 2930, 1720, 1650, 1635 cm^{-1}

NMR (DMSO- d_6 , δ) : 0.83-1.06 (2H, m), 1.25-1.44 (4H,
m), 1.38 (9H, s), 1.54-1.86 (5H, m), 2.15-2.33
(3H, m), 2.56-2.73 (2H, m), 2.90-3.10 (1H, m),
3.39-3.98 (6H, m), 4.08-4.59 (2H, m), 7.45-7.56
(3H, m), 7.83-7.87 (2H, m), 8.13-8.23 (1H, m),
8.60-8.66 (1H, m)

Mass (m/z) : 559 (M^+ +1)

- (6) N-[(R)-1-{3-(1-tert-butoxycarbonyl-4-piperidyl)propionyl}-3-piperidylcarbonyl]-2(S)-phenylsulfonylamino- β -alanine

IR (Nujol) : 3370, 3250, 3180, 1700, 1685, 1640 cm^{-1}

NMR (DMSO- d_6 , δ) : 0.80-1.06 (2H, m), 1.14-1.43 (6H, m), 1.38 (9H, s), 1.55-1.71 (3H, m), 1.88-2.34 (3H, m), 2.42-2.71 (2H, m), 2.83-3.14 (2H, m), 3.23-3.40 (2H, m), 3.71-3.97 (4H, m), 4.14-4.40 (1H, m), 7.50-7.68 (3H, m), 7.75-7.79 (2H, m), 7.95-8.06 (1H, m), 8.16 (1H, t, $J=8.6\text{Hz}$), 12.66-12.80 (1H, br)

Mass (m/z) : 595 (M^++1)

- (7) N-[(R)-1-{3-(1-tert-butoxycarbonyl-4-piperidyl)propionyl}-3-piperidylcarbonyl]-2(S)-n-butansulfonylamino- β -alanine

IR (Nujol) : 3330, 3250, 1715, 1690, 1640

NMR (DMSO- d_6 , δ) : 0.87 (3H, t, $J=7.3\text{Hz}$), 0.84-1.07 (2H, m), 1.30-1.46 (7H, m), 1.38 (9H, s), 1.57-1.90 (7H, m), 2.29-2.36 (2H, m), 2.55-2.75 (3H, m), 2.85-3.50 (3H, m), 2.96 (2H, t, $J=7.7\text{Hz}$), 3.77-4.01 (4H, m), 4.19-4.42 (1H, m), 7.50-7.57 (1H, m), 8.02-8.11 (1H, m), 12.93-13.00 (1H, br)

Mass (m/z) : 475 ($M^++1-\text{Boc}$)

- (8) N-[(R)-1-{3-(1-tert-butoxycarbonyl-4-piperidyl)propionyl}-3-piperidylcarbonyl]-3(S)-ethynyl- β -alanine

IR (KBr) : 3430, 3300, 1731, 1686, 1662 cm^{-1}

NMR (DMSO- d_6 , δ) : 0.92-1.17 (2H, m), 1.38 (9H, s), 1.49-1.77 (9H, m), 1.91, 1.99 (total 1H, s), 2.13-2.64 (8H, m), 2.89-3.06 (1H, m), 3.17-3.28 (1H, m), 3.76-4.32 (3H, m), 4.78-4.84 (1H, m), 8.37-8.44 (1H, m), 12.39 (1H, br)

- (9) N-[(R)-1-{3-(1-tert-butoxycarbonyl-4-piperidyl)propionyl}-3-piperidylcarbonyl]-3(S)-propargylaminocarbonyl- β -alanine

IR (Film) : 3380, 1710, 1640 cm^{-1}

NMR (DMSO- d_6 , δ) : 0.85-1.08 (2H, m), 1.38 (9H, s),
1.42-1.91 (8H, m), 2.26-2.37 (3H, m), 2.54-2.76
(6H, m), 2.88-3.12 (2H, m), 3.69-3.98 (5H, m),
4.08-4.37 (1H, m), 4.46-4.57 (1H, m), 7.18-7.33
(1H, m), 8.08-8.18 (1H, m), 8.31-8.36 (1H, m)

Mass (m/z) : 521 ($M^+ + 1$)

- (10) N-[(S)-1-{3-(1-tert-butoxycarbonyl-4-piperidyl)-propionyl}-3-piperidylcarbonyl]-3-ethynyl- β -alanine

IR (Film) : 3000, 2930, 2870, 1720, 1640 cm^{-1}

NMR (DMSO- d_6 , δ) : 0.85-1.10 (2H, m), 1.38 (9H, s),
1.21-1.86 (8H, m), 2.08-2.40 (3H, m), 2.56-2.71
(4H, m), 2.87-3.12 (3H, m), 3.21 (1H, dd, $J=5.4$
and 2.3Hz), 3.71-4.43 (4H, m), 4.74-4.87 (1H,
m), 8.39-8.46 (1H, m), 12.40-12.50 (1H, br)

Mass (m/z) : 464 ($M^+ + 1$)

- (11) N-[(S)-1-{2-(1-benzyloxycarbonyl-4-piperidyloxy)acetyl}-3-piperidylcarbonyl]- β -alanine

IR (Film) : 3300, 2930, 1720, 1620 cm^{-1}

NMR (DMSO- d_6 , δ) : 1.32-1.91 (8H, m), 2.06-2.30 (1H,
m), 2.36 (2H, t, $J=6.9\text{Hz}$), 2.57-2.71 (1H, m),
2.85-3.29 (5H, m), 3.47-3.79 (4H, m), 4.01-4.33
(3H, m), 5.06 (2H, s), 7.30-7.37 (5H, m), 7.93-
8.01 (1H, br), 12.15-12.30 (1H, br)

Mass (m/z) : 476 ($M^+ + 1$)

- (12) N-[(R)-1-{3-(1-benzyloxycarbonyl)-4-piperidyl}propionyl]-3-piperidylcarbonyl-2(S)-(4-chlorobenzoyl)amino- β -alanine

IR (Film) : 3400, 1720, 1635, 1600 cm^{-1}

NMR (DMSO-d₆, δ) : 0.87-1.19 (2H, m), 1.31-1.44 (3H, m), 1.53-1.85 (4H, m), 2.12-2.34 (2H, m), 2.59-2.83 (1H, m), 3.93-4.05 (2H, m), 4.14-4.58 (1H, m), 5.05 (2H, s), 7.29-7.40 (5H, m), 7.57 (2H, d, J=8.5Hz), 7.82-7.89 (2H, m), 8.11-8.20 (1H, m), 8.66-8.74 (1H, m)

Mass (m/z) : 627 (M⁺+1)

(13) N-[(R)-1-{3-(1-benzyloxycarbonyl-4-piperidyl)propionyl}-3-piperidylcarbonyl]-2(S)-(4-methoxybenzoylamino)-β-alanine

IR (Film) : 3350, 2920, 1715, 1630, 1600 cm⁻¹

NMR (DMSO-d₆, δ) : 0.85-1.84 (12H, m), 2.07-2.44 (3H, m), 2.56-3.23 (5H, m), 3.37-3.75 (2H, m), 3.81 (3H, s), 3.91-4.08 (2H, m), 4.14-4.56 (1H, m), 5.05 (2H, s), 7.01 (2H, d, J=8.8Hz), 7.30-7.37 (5H, m), 7.83 (2H, d, J=8.7Hz), 8.11-8.19 (1H, m), 8.42-8.49 (1H, m), 12.68-12.75 (1H, br)

Mass (m/z) : 623 (M⁺+1)

(14) N-[1-{3-(1-benzyloxycarbonyl)-4-piperidyl}propionyl]-3-piperidyl]-2(S)-benzoylamino succinamic acid

IR (Film) : 3250, 2900, 1710, 1635 cm⁻¹

NMR (DMSO-d₆, δ) : 0.84-1.05 (2H, m), 1.31-1.47 (5H, m), 1.57-1.83 (4H, m), 2.15-2.35 (2H, m), 2.62-2.82 (4H, m), 2.94-3.09 (2H, m), 3.50-3.82 (3H, m), 3.90-4.03 (2H, m), 4.69-4.81 (1H, m), 5.05 (2H, s), 7.33-7.40 (5H, m), 7.44-7.57 (3H, m), 7.83-8.05 (3H, m), 8.58-8.68 (1H, m)

Mass (m/z) : 593 (M⁺+1)

(15) N-[(R)-1-{3-(1-benzyloxycarbonyl-4-piperidyl)propionyl}-3-piperidylcarbonyl]-2(S)-cyclopropylcarbonylamino-β-alanine

IR (Film) : 3300, 3000, 2930, 2860, 1720, 1640 cm⁻¹

NMR (DMSO-d₆, δ) : 0.66 (4H, d, J=6.5Hz), 0.89-1.10 (2H, m), 1.21-1.87 (10H, m), 2.07-2.37 (3H, m), 2.58-3.55 (6H, m), 3.71-3.84 (1H, m), 3.94-4.05 (2H, m), 4.17-4.40 (2H, m), 5.06 (2H, s), 7.35-7.39 (5H, m), 7.96-8.06 (1H, m), 8.24-8.31 (1H, m), 12.63-12.71 (1H, br)

Mass (m/z) : 557 (M⁺+1)

(16) N-[(R)-1-{3-(1-benzyloxycarbonyl-4-piperidyl)propionyl}-3-piperidylcarbonyl]-2(S)-(3-methoxypropionyl)amino-β-alanine

IR (Film) : 3480, 2920, 1710, 1640 cm⁻¹

NMR (DMSO-d₆, δ) : 0.94-1.29 (2H, m), 1.37-1.84 (11H, m), 2.06-2.40 (2H, m), 2.36 (2H, t, J=6.5Hz), 2.56-3.04 (3H, m), 3.20 (3H, s), 3.36-3.55 (2H, m), 3.51 (2H, t, J=6.5Hz), 3.73-3.83 (1H, m), 3.94-4.06 (2H, m), 4.18-4.39 (2H, m), 5.05 (2H, s), 7.35 (5H, s), 7.90-8.09 (2H, m)

Mass (m/z) : 575 (M⁺+1)

(17) N-[(R)-1-{3-(1-benzyloxycarbonyl-4-piperidyl)propionyl}-3-piperidylcarbonyl]-2(S)-(4-hydroxybenzoyl)amino-β-alanine

IR (Nujol) : 3250, 1720, 1630, 1600 cm⁻¹

NMR (DMSO-d₆, δ) : 0.89-1.86 (12H, m), 2.11-2.34 (3H, m), 2.51-3.09 (4H, m), 3.45-3.84 (2H, m), 3.95-4.05 (2H, m), 4.12-4.54 (2H, m), 5.06 (2H, s), 6.82 (2H, d, J=6.8Hz), 7.30-7.39 (5H, m), 7.72 (2H, d, J=7.2Hz), 8.10-8.19 (1H, m), 8.32-8.39 (1H, m), 10.02 (1H, s), 12.65-12.74 (1H, br)

Mass (m/z) : 609 (M⁺+1)

(18) N-[1-{3-(1-benzyloxycarbonyl-4-piperidyl)propionyl}-3-piperidyl]-2(S)-acetylaminosuccinamic acid

IR (Film) : 3270, 2900, 1720, 1640 cm^{-1}

NMR (DMSO- d_6 , δ) : 0.90-1.12 (2H, m), 1.29-1.52 (5H, m), 1.61-1.80 (4H, m), 1.82 (3H, s), 1.92-2.36 (2H, m), 2.44-3.08 (5H, m), 3.17-3.87 (3H, m), 3.94-4.05 (3H, m), 4.39-4.59 (1H, m), 5.05 (2H, s), 7.23-7.39 (6H, m), 7.76-8.13 (1H, m)

Mass (m/z) : 531 ($M^+ + 1$)

(19) N-[1-{3-(1-benzyloxycarbonyl)-4-piperidyl}propionyl]-3-piperidyl]-3(R)-benzoylamino succinamic acid

IR (Film) : 3280, 2910, 2850, 1715, 1640 cm^{-1}

NMR (DMSO- d_6 , δ) : 0.85-1.05 (2H, m), 1.22-1.50 (5H, m), 1.54-1.83 (4H, m), 2.11-2.35 (2H, m), 2.55-2.83 (4H, m), 2.90-3.06 (2H, m), 3.17-3.76 (3H, m), 3.88-4.05 (2H, m), 4.67-4.80 (1H, m), 5.05 (2H, s), 7.33 (5H, s), 7.40-7.54 (3H, m), 7.82-7.90 (2H, m), 7.92-8.11 (1H, m), 8.60-8.69 (1H, m)

Mass (m/z) : 593 ($M^+ + 1$)

(20) N-[(R)-1-{3-(1-benzyloxycarbonyl)-4-piperidyl}propionyl]-3-piperidyl carbonyl]-2(S)-(4-biphenyl carbonylamino- β -alanine

IR (Film) : 3300, 2940, 1730, 1690, 1660, 1640 cm^{-1}

NMR (DMSO- d_6 , δ) : 0.86-1.05 (2H, m), 1.11-1.45 (4H, m), 1.54-1.88 (6H, m), 2.05-2.34 (3H, m), 2.58-3.11 (3H, m), 3.23-3.80 (4H, m), 3.90-4.57 (3H, m), 5.05 (2H, s), 7.34 (5H, s), 7.40-7.55 (3H, m), 7.72-7.82 (4H, m), 7.93-7.99 (2H, m), 8.14-8.23 (1H, m), 8.64-8.71 (1H, m)

Mass (m/z) : 669 ($M^+ + 1$)

(21) N-[(R)-1-{3-(1-benzyloxycarbonyl)-4-piperidyl}propionyl]-3-piperidyl carbonyl]-2(S)-(n-hexanoyl)amino- β -alanine

IR (Film) : 3350, 3000, 2930, 2860, 1700, 1640 cm^{-1}

NMR (DMSO-d_6 , δ) : 0.85 (3H, t, $J=6.6\text{Hz}$), 0.90-1.09 (2H, m), 1.14-1.29 (5H, m), 1.39-1.85 (10H, m), 2.09 (2H, t, $J=7.4\text{Hz}$), 2.28-2.36 (2H, m), 2.57-3.54 (7H, m), 3.71-3.84 (1H, m), 3.94-4.06 (2H, m), 4.17-4.40 (2H, m), 5.06 (2H, s), 7.30-7.42 (5H, m), 7.90-8.03 (2H, m)

Mass (m/z) : 587 (M^++1)

(22) N-[(R)-1-{3-(1-tert-butoxycarbonyl-4-piperidyl)propionyl}-3-piperidylcarbonyl]-2(S)-acetylamino- β -alanine

IR (Film) : 3280, 2960, 2920, 1720, 1650 cm^{-1}

NMR (DMSO-d_6 , δ) : 0.83-1.09 (2H, m), 1.38 (9H, s), 1.38-1.80 (9H, m), 1.84 (3H, s), 2.07-2.39 (3H, m), 2.51-3.22 (6H, m), 3.73-4.40 (5H, m), 7.96-8.10 (2H, m)

Mass (m/z) : 497 (M^++1)

Example 12

(1) To a solution of N-[1-{2-(1-benzyloxycarbonyl-4-piperidyloxy)acetyl}-3-piperidylcarbonyl]- β -alanine methyl ester (1.33 g) in methanol (10 ml), H_2O (10 ml) and tetrahydrofuran (10 ml) was added 1N NaOH (8.55 ml) under stirring at 0°C . After stirring at ambient temperature for 3 hours, the mixture was acidified with 10% KHSO_4 aqueous solution, and extracted with ethyl acetate. The extract was washed with water and brine, and dried over MgSO_4 , and evaporated in vacuo to give N-[1-{2-(1-benzyloxycarbonyl-4-piperidyloxy)acetyl}-3-piperidylcarbonyl]- β -alanine (1.22 g) as an oil.

IR (Film) : 3330, 2940, 1700, 1630 cm^{-1}

NMR (DMSO-d_6 , δ) : 1.25-1.90 (8H, m), 2.09-2.31 (1H, m), 2.36 (2H, t, $J=6.9\text{Hz}$), 2.56-2.70 (1H, m), 2.85-3.29 (5H, m), 3.50-3.84 (4H, m), 4.10-4.34

(3H, m), 5.06 (2H, s), 7.28-7.39 (5H, m), 7.91-8.03 (1H, m), 12.09-12.10 (1H, br)
Mass (m/z) : 476 ($M^+ + 1$)

5 The following compounds were obtained according to a similar manner to that of Example 12.(1).

10
15
20
25
30
35
40
45
50
55
60
65
70
75
80
85
90
95
100
105
110
115
120
125
130
135
140
145
150
155
160
165
170
175
180
185
190
195
200
205
210
215
220
225
230
235
240
245
250
255
260
265
270
275
280
285
290
295
300
305
310
315
320
325
330
335
340
345
350
355
360
365
370
375
380
385
390
395
400
405
410
415
420
425
430
435
440
445
450
455
460
465
470
475
480
485
490
495
500
505
510
515
520
525
530
535
540
545
550
555
560
565
570
575
580
585
590
595
600
605
610
615
620
625
630
635
640
645
650
655
660
665
670
675
680
685
690
695
700
705
710
715
720
725
730
735
740
745
750
755
760
765
770
775
780
785
790
795
800
805
810
815
820
825
830
835
840
845
850
855
860
865
870
875
880
885
890
895
900
905
910
915
920
925
930
935
940
945
950
955
960
965
970
975
980
985
990
995
1000
1005
1010
1015
1020
1025
1030
1035
1040
1045
1050
1055
1060
1065
1070
1075
1080
1085
1090
1095
1100
1105
1110
1115
1120
1125
1130
1135
1140
1145
1150
1155
1160
1165
1170
1175
1180
1185
1190
1195
1200
1205
1210
1215
1220
1225
1230
1235
1240
1245
1250
1255
1260
1265
1270
1275
1280
1285
1290
1295
1300
1305
1310
1315
1320
1325
1330
1335
1340
1345
1350
1355
1360
1365
1370
1375
1380
1385
1390
1395
1400
1405
1410
1415
1420
1425
1430
1435
1440
1445
1450
1455
1460
1465
1470
1475
1480
1485
1490
1495
1500
1505
1510
1515
1520
1525
1530
1535
1540
1545
1550
1555
1560
1565
1570
1575
1580
1585
1590
1595
1600
1605
1610
1615
1620
1625
1630
1635
1640
1645
1650
1655
1660
1665
1670
1675
1680
1685
1690
1695
1700
1705
1710
1715
1720
1725
1730
1735
1740
1745
1750
1755
1760
1765
1770
1775
1780
1785
1790
1795
1800
1805
1810
1815
1820
1825
1830
1835
1840
1845
1850
1855
1860
1865
1870
1875
1880
1885
1890
1895
1900
1905
1910
1915
1920
1925
1930
1935
1940
1945
1950
1955
1960
1965
1970
1975
1980
1985
1990
1995
2000
2005
2010
2015
2020
2025
2030
2035
2040
2045
2050
2055
2060
2065
2070
2075
2080
2085
2090
2095
2100
2105
2110
2115
2120
2125
2130
2135
2140
2145
2150
2155
2160
2165
2170
2175
2180
2185
2190
2195
2200
2205
2210
2215
2220
2225
2230
2235
2240
2245
2250
2255
2260
2265
2270
2275
2280
2285
2290
2295
2300
2305
2310
2315
2320
2325
2330
2335
2340
2345
2350
2355
2360
2365
2370
2375
2380
2385
2390
2395
2400
2405
2410
2415
2420
2425
2430
2435
2440
2445
2450
2455
2460
2465
2470
2475
2480
2485
2490
2495
2500
2505
2510
2515
2520
2525
2530
2535
2540
2545
2550
2555
2560
2565
2570
2575
2580
2585
2590
2595
2600
2605
2610
2615
2620
2625
2630
2635
2640
2645
2650
2655
2660
2665
2670
2675
2680
2685
2690
2695
2700
2705
2710
2715
2720
2725
2730
2735
2740
2745
2750
2755
2760
2765
2770
2775
2780
2785
2790
2795
2800
2805
2810
2815
2820
2825
2830
2835
2840
2845
2850
2855
2860
2865
2870
2875
2880
2885
2890
2895
2900
2905
2910
2915
2920
2925
2930
2935
2940
2945
2950
2955
2960
2965
2970
2975
2980
2985
2990
2995
3000
3005
3010
3015
3020
3025
3030
3035
3040
3045
3050
3055
3060
3065
3070
3075
3080
3085
3090
3095
3100
3105
3110
3115
3120
3125
3130
3135
3140
3145
3150
3155
3160
3165
3170
3175
3180
3185
3190
3195
3200
3205
3210
3215
3220
3225
3230
3235
3240
3245
3250
3255
3260
3265
3270
3275
3280
3285
3290
3295
3300
3305
3310
3315
3320
3325
3330
3335
3340
3345
3350
3355
3360
3365
3370
3375
3380
3385
3390
3395
3400
3405
3410
3415
3420
3425
3430
3435
3440
3445
3450
3455
3460
3465
3470
3475
3480
3485
3490
3495
3500
3505
3510
3515
3520
3525
3530
3535
3540
3545
3550
3555
3560
3565
3570
3575
3580
3585
3590
3595
3600
3605
3610
3615
3620
3625
3630
3635
3640
3645
3650
3655
3660
3665
3670
3675
3680
3685
3690
3695
3700
3705
3710
3715
3720
3725
3730
3735
3740
3745
3750
3755
3760
3765
3770
3775
3780
3785
3790
3795
3800
3805
3810
3815
3820
3825
3830
3835
3840
3845
3850
3855
3860
3865
3870
3875
3880
3885
3890
3895
3900
3905
3910
3915
3920
3925
3930
3935
3940
3945
3950
3955
3960
3965
3970
3975
3980
3985
3990
3995
4000
4005
4010
4015
4020
4025
4030
4035
4040
4045
4050
4055
4060
4065
4070
4075
4080
4085
4090
4095
4100
4105
4110
4115
4120
4125
4130
4135
4140
4145
4150
4155
4160
4165
4170
4175
4180
4185
4190
4195
4200
4205
4210
4215
4220
4225
4230
4235
4240
4245
4250
4255
4260
4265
4270
4275
4280
4285
4290
4295
4300
4305
4310
4315
4320
4325
4330
4335
4340
4345
4350
4355
4360
4365
4370
4375
4380
4385
4390
4395
4400
4405
4410
4415
4420
4425
4430
4435
4440
4445
4450
4455
4460
4465
4470
4475
4480
4485
4490
4495
4500
4505
4510
4515
4520
4525
4530
4535
4540
4545
4550
4555
4560
4565
4570
4575
4580
4585
4590
4595
4600
4605
4610
4615
4620
4625
4630
4635
4640
4645
4650
4655
4660
4665
4670
4675
4680
4685
4690
4695
4700
4705
4710
4715
4720
4725
4730
4735
4740
4745
4750
4755
4760
4765
4770
4775
4780
4785
4790
4795
4800
4805
4810
4815
4820
4825
4830
4835
4840
4845
4850
4855
4860
4865
4870
4875
4880
4885
4890
4895
4900
4905
4910
4915
4920
4925
4930
4935
4940
4945
4950
4955
4960
4965
4970
4975
4980
4985
4990
4995
5000
5005
5010
5015
5020
5025
5030
5035
5040
5045
5050
5055
5060
5065
5070
5075
5080
5085
5090
5095
5100
5105
5110
5115
5120
5125
5130
5135
5140
5145
5150
5155
5160
5165
5170
5175
5180
5185
5190
5195
5200
5205
5210
5215
5220
5225
5230
5235
5240
5245
5250
5255
5260
5265
5270
5275
5280
5285
5290
5295
5300
5305
5310
5315
5320
5325
5330
5335
5340
5345
5350
5355
5360
5365
5370
5375
5380
5385
5390
5395
5400
5405
5410
5415
5420
5425
5430
5435
5440
5445
5450
5455
5460
5465
5470
5475
5480
5485
5490
5495
5500
5505
5510
5515
5520
5525
5530
5535
5540
5545
5550
5555
5560
5565
5570
5575
5580
5585
5590
5595
5600
5605
5610
5615
5620
5625
5630
5635
5640
5645
5650
5655
5660
5665
5670
5675
5680
5685
5690
5695
5700
5705
5710
5715
5720
5725
5730
5735
5740
5745
5750
5755
5760
5765
5770
5775
5780
5785
5790
5795
5800
5805
5810
5815
5820
5825
5830
5835
5840
5845
5850
5855
5860
5865
5870
5875
5880
5885
5890
5895
5900
5905
5910
5915
5920
5925
5930
5935
5940
5945
5950
5955
5960
5965
5970
5975
5980
5985
5990
5995
6000
6005
6010
6015
6020
6025
6030
6035
6040
6045
6050
6055
6060
6065
6070
6075
6080
6085
6090
6095
6100
6105
6110
6115
6120
6125
6130
6135
6140
6145
6150
6155
6160
6165
6170
6175
6180
6185
6190
6195
6200
6205
6210
6215
6220
6225
6230
6235
6240
6245
6250
6255
6260
6265
6270
6275
6280
6285
6290
6295
6300
6305
6310
6315
6320
6325
6330
6335
6340
6345
6350
6355
6360
6365
6370
6375
6380
6385
6390
6395
6400
6405
6410
6415
6420
6425
6430
6435
6440
6445
6450
6455
6460
6465
6470
6475
6480
6485
6490
6495
6500
6505
6510
6515
6520
6525
6530
6535
6540
6545
6550
6555
6560
6565
6570
6575
6580
6585
6590
6595
6600
6605
6610
6615
6620
6625
6630
6635
6640
6645
6650
6655
6660
6665
6670
6675
6680
6685
6690
6695
6700
6705
6710
6715
6720
6725
6730
6735
6740
6745
6750
6755
6760
6765
6770
6775
6780
6785
6790
6795
6800
6805
6810
6815
6820
6825
6830
6835
6840
6845
6850
6855
6860
6865
6870
6875
6880
6885
6890
6895
6900
6905
6910
6915
6920
6925
6930
6935
6940
6945
6950
6955
6960
6965
6970
6975
6980
6985
6990
6995
7000
7005
7010
7015
7020
7025
7030
7035
7040
7045
7050
7055
7060
7065
7070
7075
7080
7085
7090
7095
7100
7105
7110
7115
7120
7125
7130
7135
7140
7145
7150
7155
7160
7165
7170
7175
7180
7185
7190
7195
7200
7205
7210
7215
7220
7225
7230
7235
7240
7245
7250
7255
7260
7265
7270
7275
7280
7285
7290
7295
7300
7305
7310
7315
7320
7325
7330
7335
7340
7345
7350
7355
7360
7365
7370
7375
7380
7385
7390
7395
7400
7405
7410
7415
7420
7425
7430
7435
7440
7445
7450
7455
7460
7465
7470
7475
7480
7485
7490
7495
7500
7505
7510
7515
7520
7525
7530
7535
7540
7545
7550
7555
7560
7565
7570
7575
7580
7585
7590
7595
7600
7605
7610
7615
7620
7625
7630
7635
7640
7645
7650
7655
7660
7665
7670
7675
7680
7685
7690
7695
7700
7705
7710
7715
7720
7725
7730
7735
7740
7745
7750
7755
7760
7765
7770
7775
7780
7785
7790
7795
7800
7805
7810
7815
7820
7825
7830
7835
7840
7845
7850
7855
7860
7865
7870
7875
7880
7885
7890
7895
7900
7905
7910
7915
7920
7925
7930
7935
7940
7945
7950
7955
7960
7965
7970
7975
7980
7985
7990
7995
8000
8005
8010
8015
8020
8025
8030
8035
8040
8045
8050
8055
8060
8065
8070
8075
8080
8085
8090
8095
8100
8105
8110
8115
8120
8125
8130
8135
8140
8145
8150
8155
8160
8165
8170
8175
8180
8185
8190
8195
8200
8205
8210
8215
8220
8225
8230
8235
8240
8245
8250
8255
8260
8265
8270
8275
8280
8285
8290
8295
8300
8305
8310
8315
8320
8325
8330
8335
8340
8345
8350
8355
8360
8365
8370
8375
8380
8385
8390
8395
8400
8405
8410
8415
8420
8425
8430
8435
8440
8445
8450
8455
8460
8465
8470
8475
8480
8485
8490
8495
8500
8505
8510
8515
8520
8525
8530
8535
8540
8545
8550
8555
8560
8565
8570
8575
8580
8585
8590
8595
8600
8605
8610
8615
8620
8625
8630
8635
8640
8645
8650
8655
8660
8665
8670
8675
8680
8685
8690
8695
8700
8705
8710
8715
8720
8725
8730
8735
8740
8745
8750
8755
8760
8765
8770
8775
8780
8785
8790
8795
8800
8805
8810
8815
8820
8825
8830
8835
8840
8845
8850
8855
8860
8865
8870
8875
8880
8885
8890
8895
8900
8905
8910
8915
8920
8925
8930
8935
8940
8945
8950
8955
8960
8965
8970
8975
8980
8985
8990
8995
9000
9005
9010
9015
9020
9025
9030
9035
9040
9045
9050
9055
9060
9065
9070
9075
9080
9085
9090
9095
9100
9105
9110
9115
9120
9125
9130
9135
9140
9145
9150
9155
9160
9165
9170
9175
9180
9185
9190
9195
9200
9205
9210
9215
9220
9225
9230
9235
9240
9245
9250
9255
9260
9265
9270
9275
9280
9285
9290
9295
9300
9305
9310
9315
9320
9325
9330
9335
9340
9345
9350
9355
9360
9365
9370
9375
9380
9385
9390
9395
9400
9405
9410
9415
9420
9425
9430
9435
9440
9445
9450
9455
9460
9465
9470
9475
9480
9485
9490
9495
9500
9505
9510
9515
9520
9525
9530
9535
9540
9545
9550
9555
9560
9565
9570
9575
9580
9585
9590
9595
9600
9605
9610
9615
9620
9625
9630
9635
9640
9645
9650
9655
9660
9665
9670
9675
9680
9685
9690
9695
9700
9705
9710
9715
9720
9725
9730
9735
9740
9745
9750
9755
9760
9765
9770
9775
9780
9785
9790
9795
9800
9805
9810
9815
9820
9825
9830
9835
9840
9845
9850
9855
9860
9865
9870
9875
9880
9885
9890
9895
9900
9905
9910
9915
9920
9925
9930
9935
9940
9945
9950
9955
9960
9965
9970
9975
9980
9985
9990
9995
10000
10005
10010
10015
10020
10025
10030
10035
10040
10045
10050
10055
10060
10065
10070
10075
10080
10085
10090
10095
10100
10105
10110
10115
10120
10125
10130
10135
10140
10145
10150
10155
10160
10165
10170
10175
10180
10185
10190
10195
10200
10205
10210
10215
10220
10225
10230
10235
10240
10245
10250
10255
10

7.42 (5H, m), 8.10-8.18 (1H, m)
Mass (m/z) : 522 ($M^+ + 1$)

Example 13

(1) A solution of N-[1-{3-(1-tert-butoxycarbonyl-4-piperidyl)propionyl}-3-piperidylcarbonyl]- β -alanine methyl ester (2.03 g) in methanol (10 ml) and water (10 ml) was added lithium hydroxide (0.56 g) under stirring at 0°C. After stirring at ambient temperature for 1 hour, the mixture was acidified with 5% KHSO_4 aqueous solution and extracted with ethyl acetate. The extract was washed with water, brine and dried over MgSO_4 , and evaporated in vacuo to give N-[1-{3-(1-tert-butoxycarbonyl-4-piperidyl)propionyl}-3-piperidylcarbonyl]- β -alanine as an oil (1.62 g).

IR (Film) : 3300, 2920, 1715, 1630 cm^{-1}

NMR (DMSO-d_6 , δ) : 0.83-1.07 (2H, m), 1.38 (9H, s), 1.42-1.83 (9H, m), 2.26-2.40 (4H, m), 2.52-2.74 (2H, m), 2.87-3.27 (5H, m), 3.70-3.95 (3H, m), 4.16-4.38 (1H, m), 7.92-8.02 (1H, m), 12.05-12.10 (1H, br)

Mass (m/z) : 440 ($M^+ + 1$)

The following compounds were obtained according to a similar manner to that of Example 13 (1).

(2) N-[1-{3-(1-tert-butoxycarbonyl-4-piperidyl)propionyl}-4-piperidylcarbonyl]- β -alanine

IR (Film) : 3400, 3050, 2910, 1720, 1610 cm^{-1}

NMR (DMSO-d_6 , δ) : 0.80-1.07 (2H, m), 1.23-1.46 (6H, m), 1.38 (9H, s), 1.55-1.71 (4H, m), 2.27-2.36 (3H, m), 2.36 (2H, t, $J=6.9\text{Hz}$), 2.46-2.75 (2H, m), 2.89-3.05 (1H, m), 3.22 (2H, q, $J=5.9\text{Hz}$), 3.78-3.99 (3H, m), 4.28-4.40 (1H, m), 7.89 (1H, t, $J=5.5\text{Hz}$)

Mass (m/z) : 438 ($M^+ - 1$)

(3) N-[1-{4-(1-tert-butoxycarbonyl-4-piperidyl)butyryl}-
3-piperidylcarbonyl]glycine

IR (Film) : 3390, 2920, 2850, 1720, 1650 cm^{-1}

NMR (DMSO- d_6 , δ) : 0.84-1.10 (2H, m), 1.18-1.29 (2H, m), 1.38 (9H, s), 1.46-1.91 (8H, m), 2.24-2.38 (3H, m), 2.59-3.20 (4H, m), 3.69-4.00 (6H, m), 4.12-4.28 and 4.38-4.49 (total 1H, m), 8.25 (1H, t, $J=5.8\text{Hz}$)

Mass (m/z) : 440 ($M^+ + 1$)

(4) N-[(R)-1-{3-(1-tert-butoxycarbonyl-4-piperidyl)propionyl}-3-piperidylcarbonyl]-3(R)-(4-methoxyphenethyl)- β -alanine

IR (Film) : 3400, 3930, 3860, 1700, 1630 cm^{-1}

NMR (DMSO- d_6 , δ) : 0.85-1.09 (2H, m), 1.25-1.49 (4H, m), 1.38 (9H, s), 1.39-1.88 (8H, m), 2.10-2.72 (9H, m), 2.89-3.16 (1H, m), 3.71 (3H, s), 3.77-4.06 (4H, m), 4.12-4.39 (1H, m), 6.82 (2H, d, $J=8.6\text{Hz}$), 7.07 (2H, d, $J=8.6\text{Hz}$), 7.83 (1H, d, $J=8.4\text{Hz}$), 12.08 (1H, s)

Mass (m/z) : 574 ($M^+ + 1$)

(5) N-[(R)-1-{3-(1-tert-butoxycarbonyl-4-piperidyl)-propionyl}-3-piperidylcarbonyl]-3-phenyl- β -alanine

IR (Film) : 3380, 3020, 2940, 2870, 1710, 1660, 1630 cm^{-1}

NMR (DMSO- d_6 , δ) : 0.86-1.06 (2H, m), 1.21-1.91 (9H, m), 1.38 (9H, s), 2.16-2.35 (3H, m), 2.58-2.67 (5H, m), 2.86-3.06 (1H, m), 3.63-3.97 (3H, m), 4.05-4.42 (1H, m), 5.11-5.23 (1H, m), 7.17-7.31 (5H, m), 8.40-8.47 (1H, m)

Mass (m/z) : 516 ($M^+ + 1$)

- (6) N-[(R)-1-{3-(1-tert-butoxycarbonyl-4-piperidyl)propionyl}-3-piperidylcarbonyl]-3(R)-(3,4-dimethoxyphenethyl)- β -alanine

IR (Film) : 3300, 3430, 3360, 1720, 1640, 1625 cm^{-1}

NMR (DMSO- d_6 , δ) : 0.83-1.10 (2H, m), 1.21-1.46 (4H, m), 1.38 (9H, s), 1.61-1.91 (8H, m), 2.07-2.73 (10H, m), 2.87-3.20 (2H, m), 3.70 (3H, s), 3.73 (3H, s), 3.76-4.08 (3H, m), 6.64-6.68 (1H, m), 6.74-6.85 (2H, m), 7.83 (1H, d, $J=8.2\text{Hz}$), 11.97-12.14 (1H, br)

Mass (m/z) : 604 (M^++1)

- (7) N-[(R)-1-{3-(1-tert-butoxycarbonyl-4-piperidyl)propionyl}-3-piperidylcarbonyl]-3(R)-(3-methoxyphenethyl)- β -alanine

NMR (DMSO- d_6 , δ) : 0.92-1.12 (2H, m), 1.38 (9H, s), 1.38-1.98 (13H, m), 2.03-3.20 (14H, m), 3.72 (3H, s), 3.75-4.38 (6H, m), 6.73 (3H, d, $J=6.0\text{Hz}$), 7.17 (1H, t, $J=8.3\text{Hz}$), 7.84 (1H, d, $J=8.6\text{Hz}$)

Mass (m/z) : 574 (M^++1)

- (8) N-[(R)-1-{3-(1-tert-butoxycarbonyl-4-piperidyl)propionyl}-3-piperidylcarbonyl]-3(R)-(3-trifluoromethylphenethyl)- β -alanine

IR (Film) : 3280, 2920, 2850, 1720, 1630 cm^{-1}

NMR (DMSO- d_6 , δ) : 0.86-1.09 (2H, m), 1.38 (9H, s), 1.30-1.44 (4H, m), 1.59-1.86 (6H, m), 2.28-2.40 (5H, m), 2.60-2.74 (5H, m), 2.82-3.14 (1H, m), 3.71-4.05 (5H, m), 4.15-4.40 (1H, m), 7.48-7.56 (4H, m), 7.85-7.90 (1H, m)

Mass (m/z) : 612 (M^++1)

- (9) N-[(R)-1-{3-(1-tert-butoxycarbonyl-4-piperidyl)propionyl}-3-piperidylcarbonyl]-3(R)-(2-

methoxyphenethyl)- β -alanine

IR (Film) : 3290, 3000, 2930, 2850, 1715, 1640,
1615 cm^{-1}

NMR (DMSO-d_6 , δ) : 0.84-1.08 (2H, m), 1.30-1.45 (4H, m), 1.38 (9H, s), 1.59-1.91 (7H, m), 2.09-2.74 (10H, m), 2.89-3.18 (1H, m), 3.71-4.02 (4H, m), 3.75 (3H, s), 4.16-4.39 (1H, m), 6.81-6.94 (2H, m), 7.07-7.20 (2H, m), 7.84 (1H, d, $J=8.5\text{Hz}$), 12.12 (1H, s)

Mass (m/z) : 574 (M^++1)

(10) N-[(R)-1-{3-(1-tert-butoxycarbonyl-4-piperidyl)propionyl}-3-piperidylcarbonyl]-3(R)-(3,4-methylenedioxyphenethyl)- β -alanine

IR (Film) : 3380, 2960, 2920, 2860, 1710, 1650,
1620 cm^{-1}

NMR (DMSO-d_6 , δ) : 0.86-1.07 (2H, m), 1.24-1.94 (5H, m), 1.38 (9H, s), 1.59-1.87 (7H, m), 2.30-2.70 (9H, m), 2.90-3.15 (1H, m), 3.70-4.00 (4H, m), 4.14-4.39 (1H, m), 5.95 (2H, s), 6.59-6.63 (1H, m), 6.74-6.81 (2H, m), 7.83 (1H, d, $J=8.3\text{Hz}$), 12.09-12.19 (1H, br)

Mass (m/z) : 588 (M^++1)

(11) N-[(R)-1-{3-(1-benzyloxycarbonyl-4-piperidyl)propionyl}-3-piperidylcarbonyl]-2(R)-benzoylamino- β -alanine

IR (Film) : 3260, 2900, 1710, 1630 cm^{-1}

NMR (DMSO-d_6 , δ) : 0.86-1.04 (2H, m), 1.23-1.45 (4H, m), 1.56-1.83 (5H, m), 2.12-2.36 (3H, m), 2.57-3.81 (7H, m), 3.91-4.04 (2H, m), 4.14-4.62 (2H, m), 5.05 (2H, s), 7.28-7.35 (5H, m), 7.47-7.63 (3H, m), 7.83-7.97 (2H, m), 8.15-8.23 (1H, m), 8.64 (1H, t, $J=7.1\text{Hz}$)

Mass (m/z) : 593 (M^++1)

(12) N-[1-{3-(1-benzyloxycarbonyl-4-piperidyl)propionyl}-3-piperidyl]-3(S)-benzoylamino succinamic acid

IR (Film) : 3290, 2930, 1745, 1640 cm^{-1}

NMR (DMSO- d_6 , δ) : 0.87-1.06 (2H, m), 1.32-1.83 (9H, m), 2.15-2.35 (3H, m), 2.58-3.07 (8H, m), 3.51-3.79 (2H, m), 3.87-4.03 (2H, m), 4.67-4.80 (1H, m), 5.05 (2H, s), 7.29-7.39 (5H, m), 7.45-7.56 (3H, m), 7.81-7.89 (2H, m), 8.57-8.68 (1H, m)

Mass (m/z) : 593 ($\text{M}^+ + 1$)

(13) N-[(R)-1-{3-(1-benzyloxycarbonyl-4-piperidyl)propionyl}-3-piperidylcarbonyl]-2(R)-acetyl amino- β -alanine

IR (Film) : 3400, 2930, 2860, 1720, 1655, 1630 cm^{-1}

NMR (DMSO- d_6 , δ) : 0.90-1.12 (2H, m), 1.23-1.79 (9H, m), 1.84 (3H, s), 2.11-2.40 (4H, m), 2.61-3.48 (5H, m), 3.74-3.88 (1H, m), 3.96-4.08 (2H, m), 4.20-4.40 (2H, m), 5.06 (2H, s), 7.28-7.42 (5H, m), 7.98-8.08 (2H, m)

Mass (m/z) : 531 ($\text{M}^+ + 1$)

The following compound was obtained according to a similar manner to that of Example 12 (1).

Example 14

(1) N-[2-[1-{2-(1-tert-butoxycarbonyl-4-piperidyl)acetyl}-3-piperidyl]acetyl]- β -alanine

IR (Film) : 3300, 2920, 2850, 1710, 1635 cm^{-1}

NMR (DMSO- d_6 , δ) : 0.87-1.31 (4H, m), 1.38 (9H, s), 1.55-2.06 (9H, m), 2.14-2.28 (2H, m), 2.37 (2H, t, $J=6.8\text{Hz}$), 2.60-3.02 (4H, m), 3.23 (2H, q, $J=6.0\text{Hz}$), 3.68-4.27 (4H, m), 7.91-8.03 (1H, m)

Mass (m/z) : 438 ($\text{M}^+ - 1$)

(2) N-[2-[1-{2-(1-tert-butoxycarbonyl-4-

piperidylidene)acetyl}-3-piperidyl]acetyl]- β -alanine

IR (Film) : 3200, 2925, 1680, 1650 cm^{-1}

NMR (DMSO-d_6 , δ) : 1.09-1.41 (3H, m), 1.41 (9H, s),
1.57-1.91 (4H, m), 1.96-2.00 (2H, m), 2.14-2.24
(2H, m), 2.28-2.40 (3+1/2H, m), 2.64-2.83 (1H,
m), 2.91-3.06 (1/2H, m), 3.19-3.46 (5H, m),
3.71-3.83 (1H, m), 4.02-4.26 (1H, m), 5.90 and
5.96 (total 1H, s), 7.69-8.03 (1H, m), 12.17-
12.24 (1H, br)

Mass (m/z) : 438 (M^++1)

- (3) 4-[3-{3-(1-tert-butoxycarbonyl-4-piperidyl)-
propionylamino}-1-piperidyl]-4-oxo-butyric acid

IR (Film) : 3250, 2920, 1710, 1660, 1640, 1620 cm^{-1}

NMR (DMSO-d_6 , δ) : 0.82-1.04 (2H, m), 1.38 (9H, s),
1.38-1.85 (11H, m), 1.99-2.11 (2H, m), 2.41-2.43
(3H, m), 2.56-2.76 (2H, m), 2.98-3.12 (1H, m),
3.60-3.76 and 4.09-4.20 (total 3H, m), 3.85-3.96
(2H, m), 7.73, 7.84 (total 1H, d, $J=8.0$ and
6.4Hz), 12.03 (1H, s)

Mass (m/z) : 440 (M^++1)

- (4) N-[4-{3-(1-tert-butoxycarbonyl-4-
piperidyl)propionyl}-2-morpholinylcarbonyl]- β -alanine

IR (Film) : 3400, 2980, 2920, 2880, 1710, 1640 cm^{-1}

NMR (DMSO-d_6 , δ) : 0.84-1.08 (2H, m), 1.38 (9H, s),
1.38-1.49 (3H, m), 1.59-1.70 (4H, m), 2.29-2.44
(1H, m), 2.40 (2H, t, $J=7.0\text{Hz}$), 2.58-2.92 (3H,
m), 3.09-3.56 (3H, m), 3.70-3.98 (5+1/2H, m),
4.41-4.51 (1/2H, m), 7.77-7.94 (1H, m)

Mass (m/z) : 440 (M^+-1)

- (5) N-[1-{3-(1-tert-Butoxycarbonyl-4-
piperidyl)propionyl}-3-piperidyl]succinamic acid

IR (Film) : 3400, 1710, 1680, 1630 cm^{-1}

NMR (DMSO-d₆, δ) : 0.84-1.06 (2H, m), 1.26-1.31 (6H, m), 1.38 (9H, s), 1.59-1.84 (4H, m), 2.20-2.46 (6H, m), 2.57-2.74 (2H, m), 2.91-3.08 (2H, m), 3.45-3.76 (2H, m), 3.84-3.96 (2H, m), 7.76-7.92 (1H, m), 12.00-12.06 (1H, br)

Mass (m/z) : 340 (M⁺+1-Boc)

(6) N-[(R)-1-{2-(4-piperidyloxy)acetyl}-3-piperidylcarbonyl]-β-alanine trifluoroacetate

[α]_D²⁰ = 20.07° (C=1.0, MeOH)

IR (Film) : 2940, 1760, 1820, 1660, 1630 cm⁻¹

NMR (DMSO-d₆, δ) : 1.25-2.02 (8H, m), 2.10-2.16 (1H, m), 2.37 (2H, t, J=6.8Hz), 2.55-2.71 (1H, m), 2.86-3.25 (7H, m), 3.59-3.72 (2H, m), 4.07-4.31 (3H, m), 7.99 (1H, t, J=5.5Hz), 8.42-8.60 (2H, br)

Mass (m/z) : 342 (M⁺+1) free of compound

Example 15

A mixture of N-[(R)-1-{3-(1-tert-butoxycarbonyl-4-piperidyl)propionyl}-3-piperidylcarbonyl]-3(S)-vinyl-β-alanine ethyl ester (0.8 g) and PtO₂ (0.2 g) in ethanol (10 ml) was hydrogenated at atmospheric pressure for 2 hours. After the catalyst was removed by filtration, the filtrate was concentrated in vacuo to give N-[(R)-1-{3-(1-tert-butoxycarbonyl-4-piperidyl)propionyl}-3-piperidylcarbonyl]-3(S)-ethyl-β-alanine ethyl ester (0.73 g) as a colorless oil.

IR (Film) : 3300, 1740, 1620 cm⁻¹

NMR (CDCl₃, δ) : 0.92 (3H, t, J=7.5Hz), 1.08-1.30 (6H, m), 1.45 (9H, s), 1.52-2.03 (11H, m), 2.33-2.74 (6H, m), 3.26-3.51 (2H, m), 3.72 (2H, q, J=7.5Hz), 3.77-4.17 (5H, m), 6.64-6.69 (1H, br)

Example 16

The solution of 4-[3-{3-(1-tert-butoxycarbonyl-4-piperidyl)propionylamino}-1-piperidyl]-4-oxo-2(S)benzyloxycarbonylaminobutyric acid tert-butyl ester (1.35 g) in tetrahydrofuran (10 ml) and methanol (10 ml) was added 10% Pd-C (0.27 g, 50% wet) was hydrogenated at atmospheric pressure for 6 hours. After the catalyst was removed by filtration, the filtrate was concentrated in vacuo to give 4-[3-{3-(1-tert-butoxycarbonyl-4-piperidyl)propionylamino}-1-piperidyl]-4-oxo-2(S)-aminobutyric acid tert-butyl ester (1.07 g) as an oil.

IR (Film) : 2970, 2930, 2880, 1720, 1650 cm^{-1}

NMR (CDCl_3 , δ) : 0.97-1.20 (2H, m), 1.45 (18H, s), 1.33-1.84 (9H, m), 2.15-2.46 (2H, m), 2.53-2.76 (3H, m), 2.85-3.60 (5H, m), 3.70-4.40 (4H, m), 7.35 (1H, s)

Mass (m/z) : 511 ($\text{M}^+ + 1$)

Example 17

To a mixture of thioanisole (13.7 ml) and m-cresol (12.2 ml) in tetrahydrofuran (150 ml) was added N-[(R)-1-{2-(1-benzyloxycarbonyl-4-piperidyloxy)acetyl}-3-piperidylcarbonyl]-3-ethynyl- β -alanine ethyl ester (1.54 g). After stirring at ambient temperature for 2 hours, the mixture was poured into water and washed with diethyl ether. The extract was purified by HPLC on C18 silica gel eluting with (0.1% TFA aqueous solution: CH_3CN = 4:1) to give N-[(R)-1-{2-(4-piperidyloxy)acetyl}-3-piperidylcarbonyl]-3-ethynyl- β -alanine ethyl ester trifluoroacetate as an oil (0.17 g).

NMR ($\text{DMSO}-d_6$, δ) : 1.78 and 1.18 (total 3H, t, $J=7.1$ and 7.0Hz), 1.29-2.71 (10H, m), 2.65 (1H, d, $J=7.2\text{Hz}$), 2.90-3.2 (5H, m), 3.57-3.63 (3H, m), 4.01-4.39 (7H, m), 4.80-4.90 (1H, m), 8.45-8.56 (1H, m)

Mass (m/z) : 394 ($\text{M}^+ + 1$) free of compound

Example 18

A mixture of N-[(R)-1-{3-(1-tert-butoxycarbonyl-4-piperidyl)propionyl}-3-piperidylcarbonyl]-3(S)-(4-methoxyphenethylamino)carbonyl- β -alanine benzyl ester (0.9 g) and 10% Pd-C (0.2 g, 50% wet) in acetic acid (10 ml) was hydrogenated at atmospheric pressure for 3 hours. After the catalyst was removed by filtration, the filtrate was concentrated in vacuo. The residue was poured into water and extract with ethyl acetate. The extract washed with water, brine and dried over MgSO₄, and evaporated in vacuo. To give N-[(R)-1-{3-(1-tert-butoxycarbonyl)-4-piperidyl}propionyl]-3-piperidylcarbonyl]-3(S)-(4-methoxyphenethylamino)carbonyl- β -alanine as an oil (0.79 g).

IR (Film) : 3390, 2930, 1710, 1645 cm⁻¹

NMR (DMSO-d₆, δ) : 0.80-1.10 (3H, m), 1.30-1.84 (9H, m), 1.38 (9H, s), 1.91-1.99 (2H, m), 2.15-2.40 (3H, m), 2.58-2.69 (4H, m), 2.88-3.26 (5H, m), 3.71 (3H, s), 3.76-4.53 (3H, m), 6.84 (2H, d, J=8.4Hz), 7.11 (2H, d, J=8.3Hz), 7.93-8.02 (1H, m), 8.09-8.18 (1H, m), 12.11-12.28 (1H, br)

Mass (m/z) : 617 (M⁺+1)

Example 19

(1) Thionyl chloride (0.05 ml) was added to ethanol (1 ml) under stirring at -10°C. After stirring at -10°C for 10 minutes, N-[(R)-1-{3-(4-piperidyl)propionyl}-3-piperidylcarbonyl]-3(R)-(3-methoxyphenethyl)- β -alanine hydrochloride (100 mg) was added. The mixture was stirred at ambient temperature for 2 hours, and evaporated in vacuo. The residue was dissolved in water and desalted by HP-20 eluting with (IPA:water = 1:1) to give N-[(R)-1-{3-(4-piperidyl)propionyl}-3-piperidylcarbonyl]-3(R)-(3-methoxyphenethyl)- β -alanine ethyl ester (80 mg).

NMR (DMSO-d₆, δ) : 1.15 (3H, t, J=7.1Hz), 1.19-1.93

(12H, m), 2.10-3.19 (14H, m), 3.72 (3H, s),
3.96-4.05 (5H, m), 4.12-4.39 (1H, m), 6.72-6.75
(3H, m), 7.14-7.22 (1H, m), 7.89 (1H, d,
J=8.2Hz)

Mass (m/z) : 502 ($M^+ + 1$)

The following compound was obtained according to a
similar manner to that of Example 19 (1).

(2) N-[(R)-1-{3-(4-piperidyl)propionyl}-3-
piperidylcarbonyl]-3(S)-ethynyl- β -alanine methyl
ester hydrochloride

IR (Film) : 3300, 2950, 1725, 1640, 1620 cm^{-1}

NMR (DMSO- d_6 , δ) : 1.20-1.87 (12H, m), 2.14-2.42
(3H, m), 2.60-3.29 (7H, m), 3.16 (3H, s), 3.59-
3.84 (2H, m), 4.10-4.40 (1H, m), 4.77-4.92 (1H,
m), 8.51 and 8.61 (total 1H, d, J=8.0 and
8.3Hz), 8.74-8.90 (1H, br), 9.05-9.15 (1H, br)

Mass (m/z) : 378 ($M^+ + 1$) free of compound

Example 20

To a solution of N-[(R)-1-{3-(1-benzyloxycarbonyl-4-
piperidyl)propionyl}-3-piperidylcarbonyl]-2(S)-amino- β -
alanine ethyl ester hydrochloride (250 mg) in
tetrahydrofuran (2 ml), ethanol (2 ml) was added a
solution of lithium hydroxide (17 mg) in water (2 ml)
under stirring at 0°C. After stirring at ambient
temperature for 1 hour, the mixture was evaporated in
vacuo. The residue was purified by HPLC on C18 silica gel
eluting with a solution of 40% CH_3CN in 0.1% aqueous
trifluoroacetic acid solution. The fractions containing
object compound were combined and evaporated in vacuo, and
freeze-dried to give N-[(R)-1-{3-(1-benzyloxycarbonyl-4-
piperidyl)propionyl}-3-piperidylcarbonyl]-2(S)-amino- β -

alanine trifluoroacetate (230 mg).

IR (Nujol) : 1770, 1730, 1650 cm^{-1}

NMR (DMSO-d_6 , δ) : 0.87-1.14 (2H, m), 1.24-1.56 (4H, m), 1.60-1.91 (4H, m), 2.09-2.17 (3H, m), 2.59-3.23 (5H, m), 3.32-3.84 (2H, m), 3.93-4.04 (4H, m), 4.13-4.43 (1H, m), 5.06 (2H, s), 4.88-5.28 (1H, br), 7.27-7.40 (5H, m), 8.14-8.28 (3H, m)

Mass (m/z) : 489 ($M^+ + 1$) free of compound

Example 21

(1) A solution of N-[(R)-1-{3-(1-tert-butoxycarbonyl-4-piperidyl)propionyl}-3-piperidylcarbonyl]-3-ethynyl- β -alanine (1.12 g) in ethyl acetate (12 ml) was added 4N HCl in ethyl acetate (6.04 ml) under stirring at 0°C. After stirring at ambient temperature for 2 hours, and evaporated in vacuo. The residue was purified by HPLC on C18 silica gel column eluting with (0.1% trifluoroacetic acid aqueous solution (TFA): CH_3CN = 89:11) to give one isomer of N-[(R)-1-{3-(4-piperidyl)propionyl}-3-piperidylcarbonyl]-3(S)-ethynyl- β -alanine trifluoroacetate $[\alpha]_D^{20} -31.63^\circ$ (C=1.0, MeOH) : object compound (1)] (0.32 g) and the other isomer $[\alpha]_D^{20} -1.47^\circ$ (C=1.0, MeOH) : object compound (2)] (0.35 g).

object compound (1),

IR (Film) : 3270, 2930, 1720, 1630 cm^{-1}

NMR (DMSO-d_6 , δ) : 1.15-1.73 (8H, m), 1.81 (3H, d, $J=13.6\text{Hz}$), 2.08-2.37 (3H, m), 2.59 (2H, d, $J=8.8\text{Hz}$), 2.69-2.93 (3H, m), 2.97-3.28 (4H, m), 3.68-3.83 (2H, m), 4.10-4.34 (1H, m), 4.75-4.89 (1H, m), 8.14-8.30 (1H, br), 8.39-8.46 (1H, m), 8.50-8.61 (1H, br)

Mass (m/z) : 364 ($M^+ + 1$) free of compound

object compound (2)

IR (Film) : 3230, 2930, 1725, 1620 cm^{-1}

NMR (DMSO-d_6 , δ) : 1.14-1.66 (8H, m), 1.81 (3H, d, $J=13.8\text{Hz}$), 2.08-2.43 (3H, m), 2.58 (2H, d, $J=7.6\text{Hz}$), 2.69-3.00 (5H, m), 3.10-3.29 (4H, m), 3.69-3.85 (1H, m), 4.04-4.16 and 4.31-4.42 (total 1H, m), 8.11-8.27 (1H, br), 8.40-8.45 (1H, m), 8.44-8.59 (1H, br)

Mass (m/z) : 364 (M^++1) free of compound

As a result of further study, we identified the object compound (1) with N-[(R)-1-{3-(4-piperidyl)-propionyl}-3-piperidylcarbonyl]-3(S)-ethynyl- β -alanine trifluoroacetate and identified the object compound (2) with N-[(R)-1-{3-(4-piperidyl)propionyl}-3-piperidyl-carbonyl]-3(R)-ethynyl- β -alanine trifluoroacetate.

The following compounds were obtained according to a similar manner to that of Example 21 (1).

(2) (3R)-N-[(R)-1-{3-(4-Piperidyl)propionyl}-3-piperidylcarbonyl]-3-methyl- β -alanine hydrochloride
mp : 105-108°C

IR (Nujol) : 1720, 1620, 1605 cm^{-1}

NMR (DMSO-d_6 , δ) : 1.04-1.09 (3H, m), 1.28-1.83 (12H, m), 2.06-2.49 (5H, m), 2.58-3.23 (6H, m), 3.70-3.83 (1H, m), 4.16-4.33 (1H, m), 7.94 (1H, dd, $J=17$ and 7.8Hz), 8.71-8.98 (1H, m), 9.01-9.20 (1H, m)

Mass (m/z) : 354 (M^++1) free of compound

Elemental Analysis $\text{C}_{17}\text{H}_{29}\text{N}_3\text{O}_4 \cdot \text{HCl} \cdot 1.25\text{AcOEt} \cdot 1.6\text{H}_2\text{O}(\%)$

Calcd. : C 51.32, H 8.46, N 8.16

Found : C 51.22, H 8.77, N 7.92

(3) N-[(R)-1-{3-(4-piperidyl)propionyl}-3-piperidylcarbonyl]- β -alanine hydrochloride

$[\alpha]_D^{20}$ -24.3° (C=1.0, MeOH)

mp : 84°C

IR (Nujol) : 3320, 1700, 1650 cm^{-1}

NMR (DMSO- d_6 , δ) : 1.21-1.65 (7H, m), 1.80 (3H, d, $J=13.2\text{Hz}$), 2.29-2.41 (4H, m), 2.56-3.07 (4H, m), 3.15-3.26 (4H, m), 3.70-3.85 (1H, m), 4.13-4.37 (4H, m), 7.97-8.10 (1H, m), 8.60-8.76 (1H, br), 8.91-9.03 (1H, br)

Mass (m/z) : 340 (M^++1) free of compound

Elemental Analysis $\text{C}_{17}\text{H}_{29}\text{N}_3\text{O}_4 \cdot \text{HCl} \cdot 1.5\text{AcOEt} \cdot 3\text{H}_2\text{O}$ (%)

Calcd. : C 49.15, H 8.61, N 7.48

Found : C 49.08, H 8.23, N 7.29

(4) N-[(R)-1-{3-(4-piperidyl)propionyl}-3-piperidylcarbonyl]-3(S)-(4-methoxyphenethyl-aminocarbonyl)- β -alanine hydrochloride

$[\alpha]_D^{20}$ = -19.07°C (C=1.0, MeOH)

mp : 82°C

IR (Nujol) : 3280, 1725, 1630, 1600 cm^{-1}

NMR (DMSO- d_6 , δ) : 0.99-1.69 (10H, m), 2.11-2.82 (11H, m), 2.94-3.09 (4H, m), 3.49 (3H, s), 3.86-4.30 (4H, m), 6.63 (2H, d, $J=8.4\text{Hz}$), 6.90 (2H, d, $J=8.5\text{Hz}$), 7.81-8.19 (2H, m), 8.41-8.68 (1H, br), 8.71-8.85 (1H, br)

Mass (m/z) : 515 (M^+-1) free of compound

(5) N-[(R)-1-{3-(4-piperidyl)propionyl}-3-piperidylcarbonyl]-3(R)-phenethyl- β -alanine hydrochloride

$[\alpha]_D^{25}$ = -32.33° (C=1.0, MeOH)

IR (Nujol) : 3300, 1700, 1620 cm^{-1}

NMR (DMSO- d_6 , δ) : 1.03-1.91 (13H, m), 2.06-3.07 (11H, m), 3.12-3.24 (2H, m), 3.70-3.90 (1H, m), 3.98-4.38 (2H, m), 7.16-7.51 (5H, m), 7.93-8.05 (1H, m), 8.71-9.01 (12H, m), 9.08-9.20 (1H, br)

Mass (m/z) : 444 (M^++1) free of compound

Elemental Analysis $C_{25}H_{37}N_3O_4 \cdot HCl \cdot 2.7H_2O$

Calcd. : C 56.80, H 8.27, N 7.95

Found : C 56.94, H 8.01, N 7.58

5

- (6) N-[(R)-1-{3-(4-piperidyl)propionyl}-3-piperidylcarbonyl]-3(R)-(4-methoxyphenethyl)- β -alanine hydrochloride

$[\alpha]_D^{20} = 43.1^\circ$ (C=1.0, MeOH)

IR (Nujol) : 1715, 1620, 1600 cm^{-1}

NMR (DMSO- d_6 , δ) : 1.22-1.86 (12H, m), 2.11-3.24 (12H, m), 3.71-4.36 (5H, m), 3.71 (3H, s), 6.82 (2H, d, J=8.6Hz), 7.08 (2H, d, J=8.5Hz), 7.90 (1H, t, J=8.8Hz), 8.63-8.74 (1H, br), 8.90-9.01 (1H, br)

Mass (m/z) : 474 (M^++1) free of compound

Elemental Analysis $C_{26}H_{39}N_3O_5 \cdot HCl \cdot 2H_2O$

Calcd. : C 57.19, H 8.12, N 7.69

Found : C 56.82, H 8.17, N 7.51

- (7) N-[(R)-1-{3-(4-piperidyl)propionyl}-3-piperidylcarbonyl]-2-(2-piperidyl)acetic acid hydrochloride

IR (Nujol) : 3350, 1705, 1600 cm^{-1}

NMR (DMSO- d_6 , δ) : 1.27-1.83 (16H, m), 2.23-2.40 (2H, m), 2.56-3.23 (6H, m), 3.70-4.55 (8H, m), 4.87-5.02 (1H, m), 8.65-8.84 (1H, br), 8.96-9.10 (1H, br)

Mass (m/z) : 394 (M^++1) free of compound

- (8) N-[4-{3-(4-piperidyl)propionyl}-2-morpholinylcarbonyl]- β -alanine hydrochloride

IR (Nujol) : 3300, 1705, 1625 cm^{-1}

NMR (DMSO- d_6 , δ) : 1.29-1.50 (5H, m), 1.77-1.83 (2H, m), 2.30-2.60 (4H, m), 2.70-2.94 (2+1/2H, m),

35

3.08-3.35 (5+1/2H, m), 3.40-3.57 (1H, m), 3.72-4.05 (3+1/2H, m), 4.43-4.49 (1/2H, m), 7.79-7.97 (1H, m), 8.73-8.89 (1H, br), 9.04-9.16 (1H, br)
Mass (m/z) : 342 (M^+ +1) free of compound

5

(9) N-[(R)-1-{3-(4-piperidyl)propionyl}-3-piperidylcarbonyl]-3-phenyl- β -alanine hydrochloride
mp : 67°C

IR (Nujol) : 1710, 1630, 1600 cm^{-1}

NMR (DMSO- d_6 , δ) : 1.24-1.91 (10H, m), 2.10-2.41 (3H, m), 2.59-3.09 (5H, m), 3.14-3.25 (2H, m), 3.63-3.86 (1H, m), 4.08-4.41 (1H, m), 5.18 (1H, q, $J=7.8\text{Hz}$), 7.20-7.27 (1H, m), 7.31 (5H, s), 8.49-8.66 (1H, m), 8.80-8.94 (1H, br), 9.06-9.20 (1H, br)

Mass (m/z) : 416 (M^+ +1) free of compound

(10) N-[(R)-1-{3-(4-piperidyl)propionyl}-3-piperidylcarbonyl]-3(R)-(3,4-dimethoxyphenethyl)- β -alanine hydrochloride

$[\alpha]_D^{20} = -13.33^\circ$ (C=1.0, MeOH)

IR (Nujol) : 1730, 1635 cm^{-1}

NMR (DMSO- d_6 , δ) : 1.01-1.50 (9H, m), 1.66-1.83 (8H, m), 1.83-3.23 (11H, m), 3.71 (3H, s), 3.73 (3H, s), 4.15-4.38 (2H, m), 6.65-6.69 (1H, m), 6.77-6.85 (2H, m), 8.88-9.02 (1H, br), 9.15-9.25 (1H, br)

Mass (m/z) : 504 (M^+ +1) free of compound

(11) N-[(R)-1-{3-(4-piperidyl)propionyl}-3-piperidylcarbonyl]-3(S)-(3-methoxyphenethyl)- β -alanine hydrochloride

IR (Nujol) : 1710, 1600, 720 cm^{-1}

NMR (DMSO- d_6 , δ) : 1.13-2.00 (14H, m), 2.01-3.70 (9H, m), 3.17-3.29 (2H, m), 3.73 (3H, s), 3.97-

35

4.08 (1H, m), 4.10-4.37 (1H, m), 6.74 (3H, d like), 7.18 (1H, t like), 7.92 (1H, t like), 8.72 (1H, br), 8.99 (1H, br)

Mass (m/z) : 474 ($M^+ + 1$) free of compound

5

- (12) N-[(R)-1-{3-(4-piperidyl)propionyl}-3-piperidylcarbonyl]-2(S)-benzoylamino- β -alanine hydrochloride

IR (Nujol) : 3100, 1725, 1630 cm^{-1}

NMR (DMSO- d_6 , δ) : 1.2-1.85 (12H, m), 2.27-2.36 (2H, m), 2.57-3.10 (4H, m), 3.12-3.25 (2H, m), 3.39-3.82 (3H, m), 4.07-4.59 (3H, m), 7.45-7.56 (3h, m), 7.87-7.91 (2H, m), 8.22-8.40 (1H, m), 8.65-8.75 (1H, m), 8.89-9.02 (1H, m)

Mass (m/z) : 459 ($M^+ + 1$) free of compound

- (13) N-[(R)-1-{3-(4-piperidyl)propionyl}-3-piperidylcarbonyl]-3(R)-(3-trifluoromethylphenethyl)- β -alanine hydrochloride

mp : 118°C

$[\alpha]_D^{20} = -21.4^\circ$ (C-1.0, MeOH)

IR (Nujol) : 3300, 1715, 1630, 1610 cm^{-1}

NMR (DMSO- d_6 , δ) : 1.23-2.13 (14H, m), 2.35-2.45 (5H, m), 2.61-2.83 (5H, m), 3.15-3.28 (2H, m), 3.72-3.89 (1H, m), 3.99-4.10 (1H, m), 4.15-4.41 (1H, m), 7.49-7.55 (4H, m), 7.94-8.05 (1H, m), 8.75-8.93 (1H, m), 9.03-9.17 (1H, m)

Mass (m/z) : 512 ($M^+ + 1$) free of compound

Elemental Analysis $\text{C}_{26}\text{H}_{36}\text{F}_3\text{N}_3\text{O}_4 \cdot \text{HCl} \cdot 1.8\text{H}_2\text{O}$

Calcd. : C 53.80, H 7.05, N 7.24

Found : C 53.72, H 7.10, N 7.02

- (14) N-[(R)-1-{3-(4-piperidyl)propionyl}-3-piperidylcarbonyl]-2(S)-phenylsulfonylamino- β -alanine hydrochloride

$[\alpha]_D^{25} = -14.23^\circ$ (C=1.0, MeOH)

IR (Nujol) : 1720, 1630 cm^{-1}

NMR (DMSO- d_6 , δ) : 1.21-1.83 (11H, m), 2.04-2.37 (3H, m), 2.70-3.40 (7H, m), 3.74-3.91 (2H, m), 4.12-4.39 (2H, m), 7.55-7.62 (3H, m), 7.75-7.79 (2H, m), 8.01-8.26 (2H, m), 8.50-8.66 (1H, br), 8.82-8.94 (1H, br)

Mass (m/z) : 495 ($\text{M}^+ + 1$) free of compound

(15) N-[(R)-1-{3-(4-piperidyl)propionyl}-3-piperidylcarbonyl]-3(R)-(2-methoxyphenethyl)- β -alanine hydrochloride

$[\alpha]_D^{20} = -17.73^\circ$ (C=1.0, MeOH)

IR (Nujol) : 1725, 1640, 1600 cm^{-1}

NMR (DMSO- d_6 , δ) : 1.21-1.91 (16H, m), 2.30-3.24 (11H, m), 3.75 (3H, s), 3.70-3.89 (1H, m), 4.12-4.39 (1H, m), 6.81-6.94 (2H, m), 7.07-7.20 (2H, m), 7.84-7.94 (1H, m), 8.60-8.75 (1H, br), 8.91-9.03 (1H, br)

Mass (m/z) : 474 ($\text{M}^+ + 1$) free of compound

(16) N-[(R)-1-{3-(4-piperidyl)propionyl}-3-piperidylcarbonyl]-2(S)-(n-butanesulfonylamino)- β -alanine hydrochloride

$[\alpha]_D^{25} = -31.37^\circ$ (C=1.0, MeOH)

IR (Nujol) : 1715, 1620 cm^{-1}

NMR (DMSO- d_6 , δ) : 0.88 (3H, t, $J=7.2\text{Hz}$), 1.14-1.89 (15H, m), 2.29-2.40 (2H, m), 2.77-3.06 (6H, m), 3.19-3.27 (2H, m), 3.77-4.41 (5H, m), 7.51-7.60 (1H, m), 8.04-8.18 (1H, m), 8.43-8.18 (1H, m), 8.43-8.60 (1H, br), 8.73-8.86 (1H, br)

Mass (m/z) : 475 ($\text{M}^+ + 1$) free of compound

(17) N-[(R)-1-{3-(3-piperidyl)propionyl}-3-piperidylcarbonyl]-3(R)-(3,4-methylenedioxy-

phenethyl)- β -alanine hydrochloride

$[\alpha]_D^{25}$: -17.27° (C=1.0, MeOH)

IR (Nujol) : 1725, 1685, 1620 cm^{-1}

NMR (DMSO- d_6 , δ) : 0.84-1.50 (6H, m), 1.59-1.91 (6H, m), 1.06-3.28 (12H, m), 3.60-4.27 (5H, m), 4.30-4.40 (1H, m), 5.95 (2H, s), 6.59-6.63 (1H, m), 6.75-6.81 (2H, m), 7.84-7.90 (1H, m)

Mass (m/z) : 488 ($M^+ + 1$) free of compound

Elemental Analysis $\text{C}_{26}\text{H}_{37}\text{N}_3\text{O}_6 \cdot \text{HCl} \cdot 1/4\text{EtOAc} \cdot 1.4\text{H}_2\text{O}$

Calcd. : C 56.77, H 7.55, N 7.36

Found : C 56.81, H 7.69, N 7.11

(18) N-[(R)-1-{3-(4-piperidyl)propionyl}-3-piperidylcarbonyl]-3(S)-ethynyl- β -alanine hydrochloride

IR (KBr) : 3425, 3250, 1726, 1638, 1614 cm^{-1}

NMR (DMSO- d_6 , δ) : 1.27-1.83 (11H, m), 2.08-2.32 (3H, m), 2.58-3.09 (5H, m), 3.18-3.22 (3H, m), 3.75-3.80 (1H, m), 4.08-4.32 (1H, m), 4.79-4.82 (1H, m), 8.42-8.54 (1H, m), 8.75 (1H, br), 9.04 (1H, br)

Mass (m/z) : 364 ($M^+ + 1$) free of compound

(19) N-[1-{3-(4-piperidyl)propionyl}-3-piperidyl]succinamic acid hydrochloride

IR (Nujol) : 3200, 1710, 1620 cm^{-1}

NMR (DMSO- d_6 , δ) : 1.25-1.52 (7H, m), 1.69-1.86 (4H, m), 2.21-2.46 (6H, m), 2.69-3.06 (4H, m), 3.15-3.26 (2H, m), 3.47-3.84 (2H, m), 4.14-4.24 (1H, m), 7.80-7.97 (1H, m), 8.64-8.78 (1H, br) 8.95-9.06 (1H, br)

Mass (m/z) : 340 ($M^+ + 1$) free of compound

(20) N-[(R)-1-{3-(4-piperidyl)propionyl}-3-

piperidylcarbonyl]-3(S)-propargylaminocarbonyl- β -alanine hydrochloride

$[\alpha]_D^{20} = -11.9^\circ$ (C=1.0, MeOH)

IR (Nujol) : 1735, 1640 cm^{-1}

5 NMR (DMSO- d_6 , δ) : 1.21-1.69 (7H, m), 1.75-1.86 (3H, m), 2.06-2.40 (3H, m), 2.56-3.04 (5H, m), 3.17-3.26 (4H, m), 3.68-3.87 (3H, m), 4.08-4.56 (3H, m), 8.11-8.30 (1H, m), 8.34-8.50 (1H, m), 8.60-8.73 (1H, br), 8.90-9.02 (1H, m)

10 Mass (m/z) : 421 ($\text{M}^+ + 1$) free of compound

(21) 4-[3-{3-(4-piperidyl)propionylamino}-1-piperidyl]-4-oxo-butyric acid hydrochloride

IR (Nujol) : 1735, 1700, 1610 cm^{-1}

15 NMR (DMSO- d_6 , δ) : 1.25-1.50 (9H, m), 1.71-1.83 (4H, m), 2.06-2.16 (2H, m), 2.39-2.46 (3H, m), 2.70-2.87 (2H, m), 2.96-3.08 (1H, m), 3.15-3.25 (2H, m), 3.52-3.76 (2H, m), 4.08-4.16 (1H, m), 7.84, 7.95 (total 1H, d, J=7.8 and 6.5Hz), 8.73-8.88 (1H, br), 9.00-9.10 (1H, br)

20 Mass (m/z) : 340 ($\text{M}^+ + 1$) free of compound

(22) N-[(S)-1-{3-(4-piperidyl)propionyl}-3-piperidyl-carbonyl]-3(R)-ethynyl- β -alanine trifluoroacetate

25 $[\alpha]_D^{20} = 35.7^\circ$ (C=0.65, MeOH)

IR (Film) : 3250, 2930, 2850, 1760, 1700, 1610 cm^{-1}

30 NMR (DMSO- d_6 , δ) : 1.14-1.84 (1H, m), 2.09-2.40 (3H, m), 2.57-3.28 (9H, m), 3.69-3.83 (1H, m), 4.08-4.33 (1H, m), 4.75-4.86 (1H, m), 4.14-8.29 (1H, br), 8.38-8.47 (1H, m), 8.49-8.60 (1H, br)

Mass (m/z) : 364 ($\text{M}^+ + 1$) free of compound

and

N-[(S)-1-{3-(4-piperidyl)propionyl}-3-piperidyl-carbonyl]-3(S)-ethynyl- β -alaninetrifluoro acetate

35 IR (Film) : 3250, 2930, 2850, 1740, 1700, 1610 cm^{-1}

NMR (DMSO- d_6 , δ) : 1.15-1.85 (11H, m), 2.05-2.40
(3H, m), 2.56-3.00 (6H, m), 3.11-3.28 (3H, m),
3.70-3.88 (1H, m), 4.05-4.15 and 4.30-4.44
(total 1H, m), 4.75-4.90 (1H, m), 8.15-8.30 (1H,
br), 8.40-8.49 (1H, m), 8.49-8.60 (1H, br)
Mass (m/z) : 364 (M^+ +1) free of compound

Example 22

A mixture of N-[1-{2-(1-benzyloxycarbonyl-4-
piperidyloxy)acetyl}-3-piperidylcarbonyl]- β -alanine (1.16
g) and 10% Pd-C (0.23 g, 50% wet) in a solution of 1N HCl
(2.44 ml) and tetrahydrofuran (20 ml) was hydrogenated at
atmospheric pressure for 2 hours. After the catalyst was
removed by filtration, the filtrate was concentrated in
vacuo and freeze-dried to give N-[1-{2-(4-
piperidyloxy)acetyl}-3-piperidylcarbonyl]- β -alanine
hydrochloride (0.69 g).

IR (Nujol) : 3290, 1700, 1625 cm^{-1}

NMR (DMSO- d_6 , δ) : 1.15-2.09 (9H, m), 2.11-2.69 (2H,
m), 2.84-3.25 (8H, m), 3.56-3.74 (2H, m), 4.07-
4.32 (3H, m), 8.06-8.24 (1H, m)

Mass (m/z) : 342 (M^+ +1) free of compound

Elemental Analysis $\text{C}_{16}\text{H}_{27}\text{N}_3\text{O}_5 \cdot \text{HCl} \cdot 1.8\text{H}_2\text{O}$ (%)

Calcd. : C 46.84, H 7.76, N 10.24

Found : C 47.09, H 7.46, N 9.91

Example 23

(1) A mixture of N-[(R)-1-{3-(1-benzyloxycarbonyl-4-
piperidyl)propionyl}-3-piperidylcarbonyl]-2(S)-
acetylamino- β -alanine (67 mg) and 10% Pd-C (15 mg, 50%
wet) in a mixture of 1N HCl (0.13 ml) and tetrahydrofuran
(2 ml) was hydrogenated at atmospheric pressure for 1
hour. After the catalyst was removed by filtration, the
filtrate was concentrated in vacuo. The residue was
dissolved in water (5 ml) and then freeze-dried to give

N-[(R)-1-{3-(4-piperidyl)propionyl}-3-piperidylcarbonyl]-
2(S)-acetylamino- β -alanine hydrochloride (50 mg).

$[\alpha]_D^{25} = -21.37^\circ$ (C=0.75, MeOH)

IR (Nujol) : 1720, 1640, 1610 cm^{-1}

NMR (DMSO- d_6 , δ) : 1.20-1.82 (12H, m), 1.85 (3H, s),
2.10-2.43 (5H, m), 2.59-3.27 (4H, m), 3.74-3.83
(2H, m), 4.14-4.37 (2H, m), 8.02-8.19 (2H, m),
8.42-8.59 (1H, br), 8.72-8.84 (1H, br)

Mass (m/z) : 397 (M^+ +1) free of compound

The following compounds were obtained according to a
similar manner to that of Example 23 (1).

(2) N-[2-[1-{3-(4-piperidyl)propionyl}-3-
piperidyl]acetyl]glycine hydrochloride

IR (Film) : 3350, 2940, 1715, 1630 cm^{-1}

NMR (DMSO- d_6 , δ) : 1.11-1.82 (12H, m), 2.00-2.11
(2H, m), 2.24-2.40 (2H, m), 2.62-3.03 (4H, m),
3.20 (2H, d, $J=12.6\text{Hz}$), 3.64-3.82 (3H, m), 4.07-
4.24 (1H, m), 8.25-8.35 (1H, m), 8.75-8.91 (1H,
br), 9.09-9.20 (1H, br)

Mass (m/z) : 340 (M^+ =1) free of compound

(3) N-[1-{3-(4-piperidyl)propionyl}-3-piperidylcarbonyl]-
3-methyl- β -alanine hydrochloride

IR (Nujol) : 3250, 1705, 1610 cm^{-1}

NMR (DMSO- d_6 , δ) : 1.04-1.09 (3H, m), 1.28-1.83
(11H, m), 2.10-3.44 (9H, m), 3.71-3.83 (1H, m),
3.98-4.34 (2H, m), 7.86-7.96 (1H, m), 8.74-8.87
(1H, m), 9.01-9.15 (1H, m)

Mass (m/z) : 354 (M^+ +1) free of compound

(4) N-[(R)-1-{2-(4-piperidyloxy)acetyl}-3-piperidyl-
carbonyl]- β -alanine ethyl ester hydrochloride

IR (Film) : 2930, 1720, 1625 cm^{-1}

NMR (DMSO-d₆, δ) : 1.18 (3H, t, J=7.1Hz), 1.46-2.47 (11H, m), 2.60-2.70 (1H, m), 2.86-3.27 (8H, m), 3.55-3.72 (2H, m), 4.05 (2H, q, J=7.1Hz), 4.17-4.30 (2H, m), 8.06-8.21 (1H, m), 9.00-9.14 (2H, br)

Mass (m/z) : 370 (M⁺+1) free of compound

(5) N-[1-{3-(4-piperidyl)propionyl}-1,2,3,4-tetrahydro-3-quinolylcarbonyl]- β -alanine hydrochloride

IR (Film) : 3450, 3930, 1720, 1630 cm⁻¹

NMR (DMSO-d₆, δ) : 1.12-1.89 (9H, m), 2.10-2.21 (2H, m), 2.39 (2H, d, J=6.7Hz), 2.70-3.84 (7H, m), 4.26 (2H, t, J=7.0Hz), 7.06-7.20 (4H, m), 8.13-8.24 (1H, m)

Mass (m/z) : 386 (M⁺-1) free of compound

(6) N-[(S)-1-{2-(4-piperidyloxy)acetyl}-3-piperidylcarbonyl]- β -alanine hydrochloride

IR (Film) : 3290, 2920, 1710, 1620 cm⁻¹

NMR (DMSO-d₆, δ) : 1.24-2.07 (9H, m), 2.11-2.69 (2H, m), 2.89-3.27 (8H, m), 3.57-3.74 (2H, m), 4.07-4.30 (3H, m), 8.03-8.87 (1H, m)

Mass (m/z) : 342 (M⁺+1) free of compound

(7) N-[(R)-1-{3-(4-piperidyl)propionyl}-3-piperidylcarbonyl]-2(S)-(n-hexanoylamino)- β -alanine hydrochloride

$[\alpha]_D^{20} = -27.7^\circ$ (C=1.0, MeOH)

mp : 156-157°C

IR (Nujol) : 3200, 1720, 1660, 1600 cm⁻¹

NMR (DMSO-d₆, δ) : 0.85 (3H, t, J=6.5Hz), 1.55-1.88 (17H, m), 2.10 (2H, t, J=7.4Hz), 2.27-3.82 (12H, m), 4.14-4.35 (2H, m), 7.97-8.10 (2H, m), 8.37-8.51 (1H, br), 8.69-8.89 (1H, br)

Mass (m/z) : 453 (M⁺+1) free of compound

- (8) N-[(R)-1-{3-(4-piperidyl)propionyl}-3-piperidylcarbonyl]-2(S)-(4-chlorobenzoylamino)- β -alanine hydrochloride

$[\alpha]_D^{20} = -35.6^\circ$ (C=1.0, MeOH)

IR (Nujol) : 3200, 1730, 1710, 1640 cm^{-1}

NMR (DMSO- d_6 , δ) : 1.16-1.85 (11H, m), 2.11-2.34 (3H, m), 2.60-3.25 (6H, m), 3.34-3.82 (3H, m), 4.18-4.35 (1H, m), 4.44-4.54 (1H, m), 7.44-7.59 (2H, m), 7.84-7.92 (2H, m), 8.18-8.31 (1H, m), 8.41-8.55 (1H, m), 8.60-8.83 (2H, m)

Mass (m/z) : 493 (M^++1) free of compound

- (9) N-[(R)-1-{3-(4-piperidyl)propionyl}-3-piperidylcarbonyl]-2(S)-(4-methoxybenzoylamino)- β -alanine hydrochloride

$[\alpha]_D^{20} = -31.8^\circ$ (C=1.0, MeOH)

IR (Nujol) : 3210, 1720, 1620, 1600 cm^{-1}

NMR (DMSO- d_6 , δ) : 1.11-1.89 (12H, m), 2.12-2.39 (3H, m), 2.60-3.79 (8H, m), 3.82 (3H, s), 4.10-4.35 (1H, m), 4.44-4.54 (1H, m), 7.02 (2H, d, $J=8.8\text{Hz}$), 7.55 (2H, d, $J=8.1\text{Hz}$), 8.13-8.31 (1H, m), 8.44-8.55 (2H, m), 8.70-8.84 (1H, m)

Mass (m/z) : 489 (M^++1) free of compound

- (10) N-[(R)-1-{3-(4-piperidyl)propionyl}-3-piperidylcarbonyl]-2(S)-amino- β -alanine hydrochloride

IR (Film) : 3250, 2910, 1745, 1640 cm^{-1}

NMR (DMSO- d_6 , δ) : 1.19-1.91 (12H, m), 2.07-2.43 (4H, m), 2.58-3.24 (2H, m), 3.50-3.57 (2H, m), 3.74-4.40 (3H, m), 8.30-8.96 (5H, m)

Mass (m/z) : 355 (M^++1) free of compound

- (11) N-[(R)-1-{3-(4-piperidyl)propionyl}-3-piperidylcarbonyl]-2(S)-benzoylamino- β -alanine 1-(cyclohexyloxycarbonyloxy)ethyl ester hydrochloride

IR (Nujol) : 3240, 1750, 1640 cm^{-1}

NMR (DMSO-d_6 , δ) : 1.01-1.91 (23H, m), 1.76 (3H, d, $J=5.7\text{Hz}$), 2.11-2.39 (3H, m), 2.58-3.25 (2H, m), 3.35-4.40 (7H, m), 4.49-4.66 (2H, m), 6.63 (1H, t, $J=5.1\text{Hz}$), 7.43-7.57 (5H, m), 7.85-7.95 (1H, m)

Mass (m/z) : 629 (M^++1) free of compound

(12) N-{1-[3-(4-piperidyl)propionyl]-3-piperidyl}-2(S)-benzoylamino succinamic acid hydrochloride

IR (Nujol) : 3300, 1720, 1630 cm^{-1}

NMR (DMSO-d_6 , δ) : 1.16-1.54 (6H, m), 1.64-1.85 (6H, m), 2.24-2.34 (1H, m), 2.63-3.03 (5H, m), 3.13-3.84 (7H, m), 4.70-4.83 (1H, m), 7.41-7.53 (3H, m), 7.83-7.90 (2H, m), 8.60-8.72 (1H, m)

Mass (m/z) : 459 (M^++1) free of compound

(13) N-[(R)-1-[3-(4-piperidyl)propionyl]-3-piperidylcarbonyl]-2(S)-cyclopropylcarbonylamino- β -alanine hydrochloride

$[\alpha]_D^{20} = -20.2^\circ$ ($C=1.0$, MeOH)

IR (Nujol) : 1715, 1645, 1610 cm^{-1}

NMR (DMSO-d_6 , δ) : 0.67 (4H, d, $J=6.3\text{Hz}$), 1.18-1.84 (12H, m), 2.10-2.43 (3H, m), 2.60-3.34 (7H, m), 3.74-3.83 (2H, m), 4.15-4.35 (2H, m), 8.04-8.22 (1H, m), 8.39 (1H, dd, $J=19.6$ and 7.9Hz), 8.51-8.69 (1H, br), 8.82-8.86 (1H, br)

Mass (m/z) : 423 (M^++1) free of compound

(14) N-[(R)-7-[3-(4-piperidyl)propionyl]-3-piperidylcarbonyl]-2(S)-(3-methoxypropionyl)amino- β -alanine hydrochloride

$[\alpha]_D^{20} = -20.2^\circ$ ($C=1.0$, MeOH)

IR (Nujol) : 3250, 1720, 1650, 1610 cm^{-1}

NMR (DMSO-d_6 , δ) : 1.12-1.89 (15H, m), 2.11-2.43

(3H, m), 2.37 (2H, t, J=6.5Hz), 2.72-3.12 (3H, m), 3.21 (3H, s), 3.25-3.44 (2H, m), 3.52-2H, t, J=6.5Hz), 3.61-3.84 (2H, m), 4.14-4.39 (2H, m), 7.94-8.09 (2H, m)

Mass (m/z) : 441 ($M^+ + 1$) free of compound

(15) N-[(R)-1-{3-(4-piperidyl)propionyl}-3-piperidylcarbonyl]-2(R)-benzoylamino- β -alanine hydrochloride

$[\alpha]_D^{20} = -14.3^\circ$ (C=1.0, MeOH)

IR (Nujol) : 1750, 1730, 1640 cm^{-1}

NMR (DMSO- d_6 , δ) : 1.15-1.86 (12H, m), 2.25-3.05 (6H, m), 3.10-3.26 (2H, m), 3.37-3.84 (3H, m), 4.12-4.61 (2H, m), 7.45-7.63 (3H, m), 7.88-7.97 (2H, m), 8.28-8.45 (1H, m), 8.72-8.77 (1H, m), 8.66-8.84 (1H, br), 8.97-9.11 (1H, br)

Mass (m/z) : 459 ($M^+ + 1$) free of compound

(16) N-[(R)-1-{3-(4-piperidyl)propionyl}-3-piperidylcarbonyl]-2(S)-(4-hydroxybenzoylamino)- β -alanine hydrochloride

$[\alpha]_D^{20} = -40.5$ (C=1.0, MeOH)

IR (Nujol) : 1715, 1630, 1640, 1600 cm^{-1}

NMR (DMSO- d_6 , δ) : 1.17-1.85 (12H, m), 2.11-2.38 (3H, m), 2.60-3.06 (3H, m), 3.11-3.23 (2H, m), 3.36-3.84 (4H, m), 4.01-4.51 (2H, m), 6.83 (2H, d, J=8.5Hz), 7.76 (2H, d, J=8.6Hz), 8.20-8.46 (2H, m), 8.56-8.71 (1H, br), 8.85-8.98 (1H, br)

Mass (m/z) : 473 ($M^+ - 1$) free of compound

(17) N-[1-{3-(4-piperidyl)propionyl}-3-piperidyl]-3(S)-benzoylaminosuccinamic acid hydrochloride

IR (KBr, pellet) : 2949, 2393, 1734, 1718, 1651 cm^{-1}

NMR (DMSO- d_6 , δ) : 1.16-1.89 (11H, m), 2.11-2.38 (1H, m), 2.61-3.07 (4H, m), 3.13-3.85 (8H, m),

4.66-4.86 (1H, m), 7.44-7.59 (3H, m), 7.85-7.88
(2H, m), 7.93-8.11 (1H, m), 8.44-8.60 (1H, br),
8.63-8.74 (1H, m), 8.77-8.90 (1H, br)

Mass (m/z) : 457 ($M^+ - 1$) free of compound

5

- (18) N-[1-{3-(4-piperidyl)propionyl}-3-piperidyl]-2(S)-
acetylaminosuccinamic acid hydrochloride

IR (KBr, pellet) : 3057, 2945, 2864, 1734, 1653,
1618 cm^{-1}

NMR (DMSO- d_6 , δ) : 1.20-1.59 (7H, m), 1.73-1.97 (4H,
m), 1.83 (3H, s), 2.24-2.36 (2H, m), 2.44-3.10
(4H, m), 3.17-3.28 (3H, m), 3.47-4.21 (4H, m),
4.43-4.59 (1H, m), 7.81-8.21 (2H, m), 8.56-8.76
(1H, br), 8.89-9.03 (1H, br)

Mass (m/z) : 397 ($M^+ + 1$) free of compound

- (19) N-[(R)-1-{3-(4-piperidyl)propionyl}-3-
piperidylcarbonyl]-2(R)-acetyl-amino- β -alanine
hydrochloride

$[\alpha]_D^{20} = -21.7^\circ$ (C=1.0, MeOH)

IR (KBr, pellet) : 2947, 2864, 1734, 1653, 1616 cm^{-1}

NMR (DMSO- d_6 , δ) : 1.17-1.90 (12H, m), 1.85 (3H, s),
2.09-2.65 (4H, m), 2.70-3.08 (2H, m), 3.15-3.34
(3H, m), 3.60-3.88 (2H, m), 4.17-4.40 (2H, m),
8.00-8.20 (2H, m), 8.30-8.46 (1H, br), 8.61-8.74
(1H, br)

Mass (m/z) : 397 ($M^+ + 1$) free of compound

- (20) N-[1-{3-(4-piperidyl)propionyl}-3-piperidyl]-3(R)-
benzoylaminosuccinamic acid hydrochloride

IR (KBr, pellet) : 2947, 2864, 1734, 1647, 1605 cm^{-1}

NMR (DMSO- d_6 , δ) : 1.15-1.55 (7H, m), 1.64-1.89 (5H,
m), 2.18-2.35 (1H, m), 2.60-3.26 (8H, m), 3.48-
3.86 (4H, m), 4.69-4.84 (1H, m), 7.45-7.56 (3H,
m), 7.85-7.88 (2H, m), 8.42-8.60 (1H, br), 8.75-

35

8.89 (1H, br), 8.61-8.75 (1H, m)

Mass (m/z) : 459 ($M^+ + 1$) free of compound

(21) N-[(R)-1-{3-(4-piperidyl)propionyl}-3-piperidylcarbonyl]-2(S)-(4-biphenylcarbonylamino)- β -alanine hydrochloride

IR (KBr, pellet) : 2947, 2729, 1734, 1647, 1608 cm^{-1}

NMR (DMSO-d_6 , δ) : 1.14-1.86 (10H, m), 2.20-2.36 (2H, m), 2.63-3.26 (5H, m), 3.40-3.86 (4H, m), 4.10-4.60 (4H, m), 7.41-7.54 (3H, m), 7.74-7.82 (4H, m), 7.98-8.01 (2H, m), 8.25-8.43 (1H, m), 8.57-8.80 (1H, br), 8.68-8.82 (1H, m), 8.92-9.02 (1H, br)

Mass (m/z) : 535 ($M^+ + 1$) free of compound

Example 24

(1) A solution of N-[1-{3-(1-tert-butoxycarbonyl-4-piperidyl)propionyl}-3-piperidylcarbonyl]- β -alanine (1.58 g) in ethyl acetate (16 ml) was added 4N HCl in ethyl acetate (13.5 ml) under stirring at 0°C. After stirring at ambient temperature for 2 hours, resulting precipitate was collected by filtration to give N-[1-{3-(4-piperidyl)propionyl}-3-piperidylcarbonyl]- β -alanine hydrochloride (1.27 g).

mp : 70-72°C

IR (KBr) : 3200, 2850, 1780, 1600 cm^{-1}

NMR (DMSO-d_6 , δ) : 1.29-1.83 (10H, m), 2.09-2.42 (6H, m), 2.60-3.24 (7H, m), 3.70-3.84 (1H, m), 4.13-4.40 (1H, m), 7.97-8.18 (1H, m), 8.76-8.86 (1H, m), 9.09-9.23 (1H, m)

Mass (m/z) : 340 ($M^+ + 1$) free of compound

The following compounds were obtained according to a similar manner to that of Example 24 (1).

- (2) N-[1-{3-(4-Piperidyl)propionyl}-4-piperidylcarbonyl]-
β-alanine hydrochloride

mp : 63-65°C

IR (KBr) : 3250, 2800, 1710 cm⁻¹

NMR (DMSO-d₆, δ) : 1.28-1.90 (11H, m), 2.23-2.40
(5H, m), 2.48-3.12 (4H, m), 3.10-3.30 (4H, m),
3.79-3.98 (1H, m), 4.30-4.40 (1H, m), 4.30-4.40
(1H, m), 7.98 (1H, t, J=5.4Hz), 8.85-8.98 (1H,
br), 9.13-9.21 (1H, br)

Mass (m/z) : 340 (M⁺+1) free of compound

- (3) N-[2-[1-{2-(4-Piperidyl)acetyl}-3-piperidyl]acetyl]-
β-alanine hydrochloride

mp : 73°C

IR (Nujol) : 3200, 1725, 1605 cm⁻¹

NMR (DMSO-d₆, δ) : 1.22-1.51 (4H, m), 1.68-1.87 (3H,
m), 1.92-2.09 (4H, m), 2.23-2.30 (2H, m), 2.35-
2.45 (3H, m), 2.60-3.02 (4H, m), 3.16-3.31 (5H,
m), 3.67-3.81 (1H, m), 4.11-4.28 (1H, m), 8.00-
8.16 (1H, m)

Mass (m/z) : 340 (M⁺+1) free of compound

Elemental Analysis C₁₇H₂₉N₃O₄·HCl·1.5AcOEt·2H₂O (%)

Calcd. : C 50.78, H 8.52, N 7.72

Found : C 50.76, H 8.48, N 7.70

- (4) N-[1-{4-(4-Piperidyl)butyryl}-3-piperidylcarbonyl]-
glycine hydrochloride

IR (Nujol) : 1740 cm⁻¹

NMR (DMSO-d₆, δ) : 1.20-1.94 (13H, m), 2.30-2.40
(3H, m), 2.60-3.14 (5H, m), 3.17-3.28 (2H, m),
3.72-4.00 (2H, m), 4.00-4.10 and 4.09-4.17
(total 1H, m), 8.28-8.43 (1H, m)

Mass (m/z) : 340 (M⁺+1) free of compound

Elemental Analysis C₁₇H₂₉N₃O₄·HCl·1.25AcOEt·1.5H₂O (%)

Calcd. : C 51.51, H 8.45, N 8.19

Found : C 51.38, H 8.43, N 8.00

(5) N-[2-[1-{2-(4-Piperidylidene)acetyl}-3-piperidyl]acetyl]- β -alanine hydrochloride

mp : 63°C

IR (Nujol) : 3200, 1730 cm^{-1}

NMR (DMSO- d_6 , δ) : 1.08-1.41 (3H, m), 1.60-1.76 (3H, m), 1.76-1.92 (3H, m), 1.92-2.04 (2H, m), 2.39 (2H, t, $J=6.5\text{Hz}$), 2.44-2.51 (3H, m), 2.60-2.83 (3H, m), 2.93-3.50 (4H, m), 3.69-3.84 (1H, m), 4.04-4.28 (1H, m), 6.04 and 6.08 (total 1H, s), 8.01-8.17 (1H, m)

Mass (m/z) : 338 (M^++1) free of compound

Elemental Analysis $\text{C}_{17}\text{H}_{27}\text{N}_3\text{O}_4 \cdot \text{HCl} \cdot 1.5\text{AcOEt} \cdot 2.5\text{H}_2\text{O}$ (%)

Calcd. : C 50.50, H 7.55, N 7.68

Found : C 50.29, H 7.91, N 7.66

(6) N-[(R)-1-{3-(4-piperidyl)propionyl}-3-piperidylcarbonyl]-3(S)-phenylsulfonylmethyl- β -alanine hydrochloride

IR (Nujol) : 1730, 1650, 1610 cm^{-1}

NMR (DMSO- d_6 , δ) : 1.28-1.83 (13H, m), 2.25-2.34 (2H, m), 2.48-3.23 (9H, m), 3.54-3.67 (2H, m), 4.18-4.26 (1H, m), 7.61-7.76 (3H, m), 7.85-7.99 (2H, m), 8.02-8.13 (1H, m), 8.76 (1H, br), 9.03 (1H, br)

Mass (m/z) : 492 (M^++1) free of compound

Example 25

(1) A solution of N-[(R)-1-{3-(1-tert-butoxycarbonyl-4-piperidyl)pyropionyl}-3-piperidylcarbonyl]- β -alanine ethyl ester (0.78 g) in ethyl acetate (8 ml) was added 4N HCl in ethyl acetate (4.17 ml) under stirring at 0°C. After stirring at ambient temperature for 2 hours, and evaporated in vacuo and freeze-dried to give N-[(R)-1-{3-

(4-piperidyl)propionyl}-3-piperidylcarbonyl]- β -alanine
ethyl ester hydrochloride (0.59 g).

IR (Film) : 3320, 1700, 1605 cm^{-1}

NMR (DMSO- d_6 , δ) : 1.18 (3H, t, $J=7.1\text{Hz}$), 1.26-1.65
(7H, m), 1.80 (2H, d, $J=13\text{Hz}$), 2.06-2.70 (5H,
m), 2.75-3.10 (3H, m), 3.17-3.30 (4H, m), 3.70-
3.84 (1H, m), 4.05 (2H, q, $J=7.2\text{Hz}$), 4.17-4.38
(4H, m), 8.01-8.13 (1H, m), 8.63-8.78 (1H, br),
8.95-9.06 (1H, br)

Mass (m/z) : 368 (M^++1) free of compound

The following compounds were obtained according to a
similar manner to that of Example 25 (1).

(2) (3R)-N-[(R)-1-{3-(4-Piperidyl)propionyl}-3-piperidyl-
carbonyl]-3-methyl- β -alanine methyl ester
hydrochloride

IR (Nujol) : 3300, 2930, 2850, 1710, 1640, 1610 cm^{-1}

NMR (DMSO- d_6 , δ) : 1.04-1.10 (3H, m), 1.20-1.83
(12H, m), 2.29-2.46 (4H, m), 2.58-3.25 (7H, m),
3.58 (3H, s), 4.02-4.36 (2H, m), 7.91 (1H, t,
 $J=8.2\text{Hz}$), 8.57-8.72 (1H, br), 8.84-9.00 (1H, m)

Elemental Analysis $\text{C}_{19}\text{H}_{23}\text{N}_3\text{O}_4 \cdot \text{HCl} \cdot 2.8\text{H}_2\text{O}$ (%)

Calcd. : C 50.23, H 8.79, N 9.25

Found : C 50.36, H 8.51, N 8.97

Mass (m/z) : 368 (M^++1) free of compound

(3) N-[(R)-1-{3-(4-piperidyl)propionyl}-3-
piperidylcarbonyl]- β -alanine benzyl ester
hydrochloride

IR (Film) : 3400, 1710, 1630 cm^{-1}

NMR (DMSO- d_6 , δ) : 1.17-1.91 (12H, m), 2.29-2.36
(3H, m), 2.56-3.09 (4H, m), 3.17-3.33 (5H, m),
3.70-3.83 (1H, m), 4.20-4.37 (1H, m), 5.09 (2H,

s), 7.31-7.38 (5H, m), 7.99-8.14 (1H, m), 8.60-8.72 (1H, br), 8.89-8.99 (1H, br)

Mass (m/z) : 430 ($M^+ + 1$) free of compound

Elemental Analysis $C_{24}H_{35}N_3O_4HCl \cdot 1.6H_2O$

Calcd. : C 54.26, H 7.63, N 7.91

Found : C 54.23, H 7.54, N 7.88

(4) N-[(R)-1-{3-(4-piperidyl)propionyl}-3-piperidylcarbonyl]- β -alanine 1-(cyclohexyloxy-carbonyloxy)ethyl ester hydrochloride

IR (Film) : 3380, 2940, 2850, 1740, 1630 cm^{-1}

NMR (DMSO- d_6 , δ) : 1.15-1.53 (13H, m), 1.44 (3H, d, $J=5.4Hz$), 1.60-1.92 (10H, m), 2.05-2.39 (3H, m), 2.46-3.08 (5H, m), 3.18-3.30 (4H, m), 4.15-4.37 (1H, m), 4.50-4.60 (1H, m), 6.60-6.68 (1H, m), 8.00-8.13 (1H, m), 8.47-8.64 (1H, br), 8.79-8.90 (1H, br)

Mass (m/z) : 510 ($M^+ + 1$) free of compound

Elemental Analysis $C_{26}H_{43}N_3O_7 \cdot HCl \cdot 3H_2O$

Calcd. : C 52.04, H 8.40, N 7.00

Found : C 51.85, H 8.51, N 7.14

(5) (R)-[1-{3-(4-piperidyl)propionyl}-3-piperidylcarbonyl]-3-piperidinecarboxylic acid ethyl ester trifluoro acetate

NMR (DMSO- d_6 , δ) : 1.18 (3H, t, $J=7.0Hz$), 1.27-2.02 (16H, m), 2.23-2.43 (3H, m), 2.57-3.15 (7H, m), 3.67-3.91 (2H, m), 4.07 (2H, q, $J=7.0Hz$), 4.20-4.40 (1H, m), 4.54-4.75 (2H, m), 8.09-8.34 (1H, br), 8.51-8.65 (1H, br)

Mass (m/z) : 408 ($M^+ + 1$) free of compound

(6) N-[(R)-1-{3-(4-piperidyl)propionyl}-3-piperidylcarbonyl]-2-phenyl- β -alanine ethyl ester hydrochloride

IR (KBr, pellet) : 3421, 2943, 1728, 1643, 1624 cm^{-1}

NMR (DMSO-d_6 , δ) : 1.05-1.85 (14H, m), 2.04-2.34
(3H, m), 2.69-3.06 (3H, m), 3.13-3.25 (2H, m),
3.32-3.75 (3H, m), 3.80-3.92 (1H, m), 3.99-4.34
(4H, m), 7.20-7.38 (5H, m), 8.07-8.20 (1H, m),
8.75-8.90 (1H, br), 9.04-9.15 (1H, br)

Mass (m/z) : 444 ($M^+ + 1$) free of compound

(7) N-[(R)-1-{3-(4-piperidyl)propionyl}-3-piperidylcarbonyl]-3(S)-ethynyl- β -alanine 2-adamantyl ester hydrochloride

IR (Nujol) : 1720, 1650, 1600 cm^{-1}

NMR (DMSO-d_6 , δ) : 1.18-1.60 (8H, m), 1.70-1.99
(15H, m), 2.10-2.39 (3H, m), 2.59-3.02 (5H, m),
3.09-3.29 (3H, m), 3.69-3.84 (1H, m), 4.15-4.55
(4H, m), 4.83-4.95 (2H, m), 8.50 and 8.60 (total
1H, d, $J=8.1$ and 8.2Hz), 8.72-8.89 (1H, br),
9.03-9.12 (1H, br)

Mass (m/z) : 498 ($M^+ + 1$) free of compound

Elemental Analysis $\text{C}_{29}\text{H}_{43}\text{N}_3\text{O}_4 \cdot \text{HCl} \cdot 28\text{H}_2\text{O}$

Calcd. : C 59.58, H 8.55, N 7.19

Found : C 59.57, H 8.64, N 7.03

(8) N-[(R)-1-{3-(4-piperidyl)propionyl}-3-piperidylcarbonyl]-3(S)-ethynyl- β -alanine-n-butyl ester hydrochloride

IR (KBr, pellet) : 2958, 2872, 1734, 1647, 1616 cm^{-1}

NMR (DMSO-d_6 , δ) : 0.88 (3H, t, $J=7.2\text{Hz}$), 1.27-1.69
(12H, m), 1.59 (1H, d, $J=2.4\text{Hz}$), 1.75-1.86 (3H,
m), 2.08-2.40 (3H, m), 2.60-3.08 (6H, m), 3.17-
3.27 (3H, m), 3.69-3.84 (1H, m), 4.03 (2H, t,
 $J=6.5\text{Hz}$), 4.79-4.92 (1H, m), 8.50 and 8.59
(total (1H, d, $J=8.3$ and 8.0Hz), 8.74-8.86 (1H,
br), 9.02-9.13 (1H, br)

Elemental Analysis $\text{C}_{23}\text{H}_{37}\text{N}_3\text{O}_4 \cdot \text{HCl} \cdot 1.6\text{H}_2\text{O}$

Calcd. : C 56.98, H 8.56, N 8.67

Found : C 56.99, H 8.63, N 8.39

(9) N-[(R)-1-{3-(4-piperidyl)propionyl}-3-piperidylcarbonyl]-3(S)-ethynyl- β -alanine 5-methyl-2-oxo-1,3-dioxol-4-yl-methyl ester hydrochloride

mp : 70°C

IR (KBr, pellet) : 2947, 2866, 2729, 1817, 1743, 1653, 1616 cm^{-1}

NMR (DMSO- d_6 , δ) : 1.29-1.85 (11H, m), 2.09-2.40 (3H, m), 2.10 (3H, s), 2.60-3.09 (5H, m), 3.13-3.29 (3H, m), 3.70-3.84 (1H, m), 4.79-4.91 (1H, m), 4.98 (2H, s), 5.12-5.40 (2H, m), 8.53 and 8.62 (total 1H, d, $J=8.0\text{Hz}$), 8.76-8.90 (1H, br), 9.03-9.15 (1H, br)

Mass (m/z) : 476 (M^++1) free of compound

(10) N-[(R)-1-{3-(4-piperidyl)propionyl}-3-piperidylcarbonyl]-3(S)-ethynyl- β -alanine isobutyl ester hydrochloride

IR (KBr, pellet) : 3446, 3230, 3030, 2960, 2873, 1734, 1653, 1616 cm^{-1}

NMR (DMSO- d_6 , δ) : 0.89 (6H, d, $J=6.6\text{Hz}$), 1.21-1.91 (12H, m), 1.99-2.37 (3H, m), 2.60-3.02 (6H, m), 3.18-3.26 (3H, m), 3.83 (2H, d, $J=6.5\text{Hz}$), 4.13-4.32 (2H, m), 4.80-4.94 (1H, m), 8.46-8.57 (1H, m), 8.53-8.71 (1H, br), 8.89-9.00 (1H, br)

Mass (m/z) : 420 (M^++1) free of compound

(11) N-[(R)-1-{3-(4-piperidyl)propionyl}-3-piperidylcarbonyl]-3(S)-ethynyl- β -alanine-4-trifluoromethylbenzyl ester hydrochloride

IR (KBr, pellet) : 3456, 3240, 2947, 2864, 2360, 1740, 1653, 1618 cm^{-1}

NMR (DMSO- d_6 , δ) : 1.17-1.86 (12H, m), 2.06-2.36

(3H, m), 2.60-3.06 (6H, m), 3.12-3.31 (3H, m),
4.07-4.35 (1H, m), 4.85-4.96 (1H, m), 5.22 (2H,
s), 7.60 (2H, d, J=8.2Hz), 7.76 (2H, d,
J=8.2Hz), 8.48-8.58 (1H, m), 8.44-8.58 (1H, br),
8.74-8.85 (1H, br)

Mass (m/z) : 522 (M^+ +1) free of compound

(12) N-[(R)-1-{3-(4-piperidyl)propionyl}-3-
piperidylcarbonyl]-2(S)-acetylamino- β -alanine ethyl
ester hydrochloride

IR (KBr, pellet) : 2947, 2862, 1718, 1697, 1684,
1668 cm^{-1}

NMR (DMSO- d_6 , δ) : 1.17 (3H, t, J=7.1Hz), 1.24-1.69
(9H, m), 1.74-1.99 (4H, m), 2.07-2.40 (4H, m),
2.59-3.11 (4H, m), 3.15-3.28 (2H, m), 3.31-3.37
(2H, m), 3.73-3.86 (1H, m), 4.02 (2H, q,
J=7.1Hz), 4.15-4.31 (2H, m), 8.12-8.43 (2H, m),
8.63-8.75 (1H, br), 8.93-9.04 (1H, br)

Mass (m/z) : 425 (M^+ +1) free of compound

(13) N-[(R)-1-{3-(4-piperidyl)propionyl}-3-
piperidylcarbonyl]-2(S)-acetylamino- β -alanine benzyl
ester hydrochloride

IR (KBr) : 3377, 2943, 2864, 2731, 1740, 1653,
1608 cm^{-1}

(14) N-[(R)-1-{3-(4-piperidyl)propionyl}-3-
piperidylcarbonyl]-2(S)-acetylamino- β -alanine 1-
(cyclohexyloxycarbonyloxy)ethyl ester hydrochloride

IR (KBr) : 3417, 3062, 2945, 2862, 1761, 1653,
1608 cm^{-1}

Example 26

(1) To a solution of N-[2-[1-{3-(1-tert-butoxycarbonyl-4-
piperidyl)propionyl}-4-piperidyl]acetyl]- β -alanine methyl

ester (0.58 g) in methanol (7 ml) was added 1N NaOH aqueous solution (1.5 ml) and stirred for 1 hour at ambient temperature. The resultant mixture was poured into a mixture of ethyl acetate (20 ml) and water (10 ml) and acidified to pH 3.0 with 10% KHSO₄ aqueous solution. The organic layer was separated and washed with brine, and dried over MgSO₄. The solution was evaporated in vacuo. The residue was dissolved with ethyl acetate (5 ml) and the solution of 4N HCl in ethyl acetate (3.1 ml) was added. The resultant mixture was stirred for 1 hour at ambient temperature and evaporated in vacuo to give N-[2-[1-{3-(4-piperidyl)propionyl}-4-piperidyl]acetyl]-β-alanine hydrochloride (0.2 g).

NMR (DMSO-d₆, δ) : 0.95-1.14 (1H, m), 1.21-1.62 (7H, m), 1.76-1.83 (2H, m), 2.26-2.40 (4H, m), 2.75-3.00 (3H, m), 3.17-3.24 (5H, m), 3.78-3.84 (2H, m), 4.05-4.08 (1H, m), 4.28-4.35 (2H, m), 7.93-7.97 (1H, m), 8.70 (1H, br), 8.95 (1H, br)

The following compounds were obtained according to a similar manner to that of Example 26 (1).

(2) N-[1-{3-(4-Piperidyl)propionyl}-3-piperidylcarbonyl]-N-methyl-β-alanine hydrochloride

NMR (DMSO-d₆, δ) : 1.39-1.45 (7H, m), 1.59-1.83 (5H, m), 2.36-2.60 (4H, m), 2.69-2.88 (2H, m), 2.77, 3.02 (total 3H, s), 3.00-3.23 (3H, m), 3.40-3.80 (3H, m), 4.30-4.40 (1H, m), 8.76 (1H, br), 9.00 (1H, br)

Mass (m/z) : 354 (M⁺+1)

(3) N-[(R)-1-{3-(4-piperidyl)propionyl}-3-piperidylcarbonyl]-3(S)-[2-(3-indolyl)ethyl]-β-alanine hydrochloride

IR (Nujol) : 3200, 1720, 1630, 1610, 1540 cm⁻¹

NMR (DMSO-d₆, δ) : 1.14 (1H, t, J=7.0Hz), 1.21-1.45
(5H, m), 1.65-1.91 (6H, m), 2.10-2.42 (3H, m),
2.60-3.00 (6H, m), 3.19-3.25 (3H, m), 3.78-4.33
(7H, m), 6.91-7.08 (3H, m), 7.32 (1H, d,
J=8.0Hz), 7.47 (1H, d, J=8.0Hz), 7.90-7.96 (1H,
m), 8.58 (1H, br), 8.84 (1H, br)

Mass (m/z) : 483 (M⁺+1) free of compound

Elemental Analysis C₂₇H₃₈N₄O₄·HCl·2H₂O

Calcd. : C 57.89, H 7.99, N 8.71

Found : C 57.97, H 8.16, N 8.31

(4) N-[(R)-1-{3-(4-piperidyl)propionyl}-3-
piperidylcarbonyl]-3(S)-vinyl- β -alanine hydrochloride

IR (KBr) : 3428, 2946, 1724, 1629, 1621 cm⁻¹

NMR (DMSO-d₆, δ) : 1.17-1.99 (11H, m), 2.32-2.60
(5H, m), 2.75-3.00 (2H, m), 3.19-3.24 (2H, m),
3.82-4.38 (4H, m), 4.54-4.62 (1H, m), 5.05-5.12
(2H, m), 5.74-5.92 (1H, m), 8.00-8.06 (1H, m)

Mass (m/z) : 366 (M⁺+1) free of compound

(5) N-[(R)-1-{3-(4-piperidyl)propionyl}-3-
piperidylcarbonyl]-3(S)-ethyl- β -alanine hydrochloride

IR (KBr) : 3407, 3257, 1724, 1637 cm⁻¹

NMR (DMSO-d₆, δ) : 0.76-0.83 (3H, t, J=6.3Hz),
1.21-1.91 (14H, m), 2.18-2.40 (5H, m), 2.59-3.23
(5H, m), 3.76-4.35 (3H, m), 7.7-7.83 (1H, m)

Mass (m/z) : 368 (M⁺+1) free of compound

(6) N-[(R)-1-{3-(4-piperidyl)propionyl}-3-piperidyl-
carbonyl]-2(S)-acetylamino- β -alanine hydrochloride

$[\alpha]_D^{25} = -21.37^\circ$ (C=0.75, MeOH)

IR (Nujol) : 1720, 1640, 1610 cm⁻¹

NMR (DMSO-d₆, δ) : 1.20-1.82 (12H, m), 1.85 (3H, s),
2.10-2.43 (5H, m), 2.59-3.27 (4H, m), 3.74-3.83
(2H, m), 4.14-4.37 (2H, m), 8.02-8.19 (2H, m),

8.42-8.59 (1H, br), 8.72-8.84 (1H, br)

Mass (m/z) : 397 ($M^+ + 1$) free of compound

(7) N-[1-{3-(4-piperidyl)propionyl}-3-pyrrolidinyl-carbonyl]-3(S)-ethynyl- β -alanine hydrochloride

NMR (DMSO- d_6 , δ) : 1.21-1.30 (4H, m), 1.76-1.83 (2H, m), 2.00-2.12 (2H, m), 2.23-2.50 (2H, m), 2.57-2.61 (2H, m), 2.76-3.06 (4H, m), 3.18-3.25 (4H, m), 3.50-3.60 (6H, m), 4.81-4.85 (1H, m)

Mass (m/z) : 350 ($M^+ + 1$) free of compound

(8) N-[(R)-1-{3-(4-piperidyl)propionyl}-3-piperidylcarbonyl]-2-methyl- β -alanine

NMR (D_2O , δ) : 1.05 (3H, d, $J=7.2\text{Hz}$), 1.33-1.76 (8H, m), 1.90-1.98 (3H, m), 2.32-2.57 (4H, m), 2.76-3.01 (3H, m), 3.11-3.42 (5H, m), 3.79-3.90 (1H, m), 4.12-4.30 (1H, m)

Mass (m/z) : 354 ($M^+ + 1$)

Example 27

N-[(R)-1-{3-(4-Piperidyl)propionyl}-3-piperidyl-carbonyl]-3(S)ethynyl- β -alanine trifluoroacetate (object compound (I) of Example 25) (80.0 g) was dissolved in water and desalted by DIAION HP-20 (trademark; prepared by Mitsubishi Chemical Industries) eluting with (isopropanol: H_2O = 1:3). The eluting solution was concentrated in vacuo and freeze-dried to give N-[(R)-1-{3-(4-piperidyl)propionyl}-3-piperidylcarbonyl]-3(S)-ethynyl- β -alanine (49.8 g) as a white solid.

IR (KBr) : 3430, 3270, 1722, 1622 cm^{-1}

NMR (DMSO- d_6 , δ) : 1.23-2.06 (11H, m), 2.30-2.35 (4H, m), 2.52-2.70 (4H, m), 2.98-3.17 (4H, m), 3.01 (1H, d, $J=2.2\text{Hz}$), 3.53-3.59 (1H, m), 4.21-4.27 (1H, m), 4.68-4.72 (1H, m), 8.28-8.40 (1H, m)

Mass (m/z) : 364 ($M^+ + 1$)

Elemental Analysis $C_{19}H_{29}N_3O_4 \cdot 1.7H_2O$ (%)

Calcd.: C 57.91, H 8.29, N 10.66

Found : C 57.89, H 8.05, N 10.41

5 Example 28

A solution of N-[(R)-1-{3-(4-piperidyl)propionyl}-3-piperidylcarbonyl]-3(S)-ethynyl- β -alanine hydrochloride (89.6 g) in water (900 ml) was purified by HPLC (C-18, 7 x 50 cm) eluting with a solution of 17% CH_3CN in 0.1% TFA aqueous solution and the fractions containing object compound were combined and evaporated in vacuo. The residue was dissolved in water and desalted by HP-20 eluting with (IPA:water = 1:3). The eluting solution was concentrated in vacuo and freeze-dried to give N-[(R)-1-{3-(4-piperidyl)propionyl}-3-piperidylcarbonyl]-3(S)-ethynyl- β -alanine (55.8 g) as a white solid.

IR (KBr) : 3430, 3270, 1722, 1622 cm^{-1}

NMR (DMSO- d_6 , δ) : 1.23-2.06 (11H, m), 2.30-2.35 (4H, m), 2.52-2.70 (4H, m), 2.98-3.17 (4H, m), 3.01 (1H, d, $J=2.2Hz$), 3.53-3.59 (1H, m), 4.21-4.27 (1H, m), 4.68-4.72 (1H, m), 8.28-8.40 (1H, m)

Elemental Analysis $C_{19}H_{29}N_3O_4 \cdot 1.7H_2O$

Calcd. : C 57.91, H 8.29, N 10.66

Found : C 57.89, H, 8.05, N 10.41

Example 29

A solution of N-[(R)-1-{3-(4-piperidyl)propionyl}-3-piperidylcarbonyl]-3-phenyl- β -alanine hydrochloride in water (30 ml) was purified by HPLC on C18 silica gel eluting with 10.1% TFA aqueous solution: CH_3CN = 44:11) to give N-[(1R)-1-{3-(4-piperidyl)propionyl}-3-piperidylcarbonyl]-3(S)-phenyl- β -alanine trifluoroacetate (0.08 g) as an oil.

$[\alpha]_D^{20} = -39.62^\circ$ (C=0.45, MeOH)

IR (Film) : 2910, 2850, 1710, 1630 cm^{-1}

NMR ($\text{DMSO}-d_6$, δ) : 1.17-1.85 (11H, m), 2.12-2.36
(2+1/2H, m), 2.60-3.28 (7+1/2H, m), 3.71-3.83
(1H, m), 4.12-4.38 (2H, m), 5.18 (1H, q,
J=7.8Hz), 7.20-7.38 (5H, m), 8.18-8.32 (1H, br),
8.42 (1H, d, J=8.3Hz), 8.54-8.64 (1H, br)

Mass (m/z) : 416 ($M^+ + 1$) free of compound
and

N-[(R)-1-{3-(4-piperidyl)propionyl}-3-
piperidylcarbonyl]-3(R)-phenyl- β -alanine trifluoroacetate
(0.08 g) as an oil

$[\alpha]_D^{20} = -1.20^\circ$ (C=1.0, MeOH)

IR (Film) : 3250, 2960, 1710, 1600 cm^{-1}

NMR ($\text{DMSO}-d_6$, δ) : 1.12-1.85 (11H, m), 2.11-2.36
(3H, m), 2.66 (2H, d, J=7.5Hz), 2.79-3.11 (3H,
m), 3.17-3.29 (2H, m), 3.63-3.84 (1H, m), 4.11-
4.33 (2H, m), 5.11-5.23 (1H, m), 7.24-7.34 (5H,
m), 8.07-8.23 (1H, br), 8.40 (1H, d, J=8.1Hz),
8.40-8.53 (1H, br)

Mass (m/z) : 416 ($M^+ + 1$) free of compound

The following compound was obtained according to
similar manners to that of Example 13 (1) and Example 21
(1).

Example 30

N-[(R)-1-{3-(4-piperidyl)propionyl}-3-
piperidylcarbonyl]-2-benzyl- β -alanine hydrochloride

IR (KBr, pellet) : 3439, 2941, 1724, 1639, 1618 cm^{-1}

NMR ($\text{DMSO}-d_6$, δ) : 1.21-1.86 (11H, m), 2.09-2.40
(3H, m), 2.55-2.89 (6H, m), 2.93-3.25 (5H, m),
3.72-3.86 (1H, m), 4.12-4.41 (1H, m), 7.17-7.31
(5H, m), 8.04-8.20 (1H, m), 8.71-8.86 (1H, br),
9.00-9.14 (1H, br)

Mass (m/z) : 430 ($M^{+}+1$) free of compound

The following compound was obtained according to similar manners to that of Example 13 (1) and Example 21 (1).

Example 31

N-[(R)-1-{3-(4-piperidyl)propionyl}-3-piperidyl-carbonyl]-3-piperidynecarboxylic acid hydrochloride

NMR (DMSO- d_6 , δ) : 1.18-1.99 (17H, m), 2.17-2.40 (3H, m), 2.57-3.11 (5H, m), 3.13-3.25 (2H, m), 3.68-3.91 (2H, m), 4.27-4.40 (2H, m), 8.68-8.86 (1H, br), 8.99-9.11 (1H, br)

Mass (m/z) : 380 ($M^{+}+1$) free of compound

The following compound was obtained according to similar manners to that of Example 13 (1) and Example 21 (1).

Example 32

N-[(R)-1-{3-(4-piperidyl)propionyl}-3-piperidylcarbonyl]-2-phenyl- β -alanine hydrochloride

IR (KBr, pellet) : 3410, 3392, 2947, 1724, 1635, 1616 cm^{-1}

NMR (DMSO- d_6 , δ) : 1.21-1.86 (11H, m), 2.04-2.61 (4H, m), 2.69-3.06 (3H, m), 3.16-3.27 (2H, m), 3.31-3.84 (4H, m), 4.11-4.34 (1H, m), 7.24-7.33 (5H, m), 8.01-8.15 (1H, m), 8.73-8.85 (1H, br), 9.00-9.12 (1H, br)

Mass (m/z) : 416 ($M^{+}+1$) free of compound

The following compound was obtained to similar manners to that of Example 13 (1) and Example 21 (1).

Example 33

N-[(R)-1-{3-(4-piperidyl)propionyl}-3-piperidylcarbonyl]-N-methyl- β -alanine trifluoroacetate

IR (KBr, pellet) : 3419, 2951, 2866, 1724, 1680, 1620 cm^{-1}

NMR ($\text{DMSO}-d_6$, δ) : 1.14-1.91 (12H, m), 2.11-2.44 (3H, m), 2.70-3.15 (5H, m), 2.78 (3H, s), 3.20-3.32 (2H, m), 3.40-3.62 (2H, m), 3.73-3.88 (1H, m), 4.26-4.40 (1H, m), 8.14-8.27 (1H, br), 8.47-8.59 (1H, br)

Mass (m/z) : 354 (M^++1) free of compound

Example 34

To a solution of N-[(R)-1-{3-(1-tert-butoxycarbonyl-4-piperidyl)propionyl}-3-piperidylcarbonyl]-3(S)-hydroxymethyl- β -alanine tert-butyl ester (0.2 g) in dichloromethane (3 ml) was added trifluoroacetic acid (3 ml) at ambient temperature. After stirring for 1 hour, the mixture was evaporated in vacuo. The residue was dissolved in water and freeze-dried to give (S)-4-[(R)-1-{3-(4-piperidyl)propionyl}-3-piperidylcarbonylamino]-1,2,3,4-tetrahydro-2-furanone (0.17 g) as a pale yellow oil.

IR (KBr) : 3425, 1776, 1678, 1624, 1549 cm^{-1}

NMR (D_2O , δ) : 1.30-2.22 (11H, m), 2.44-2.62 (4H, m), 2.81-3.10 (4H, m), 3.17-3.44 (3H, m), 3.77-3.92 (1H, m), 4.17-4.34 (2H, m), 4.61-4.82 (2H, m)

Mass (m/z) : 352 (M^++1) free of compound

Example 35

(1) To a solution of N-[(R)-1-{3-(1-tert-butoxycarbonyl-4-piperidyl)propionyl}-3-piperidylcarbonyl]-3(S)-cyano- β -alanine tert-butyl ester (460.9 mg) in dichloromethane (5 ml) was added trifluoroacetic acid (4.6 ml). After stirring at ambient temperature for 2 hours, the mixture was concentrated in vacuo. The residue was dissolved in

water and desalted by HP-20 eluting with (IPA:water = 1:1). The eluting solution was concentrated in vacuo and freeze-dried to give N-[(R)-1-{3-(4-piperidyl)propionyl}-3-piperidylcarbonyl]-3(S)-cyano- β -alanine (0.12 g).

5 $[\alpha]_D^{20} = -31.63^\circ$ (C=1.0, MeOH)

IR (Film) : 3400, 2950, 2850, 1680, 1620 cm^{-1}

NMR (DMSO- d_6 , δ) : 0.96-1.82 (13H, m), 2.33-2.82 (6H, m), 2.90-3.34 (4H, m), 3.71-3.89 (1H, m), 4.21-4.47 (1H, m), 6.89-7.35 (1H, m)

10 Mass (m/z) : 365 ($M^+ + 1$)

The following compounds were obtained according to a similar manner to that of Example 35 (1).

15 (2) N-[(R)-1-{3-(4-piperidyl)propionyl}-3-piperidylcarbonyl]-3(S)-(n-butanesulfonyl-aminomethyl)- β -alanine trifluoroacetate

IR (Nujol) : 1730 cm^{-1}

20 NMR (DMSO- d_6 , δ) : 0.88 (3H, t, $J=7.2\text{Hz}$), 1.29-1.43 (14H, m), 1.78-1.84 (3H, m), 2.30-2.38 (3H, m), 2.60-2.64 (2H, m), 2.75-3.10 (8H, m), 3.22-3.28 (2H, m), 3.70-3.80 (1H, m)

Mass (m/z) : 489 ($M^+ + 1$) free of compound

25 (3) 4-{3-(4-piperidyl)propionylamino-1-piperidyl}-4-oxo-2(S)-benzoylamino-butyric acid

IR (KBr, pellet) : 3061, 2945, 2862, 1716, 1647, 1635 cm^{-1}

30 NMR (DMSO- d_6 , δ) : 1.04-1.83 (8H, m), 2.03-2.46 (2H, m), 2.60-2.78 (2H, m), 3.09-4.80 (13H, m), 4.98-5.23 (1H, m), 7.34-7.54 (3H, m), 7.84-7.94 (2H, m), 8.20-8.89 (1H, m)

Mass (m/z) : 489 ($M^+ + 1$)

35 Example 36

(1) A mixture of N-[(R)-1-{3-(4-piperidyl)propionyl}-3-piperidylcarbonyl]-3(S)-ethynyl- β -alanine trifluoroacetate (0.57 g) and 4.9 HCl in ethanol (30 ml) was stirred at ambient temperature for 2 hours, and the mixture was evaporated in vacuo. The residue was purified by HPLC on C18 silica gel eluting with a solution of 18% CH₃CN in 0.1% aqueous TFA solution, and the fractions containing object compound were combined and evaporated in vacuo and freeze-dried to give N-[(R)-1-{3-(4-piperidyl)propionyl}-3-piperidyl]-3(S)-ethynyl- β -alanine ethyl ester trifluoroacetate (0.52 g).

$[\alpha]_D^{20} = -25.60^\circ$ (C=1.0, MeOH)

IR (Film) : 3280, 2930, 2850, 1760, 2720, 1630 cm⁻¹

NMR (DMSO-d₆, δ) : 1.18 (3H, t, J=7.1Hz), 1.26-1.84 (10H, m), 2.09-2.19 (3H, m), 2.55-3.28 (9H, m), 2.66 (1H, d, J=7.5Hz), 3.68-3.82 (1H, m), 4.08 (2H, q, J=7.1Hz), 4.13-4.31 (1H, m), 4.79-4.93 (1H, m), 8.10-8.63 (3H, m)

Mass (m/z) : 394 (M⁺+1) free of compound

The following compound was obtained according to a similar manner to that of Example 36 (1).

(2) N-[(R)-1-{3-(4-piperidyl)propionyl}-3-piperidylcarbonyl]-2-benzyl- β -alanine ethyl ester trifluoroacetate

IR (KBr, pellet) : 2945, 2862, 1726, 1680, 1647, 1624 cm⁻¹

NMR (DMSO-d₆, δ) : 1.06 (3H, t, J=7.1Hz), 1.15-1.66 (7H, m), 1.75-1.87 (4H, m), 2.07-2.39 (3H, m), 2.71-2.95 (6H, m), 3.09-3.32 (5H, m), 3.68-3.84 (1H, m), 3.96 (2H, q, J=7.1Hz), 4.10-4.39 (1H, m), 7.14-7.39 (5H, m), 8.01-8.10 (1H, m), 8.16-8.30 (1H, br), 8.48-8.60 (1H, br)

Mass (m/z) : 458 (M⁺+1) free of compound

Example 37

(1) To a solution of N-[(R)-1-(1-tert-butoxycarbonyl-4-piperidyl)propionyl]-3-piperidylcarbonyl]-3(S)-ethynyl-β-alanine (0.61 g) in N,N-dimethylformamide (6 ml) was added potassium carbonate (182 mg) under stirring at 0°C. After stirring at 0°C for 15 minutes, isopropylbromide (0.91 ml) was added to the mixture. After stirring at ambient temperature for 3 days, the mixture was poured into saturated aqueous ammonium chloride, and extracted with ethyl acetate. The extract was washed with water and brine, and dried over MgSO₄, and evaporated in vacuo. The residue was purified by column chromatography on silica gel eluting with (CHCl₃:MeOH = 100:1) to give N-[(R)-1-{3-(1-tert-butoxycarbonyl-4-piperidyl)propionyl}-3-piperidylcarbonyl]-3(S)-ethynyl-β-alanine isobutyl ester (0.63 g) as an oil.

IR (Film) : 2920, 1720, 1660, 1620 cm⁻¹

NMR (CDCl₃, δ) : 0.95 (6H, d, J=6.7Hz), 1.01-1.22 (2H, m), 1.45 (9H, s), 1.40-1.75 (8H, m), 1.92-2.02 (3H, m), 2.27 (1H, d, J=2.2Hz), 2.32-2.40 (3H, m), 2.61-2.73 (4H, m), 3.20-3.63 (2H, m), 3.90 (2H, d, J=6.4Hz), 3.83-4.15 and 4.35-4.47 (total 3H, m), 5.05-5.15 (1H, m), 6.64-6.71 and 6.99-7.03 (total 1H, m)

Mass (m/z) : 520 (M⁺+1)

The following compounds were obtained according to a similar manner to that of Example 37 (1).

(2) N-[(R)-1-{3-(1-tert-butoxycarbonyl-4-piperidyl)propionyl}-3-piperidylcarbonyl]-3(S)-ethynyl-β-alanine 5-methyl-2-oxo-1,3-dioxol-4-yl-methyl ester

IR (Film) : 3000, 2920, 2850, 1810, 1740, 1640, 1610 cm⁻¹

NMR (CDCl₃, δ) : 1.02-1.23 (2H, m), 1.45 (9H, s),
1.53-2.10 (11H, m), 2.19 (3H, s), 2.30-2.36 (4H,
m), 2.60-2.81 (3H, m), 2.73 (2H, d, J=5.7Hz),
3.20-3.61 (2H, m), 3.99-4.15 (2H, m), 4.88 (2H,
s), 6.95-7.04 (1H, m)

Mass (m/z) : 576 (M⁺+1)

(3) N-[(R)-1-{3-(1-benzyloxycarbonyl-4-piperidyl)-
propionyl}-3-piperidylcarbonyl]-2(S)-benzoylamino- β -
alanine 1-(cyclohexyloxycarbonyloxy)ethyl ester

IR (Film) : 2920, 2950, 1740, 1680, 1650 cm⁻¹

NMR (CDCl₃, δ) : 0.99-2.00 (30H, m), 1.83 (3H, d,
J=5.8Hz), 2.30-2.52 (3H, m), 2.64-2.80 (1H, m),
4.07-4.21 (2H, m), 4.57-4.83 (1H, m), 5.12 (2H,
s), 7.35-7.51 (10H, m), 7.80-7.95 (1H, m), 8.03-
8.09 (1H, m)

Mass (m/z) : 763 (M⁺+1)

(4) N-[(R)-1-{3-(1-tert-butoxycarbonyl-4-piperidyl)-
propionyl}-3-piperidylcarbonyl]-3(S)-ethynyl- β -
alanine pivaloyloxymethyl ester

NMR (CDCl₃, δ) : 1.09-1.21 (2H, m), 1.23 (9H, s),
1.45 (9H, s), 1.56-1.70 (5H, m), 1.88-2.05 (5H,
m), 2.27-2.36 (4H, m), 2.62-2.77 (4H, m), 3.33-
3.53 (2H, m), 4.07-4.18 (3H, m), 5.08-5.13 (1H,
m), 5.77 (2H, s), 7.01-7.04 (1H, m)

Mass (m/z) : 578 (M⁺+1)

(5) N-[(R)-1-{3-(1-tert-butoxycarbonyl-4-
piperidyl)propionyl}-3-piperidylcarbonyl]-2(S)-
acetylamino- β -alanine benzyl ester

IR (Film) : 2920, 2850, 1730, 1650, 1620 cm⁻¹

NMR (CDCl₃, δ) : 1.03-1.22 (2H, m), 1.45 (9H, s),
1.35-1.77 (7H, m), 1.99 (2H, s), 2.08 (3H, s),
2.19-2.51 (4H, m), 2.59-2.74 (2H, m), 3.21-3.43

(2H, m), 3.47-3.89 (2H, m), 4.03-4.21 (3H, m),
4.64-4.85 (1H, m), 5.00-5.18 (2H, m), 7.06-7.19
(1h, m), 7.32-7.40 (6H, m)

5 (6) N-[(R)-1-{3-(1-tert-butoxycarbonyl-4-piperidyl)-
propionyl}-3-piperidylcarbonyl]-2(S)-acetylamino-β-
alanine 1-(cyclohexyloxycarbonyl)ethyl ester
IR (Film) : 2930, 2855, 1740, 1650, 1620 cm⁻¹
NMR (CDCl₃, δ) : 1.00-1.23 (2H, m), 1.28-1.80 (21H,
10 m), 1.45 (9H, s), 1.86-1.98 (3H, m), 2.04 (3H,
s), 2.14-2.53 (4H, m), 2.60-2.76 (2H, m), 3.12-
3.33 (2H, m), 3.41-3.80 (2H, m), 4.02-4.14 (2H,
m), 4.25-4.44 (1H, m), 4.57-4.71 (1H, m), 6.60-
15 6.69 (1H, m), 7.28-7.40 (1H, m)

Example 38

(1) To a mixture of N-[(R)-1-{3-(1-tert-butoxycarbonyl-4-
piperidyl)propionyl}-3-piperidylcarbonyl]-
3(S)ethynyl-β-alanine (0.63 g), 4-
20 (trifluoromethyl)benzyl alcohol (0.23 ml) and N,N-
dimethylaminopyridine (18 mg) in dichloromethane (7
ml) was added 1-ethyl-3-(3-dimethylaminopropyl)-
carbodiimide hydrochloride (0.32 g) under stirring at
0°C. After stirring at ambient temperature for
25 overnight, the solution was evaporated in vacuo. The
residue was poured into water and extracted with
ethyl acetate. The extract was washed with saturated
aqueous NaHCO₃ solution, water and brine, and dried
over MgSO₄, and evaporated in vacuo. The residue was
30 purified by column chromatography on silica gel
eluting with (CHCl₃:MeOH = 100:1) to give N-[(R)-1-
{3-(1-tert-butoxycarbonyl-4-piperidyl)propionyl}-3-
piperidylcarbonyl]-3(S)-ethynyl-β-alanine 4-
trifluoromethylbenzyl ester (0.71 g) as an oil.
35 IR (Film) : 2920, 2850, 1730, 1650, 1620 cm⁻¹

NMR (CDCl₃, δ) : 1.01-1.22 (2h, m), 1.45 (9H, s),
1.43-1.72 (7H, m), 1.84-2.12 (2H, m), 2.28 (1H,
d, J=2.4Hz), 2.31-2.39 (3H, m), 2.60-2.90 (2H,
m), 2.77 (2H, d, J=5.8Hz), 3.19-3.42 (2H, m),
3.50-3.64 (1H, m), 3.98-4.16 (3H, m), 5.08-5.24
(1H, m), 5.20 (2H, s), 6.61 and 7.04 (total 1H,
d, J=8.4Hz), 7.49 (2H, d, J=8.1Hz), 7.63 (2h, d,
J=8.2Hz)

Mass (m/z) : 622 (M⁺+1)

The following compounds were obtained according to a
similar manner to that of Example 38 (1).

(2) N-[(R)-1-{3-(1-tert-butoxycarbonyl-4-
piperidyl)propionyl}-3-piperidylcarbonyl]-3(S)-
ethynyl- β -alanine n-butyl ester

IR (Film) : 2910, 2850, 1720, 1650, 1620 cm⁻¹

NMR (CDCl₃, δ) : 0.94 (3H, t, J=7.2Hz), 1.01-1.22
(2H, m), 1.31-1.77 (11H, m), 1.45 (9H, s), 1.86-
2.11 (2H, m), 2.28 (1H, d, J=2.3Hz), 2.32-2.40
(3H, m), 2.60-2.80 (4H, m), 3.20-3.41 (2H, m),
3.52-3.66 and 3.85-4.00 (total 1H, m), 4.12 (2H,
t, J=6.6Hz), 4.05-4.71 (3H, m), 5.05-5.16 (1H,
m), 6.67-6.75 and 7.00-7.05 (total 1H, m)

Mass (m/z) : 520 (M⁺+1)

(3) N-[(R)-1-{3-(1-tert-butoxycarbonyl-4-
piperidyl)propionyl}-3-piperidylcarbonyl]-3(S)-
ethynyl- β -alanine 2-adamantyl ester

IR (Nujol) : 1720, 1660, 1620 cm⁻¹

NMR (CDCl₃, δ) : 1.01-1.21 (2H, m), 1.45 (9H, s),
1.35-1.63 (7H, m), 1.74-1.93 (9H, m), 2.00-2.05
(4H, m), 2.27-2.39 (4H, m), 2.61-2.81 (5H, m),
3.20-3.40 (2H, m), 3.54-3.66 (1H, m), 3.85-3.98
(1H, m), 4.05-4.16 (2H, m), 4.37-4.50 (1H, m),

4.97-5.03 (1H, m), 5.07-5.17 (1H, m), 6.70-6.78
(1H, m), 6.99-7.08 (1H, m)

Mass (m/z) : 598 ($M^+ + 1$)

5 Example 39

To a solution of N-[(R)-1-{3-(4-piperidyl)propionyl}-
3-piperidylcarbonyl]-3(S)-ethynyl- β -alanine ethyl ester
hydrochloride (0.47 g) in N,N-dimethylformamide (5 ml) was
added potassium carbonate (0.2 g) under stirring at 0°C.
After stirring at 0°C for 15 minutes, a solution of 4-
bromomethyl-5-methyl-2-oxo-1,3-dioxole (0.19 g) in N,N-
dimethylformamide (1 ml) was added to the mixture. After
stirring at ambient temperature for overnight, the mixture
was poured into saturated aqueous ammonium chloride, and
extracted with ethyl acetate. The extract was washed with
water and brine, and dried over $MgSO_4$, and evaporated in
vacuo. The residue was purified by column chromatography
on silica gel eluting with ($CHCl_3$:MeOH = 100:1) to give N-
[(R)-1-{3-{1-(5-methyl-2-oxo-1,3-dioxol-4-yl-methyl)-4-
piperidyl}propionyl}-3-piperidylcarbonyl]-3(S)-ethynyl- β -
alanine ethyl ester (90 mg) as an oil.

IR (Film) : 2930, 1810, 1730, 1700, 1655, 1620 cm^{-1}

NMR ($CDCl_3$, δ) : 1.11-1.35 (2H, m), 1.28 (3H, t,
J=7.0Hz), 1.45-1.80 (9H, m), 1.90-2.04 (4h, m),
2.23 (2H, s), 2.21-2.42 (5H, m), 2.65-3.00 (5H,
m), 3.20-3.34 (1H, m), 3.51-3.66 (1H, m), 4.06-
4.61 (1H, m), 4.18 (2H, q, J=7.1Hz), 5.05-5.15
(1H, m), 6.65-7.03 (1H, m)

Mass (m/z) : 504 ($M^+ + 1$)

The following compounds were obtained according to
similar manners to that of Example 37 (1) and Example 21
(1).

35 Example 40

(1) N-[(R)-1-{3-(4-piperidyl)propionyl}-3-piperidylcarbonyl]-3(S)-ethynyl- β -alanine benzyl ester trifluoroacetate
IR (KBr) : 3380, 3284, 1780, 1737, 1675, 1623 cm^{-1}
5 NMR (DMSO-d_6 , δ) : 1.26-1.83 (11H, m), 2.10-2.31 (3H, m), 2.56-3.01 (6H, m), 3.23-3.27 (3H, m), 3.62-3.78 (1H, m), 4.10-4.32 (1H, m), 4.87-4.90 (1H, m), 5.41 (2H, s), 7.37 (5H, m), 8.22 (1H, br), 8.49 (1H, br)
10 Mass (m/z) : 454 (M^++1) free of compound

(2) N-[(R)-1-{3-(4-piperidyl)propionyl}-3-piperidylcarbonyl]-3(S)-ethynyl- β -alanine 1-(cyclohexyloxycarbonyloxy)-1-ethyl ester trifluoroacetate
15 IR (KBr) : 3409, 3280, 1760, 1673, 1625 cm^{-1}
Mass (m/z) : 534 (M^++1) free of compound

The following compound was obtained according to similar manners to that of Example 25 (1) and Example 27.

Example 41

N-[(R)-1-{3-(4-piperidyl)propionyl}-3-piperidylcarbonyl]-3(S)-ethynyl- β -alanine pivaloyloxymethyl ester
25 NMR (D_2O , δ) : 1.20 (9H, s), 1.32-1.82 (7H, m), 1.95-2.02 (3H, m), 2.54-2.64 (3H, m), 2.78 (1H, d, $J=2.4\text{Hz}$), 2.92-3.05 (5H, m), 3.16-3.32 (1H, m), 3.40-3.47 (2H, m), 3.82-3.87 (1H, m), 4.09-30 4.29 (2H, m), 4.92-5.01 (1H, m), 5.80 (2H, s)
Mass (m/z) : 478 (M^++1)

Example 42

N-[1-{3-(4-piperidyl)propionyl}-3-piperidyl]-3(S)-benzoylaminosuccinamic acid hydrochloride (245 mg) was
35

dissolved in water and purified by HPLC on C18 silica gel eluting with (0.1% TFA aqueous solution:CH₃CN = 85:15) to give N-[1-{3-(4-piperidyl)propionyl}-3-piperidyl]-3(S)-benzoylaminosuccinamic acid trifluoroacetate (283 mg).

IR (Film) : 2500, 1720, 1610 cm⁻¹

NMR (DMSO-d₆, δ) : 1.12-1.88 (11H, m), 2.12-3.04 (8H, m), 3.15-3.31 (2H, m), 3.43-3.85 and 4.16-4.29 (total 3H, m), 4.69-4.83 (1H, m), 7.44-7.60 (3H, m), 7.82-7.95 (2H, m), 8.04-8.11 (1H, m), 8.13-8.26 (1H, br), 8.42-8.54 (1H, br), 8.65-8.74 (1H, m)

Mass (m/z) : 459 (M⁺+1) free of compound

The following compounds were obtained according to a similar manner to that of Example 38 (1).

Example 43

(1) N-[(R)-1-{3-(1-tert-butoxycarbonyl-4-piperidyl)propionyl}-3-piperidylcarbonyl]-3(S)-ethynyl-β-alanine n-pentyl ester

IR (Film) : 2930, 2860, 1720, 1650, 1620 cm⁻¹

NMR (CDCl₃, δ) : 0.91 (3H, t, J=6.7Hz), 1.01-1.23 (2H, m), 1.31-1.37 (6H, m), 1.45 (9H, s), 1.52-1.73 (9H, m), 2.28 (1H, d, J=2.3Hz), 2.33-2.40 (3H, m), 2.60-2.76 (4H, m), 3.19-3.71 (3H, m), 4.04-4.15 (3H, m), 4.11 (2H, t, J=6.6Hz), 5.05-5.15 (1H, m), 6.67-7.08 (1H, m)

(2) N-[(R)-1-{3-(1-tert-butoxycarbonyl-4-piperidyl)propionyl}-3-piperidylcarbonyl]-3(S)-ethynyl-β-alanine n-hexyl ester

IR (Film) : 2930, 2860, 1720, 1660, 1640, 1620 cm⁻¹

NMR (CDCl₃, δ) : 0.89 (3H, t, J=6.6Hz), 1.00-1.22 (2H, m), 1.27-1.40 (7H, m), 1.45 (9H, s), 1.51-1.79 (10H, m), 2.28 (1H, d, J=2.3Hz), 4.06-4.14

(3H, m), 4.11 (2H, t, J=6.6Hz), 5.05-5.16 (1H, m), 6.72-7.08 (1H, m)

(3) N-[(R)-1-{3-(1-tert-butoxycarbonyl-4-piperidyl)propionyl}-3-piperidylcarbonyl]-3(S)-ethynyl- β -alanine 4-chlorobenzyl ester

IR (Film) : 3000, 2980, 2925, 2860, 1730, 1675, 1660, 1620 cm^{-1}

NMR (CDCl_3 , δ) : 1.00-1.21 (2H, m), 1.45 (9H, s), 1.39-1.77 (9H, m), 2.27 (1H, d, J=2.3Hz), 2.31-2.39 (3H, m), 2.60-2.76 (4H, m), 3.20-3.60 (3H, m), 3.93-4.14 (3H, m), 5.05-5.19 (1H, m), 5.11 (2H, s), 6.86-7.07 (1H, m), 7.33 (4H, s)

The following compounds were obtained according to a similar manner to that of Example 25 (1).

Example 44

(1) N-[(R)-1-3-(4-piperidyl)propionyl]-3-piperidylcarbonyl]-3(S)-ethynyl- β -alanine n-pentyl ester hydrochloride

IR (KBr, pellet) : 3413, 3041, 2947, 2862, 1734, 1657, 1610 cm^{-1}

NMR ($\text{DMSO}-d_6$, δ) : 0.87 (3H, t, J=6.5Hz), 1.28-1.88 (17H, m), 2.06-2.38 (3H, m), 2.60-3.19 (8H, m), 3.32-3.80 (2H, m), 4.03 (2H, t, J=6.5Hz), 4.10-4.32 (1H, m), 4.79-4.92 (1H, m), 8.53 (1H, dd, J=13.3 and 8.1Hz), 8.51-8.69 (1H, br), 8.85-8.96 (1H, br)

(2) N-[(R)-1-3-(4-piperidyl)propionyl]-3-piperidylcarbonyl]-3(S)-ethynyl- β -alanine n-hexyl ester hydrochloride

IR (KBr) : 3408, 3035, 2958, 2933, 2858, 1736, 1653, 1616 cm^{-1}

(3) N-[(R)-1-{3-(4-piperidyl)propionyl}-3-piperidylcarbonyl]-3(S)-ethynyl- β -alanine 4-chlorobenzyl ester hydrochloride

IR (KBr, pellet) : 3458, 3034, 2949, 2862, 1736,
1649, 1618 cm^{-1}

NMR (DMSO-d_6 , δ) : 1.21-1.84 (11H, m), 2.09-2.36
(3H, m), 2.59-3.10 (7H, m), 3.17-3.31 (3H, m),
4.09-4.34 (1H, m), 4.82-4.94 (1H, m), 5.11 (2H,
s), 7.40 (2H, d, $J=9.0\text{Hz}$), 7.45 (2H, d,
 $J=8.7\text{Hz}$), 8.47-8.58 (1H, m), 8.47-8.64 (1H, br),
8.80-8.90 (1H, br)